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Mutations	in	the	ataxia	telangiectasia	mutated	(ATM)	gene	cause	the	disease	
ataxia‐telangiectasia	 (A‐T).	 Patients	 with	 this	 disease	 have	 multiple	 symptoms,	
including	 the	 eponymous	 ataxia	 and	 telangiectasia	 as	 well	 as	 immunodeficiency,	
radiation	sensitivity,	and	increased	cancer	rates.	The	ATM	protein	is	a	kinase	and	is	
activated	by	multiple	types	of	stress	to	affect	many	cellular	processes.	
At	sites	of	DNA	double‐strand	breaks	(DSBs),	ATM	is	activated	by	the	protein	
complex	 Mre11/Rad50/Nbs1	 (MRN).	 As	 part	 of	 this	 complex,	 Rad50	 binds	 and	
hydrolyzes	ATP	and	causes	large	conformational	changes	in	the	complex.	However,	
the	 importance	 of	 this	 enzymatic	 activity	 in	 the	 activation	 of	 ATM	 has	 been	
unknown.	Here	I	show	ATP	binding	by	Rad50	is	required	for	ATM	activation	while	
ATP	hydrolysis	is	dispensable.	
ATM	 is	 also	 activated	 in	 the	 presence	 of	 oxidative	 stress.	 Separation‐of‐
function	mutations	for	the	activation	of	ATM	by	DSBs	and	oxidative	stress	have	been	
characterized	 in	vitro.	Here,	 the	effects	of	 expressing	wild‐type	ATM	or	ATM	with	
these	 different	 separation‐of‐function	mutations	 in	 an	 ATM‐deficient	 lymphoblast	
cell	 line	 have	 been	 characterized.	 Analysis	 of	 the	 proteomes	 of	 these	 cells	 and	 a	
control	 cell	 line	 revealed	 that	 non‐functional	 ATM	 resulted	 in	 the	 loss	 of	 a	 large	
group	of	proteins	by	mass	spectrometry.	The	levels	of	these	proteins	were	similar	in	
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the	cells,	but	in	the	presence	of	non‐functional	ATM	they	showed	increased	levels	of	
aggregation.	Thus	my	results	suggest	ATM	may	 function	 to	prevent	aggregation	 in	
these	conditions.	Notably	neurodegeneration	is	often	associated	with	aggregation.	
In	the	phosphoproteomes	of	cells	expressing	the	various	ATM	constructs,	the	
parental	cell	line	and	cells	with	ATM	unable	to	be	activated	by	oxidative	stress	had	
lower	 levels	 of	 phosphopeptides	 predicted	 to	 be	 phosphorylated	 by	 CK2.	 This	
decrease	in	CK2	activity	was	also	associated	with	increased	aggregation,	specifically	
a	subunit	of	CK2	known	as	CK2β.	This	work	provides	insights	into	the	mechanism	of	
ATM	activation	by	MRN	and	the	potential	involvement	of	ATM	in	the	prevention	of	
protein	aggregation.	
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CHAPTER	1:		INTRODUCTION	
DNA	 double‐strand	 breaks	 (DSBs)	 are	 the	 most	 dangerous	 genetic	 lesions	
and	their	repair	requires	the	coordination	of	many	different	proteins.	These	breaks	
are	repaired	through	two	main	pathways,	non‐homologous	end	joining	(NHEJ)	and	
homologous	 recombination	 (HR).	 In	 NHEJ,	 two	 DNA	 ends	 undergo	 limited	
processing	 and	 are	 directly	 ligated	 [2].	 In	 HR,	 the	 breaks	 are	 more	 extensively	
processed	 to	 leave	 long	 3’	 ends	 that	 are	 able	 to	 invade	 and	 synthesize	 new	DNA	
from	the	homologous	chromosome	[3].	A	key	event	in	the	choice	between	NHEJ	and	
HR	is	the	processing	of	the	DNA	ends.	After	the	3’	end	has	been	resected	for	HR,	a	
break	 can	 no	 longer	 be	 repaired	 by	 NHEJ	 [3].	 This	 resection	 and	 the	 cellular	
response	 to	 DSBs	 are	 controlled	 by	 a	 signaling	 cascade	 initiated	 by	 the	 protein	
kinase	ataxia	telangiectasia	mutated	(ATM)	[4].	
ATM	 is	 activated	 by	multiple	 types	 of	 cellular	 stresses	 and	 regulates	many	
pathways.	 In	 the	 canonical	 activation	 pathway,	 ATM	 is	 activated	 at	 DNA	 double‐
strand	 breaks	 (DSBs)	 to	 initiate	 a	 signaling	 cascade	 important	 for	 DNA	 repair	
through	homologous	recombination.	More	recently,	ATM	was	shown	to	be	activated	
by	 oxidative	 stress	 in	 cells	 and	 in	 vitro	 [5].	 Additionally,	 ATM	 was	 found	 to	 be	
activated	 during	 various	 cellular	 conditions	 including	 	 hypoxia	 [6],	 hyperthermia	
[7],	 hypotonic	 stress	 [8],	 and	 mitosis	 [9].	 Activated	 ATM	 regulates	 the	
phosphorylation	 of	 hundreds	 of	 substrates	 [10‐12].	 Initially,	 most	 of	 these	
substrates	of	ATM	were	found	to	function	in	DNA	repair,	cell	cycle	checkpoints,	and	
gene	regulation.	However,	ATM	substrates	have	also	been	shown	to	be	involved	in	
other	 cellular	 functions	 including	 protein	 folding	 [12,	 13],	 the	 pentose	 phosphate	
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pathway	 [13],	 autophagy	 [14],	 protein	 synthesis	 [15],	 and	 glucose	 uptake	 [16].	
Although	less	well	understood,	these	pathways	may	represent	ATM	functions	in	the	
absence	of	DNA	damage.	
ATAXIA	TELANGIECTASIA	MUTATED	
The	 ATM	 gene	 was	 discovered	 during	 a	 search	 for	 the	 molecular	 cause	 of	 the	
neurodegenerative	 disease	 ataxia	 telangiectasia	 (A‐T)	 [17].	 Loss‐of‐function	
mutations	 in	 the	 ATM	 gene	 result	 in	 multiple	 symptoms	 including	 the	 two	
symptoms	 for	 which	 it	 is	 named	 –	 ataxia,	 the	 progressive	 loss	 of	 muscle	
coordination	 in	 affected	 patients,	 and	 telangiectasia,	 small	 dilated	 blood	 vessels	
visible	in	the	eyes	of	patients.	Other	symptoms	include	immunodeficiency,	radiation	
sensitivity,	 increased	 cancer	 rates,	 and	 infertility.	A‐T	affects	between	1	 in	40,000	
and	 1	 in	 100,000	 people	 and	 is	 inherited	 in	 an	 autosomal	 recessive	 manner.	 An	
estimated	 1.4%	 of	 the	 population	 are	 heterozygous	 carriers	 of	 a	mutant	 allele	 of	
ATM	and	heterozygosity	has	been	associated	with	an	increased	risk	for	certain	types	
of	 cancer	 [18,	 19].	 Mice	 heterozygous	 for	 ATM	 have	 also	 been	 shown	 to	 develop	
cancer	 at	 higher	 rates	 after	 exposure	 to	 radiation	 [20].	 ATM	 knockout	 mice	
recapitulate	 some	 of	 the	 phenotypes	 from	 humans	 including	 radiation	 sensitivity,	
immunodeficiency,	and	infertility	although	neurodegeneration	is	not	observed	[21].	
Notably,	kinase‐dead	ATM	is	a	recessive	lethal	gene	that	causes	embryonic	lethality	
in	 mice	 [22].	 The	 cellular	 phenotypes	 of	 ATM	 deficiency	 include	 deficits	 in	
checkpoint	 activation,	 increased	 radiosensitivity,	 and	 higher	 levels	 of	 oxidative	
stress	[4].	As	the	effects	of	the	loss	of	functional	ATM	are	so	diverse,	it	appears	ATM	
regulates	many	different	pathways	in	mammalian	cells.	
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The	 ATM	 gene	 was	 identified	 on	 chromosome	 11q22‐23	 by	 positional	
cloning	and	is	nearly	150,000	base	pairs	long	[17].	The	transcribed	mRNA	is	13,147	
nucleotides	 and	 contains	66	 exons	 that	 encode	 the	3,056	 amino	 acids	 of	 the	ATM	
protein.	 The	 ATM	 protein	 is	 a	 serine/threonine	 protein	 kinase	 in	 the	
phosphatidylinositol	3‐kinase‐related	(PI3K)	kinase	(PIKK)	family	with	a	preferred	
recognition	sequence	of	a	serine	or	threonine	followed	by	a	glutamine	(S/TQ)	[23].	
This	 family	 includes	 two	 other	 proteins	 involved	 in	 DNA	 repair,	 Ataxia	
Telangiectasia	 and	 Rad3‐related	 protein	 (ATR)	 and	 the	 DNA‐dependent	 Protein	
Kinase	 Catalytic	 Subunit	 (DNA‐PKcs)	 [24].	 In	 addition,	 the	Mammalian	 Target	 Of	
Rapamycin	 (mTOR),	 the	Suppressor	of	Morphogenesis	 in	Genitalia‐1	 (SMG‐1),	 and	
the	TRansformation/tRanscription	domain‐Associated	Protein	(TRRAP)	proteins	are	
also	members	of	this	family	[24].	The	structures	and	regulation	of	these	other	PIKK	
family	members	provide	valuable	insights	into	ATM.	
PIKK	DOMAINS	
The	 protein	 kinases	 in	 the	 PIKK	 family	 all	 share	 a	 kinase	 domain	 similar	 to	 the	
kinase	domain	of	the	PI3K	family,	a	group	of	lipid	kinases	that	phosphorylate	the	3’	
OH	 of	 inositol	 in	 phosphatidylinositols	 [25].	 Although	 the	 kinase	 domains	 are	
similar	 to	 PI3Ks,	 PIKKs	 have	 only	 been	 shown	 to	 phosphorylate	 proteins	 [24].	 In	
addition	to	the	kinase	domain,	the	PIKK	family	members	share	four	other	domains:	
an	extensive	 section	of	α‐helical	 repeats	 in	 the	N‐terminus	 followed	by	 the	FRAP‐
ATM‐TRRAP	(FAT)	domain,	the	aforementioned	kinase	domain,	the	PIKK	regulatory	
domain	(PRD),	and	finally	the	FAT	C‐terminal	(FATC)	domain	(Figure	1.1).	
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Figure	1.1	Alignment	of	the	functional	domains	of	PIKKs.	
The	colors	represent	domains	present	in	the	PIKKs:	blue,	HEAT	repeats;	green,	FAT	
domain;	 red,	 PI3K‐like	 kinase	 domain;	 orange,	 PIKK	 regulatory	 domain;	 purple,	
FATC	domain.	In	ATM,	the	domains	are	defined	as	the	following	amino	acids:	HEAT	
repeats,	 1‐1,965;	 FAT	 domain,	 1,966‐2,566;	 kinase	 domain,	 2,614‐2,960;	 PIKK	
regulatory	domain,	2,961‐3,024;	FATC	domain,	3,025‐3,056.	Adapted	from	[26].	
	
The	α‐helical	repeats	 in	 the	PIKKs	have	been	predicted	to	be	HEAT	repeats	
with	each	repeat	consisting	of	two	α‐helical	regions	of	10‐20	amino	acids	joined	by	a		
5‐8	 residue	 loop	 [27].	HEAT	 repeats	were	previously	 found	 in	 and	named	 for	 the	
Huntington,	 Elongation	 factor	 3,	 protein	 phosphatase	 2A,	 and	 TOR1	 proteins.	 In	
crystal	structures	from	these	and	other	proteins,	HEAT	repeats	stack	to	form	large	
superhelical	 scaffolds	 involved	 in	 protein‐protein	 interactions	 [28‐30].	 Notably,	
ATM	 has	 been	 shown	 to	 interact	 with	 other	 proteins	 through	 its	 N‐terminus,	
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including	its	canonical	substrate	p53	and	Nbs1,	a	protein	involved	in	recruiting	ATM	
to	DSBs	[31‐34].	
The	 FAT	 and	 FATC	 domains	 always	 occur	 together	 and	 are	 thought	 to	
interact	 to	regulate	 the	activity	of	 the	PIKKs	 [35].	 In	DNA‐PKcs,	 the	stimulation	of	
kinase	 activity	 from	 binding	 Ku70/80	 and	 DNA	 also	 causes	 large	 conformational	
changes	 in	 the	 FAT	 and	 FATC	 domains	 [36].	 The	 FATC	 domain	 sequence	 is	more	
conserved	 than	 the	FAT	domain	 sequence	 suggesting	a	 conserved	 function	 in	 this	
domain	among	the	PIKKs	[37].	Notably,	 the	FATC	domains	of	ATR,	DNA‐PKcs,	and	
mTOR	have	been	substituted	for	the	FATC	domain	of	ATM	without	a	loss	of	kinase	
activity	[38].	However,	the	FATC	domains	are	not	fully	interchangeable	as	replacing	
the	FATC	domain	of	mTOR	or	ATR	with	the	FATC	domain	of	ATM	abolishes	kinase	
activity	[39,	40].	Furthermore,	deletion	or	mutation	of	even	one	residue	of	the	FATC	
domain	 in	 mTOR	 has	 been	 shown	 to	 abolish	 kinase	 activity	 [40,	 41].	 In	 ATM,	 a	
mutation	was	 found	 in	 an	 A‐T	 patient	 that	 truncates	 the	 final	 10	 residues	 of	 the	
FATC	domain	and	severely	 reduces	kinase	activity	 in	vitro	 [5,	42,	43].	All	of	 these	
results	suggest	the	FAT	and	FATC	domains	function	in	the	regulation	of	the	activity	
of	PIKKs.	
The	PIKK	regulatory	domain	(PRD)	is	the	region	between	the	kinase	domain	
and	the	FATC	domain	[39].	Deletion	of	this	entire	region	has	been	shown	to	abolish	
kinase	activity	although	shorter	deletions	within	this	region	can	reduce	this	effect	or	
have	 the	 opposite	 effect	 [39,	 44].	 Post‐translational	 modifications	 and	 protein‐
protein	interactions	in	the	PRD	have	been	shown	to	enhance	PIKK	kinase	activity.	In	
ATR,	 Topoisomerase	 II‐binding	 protein	 1	 has	 been	 shown	 to	 stimulate	 kinase	
activity	through	an	interaction	with	the	PRD	[45].	Mutational	analysis	of	DNA‐PKcs	
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showed	specific	residues	in	the	PRD	were	autophosphorylated	and	required	for	its	
role	 in	NHEJ	 [39].	 ATM	also	undergoes	 several	 post‐translational	modifications	 in	
this	region	that	modulate	 its	kinase	activity.	These	will	be	discussed	further	 in	the	
ATM	post‐translational	modifications	 section.	 Thus,	 the	 PRD	 is	 also	 important	 for	
the	regulation	of	the	kinase	activity	in	the	PIKKs.	
PIKK	STRUCTURES	
As	 ATM	 is	 difficult	 to	 crystallize	 and	 thus	 has	 not	 been	 analyzed	 by	 X‐ray	
crystallography,	there	is	no	atomic	resolution	structure.	Llorca	et	al.	examined	ATM	
by	electron	microscopy	(EM)	and	obtained	a	structure	at	about	30	Å	resolution	[46].	
In	the	electron	micrographs,	most	of	the	ATM	was	monomeric	due	to	the	presence	
of	 detergents	 in	 the	 lysis	 buffer	 and	 sonication	 of	 the	 lysate	 [34,	 46,	 47].	 In	 this	
structure,	ATM	appears	to	have	a	distinct	arm	and	head,	possibly	corresponding	to	
the	N‐terminal	α‐helices	and	the	FAT,	kinase,	PR,	and	FATC	domains,	 respectively.	
Upon	addition	of	DNA	the	arm	appears	to	close	and	form	a	ring	structure	perhaps	
acting	 as	 a	 clamp	 [46].	 However,	 the	 DNA	 binding	 of	 ATM	 is	 not	 thought	 to	 be	
relevant	in	the	cellular	setting	as	the	recruitment	of	ATM	to	DSBs	is	dependent	on	
other	complexes.	
Two	other	PIKKs	–	mTOR	[48]	and	DNA‐PKcs	[49]	–	have	been	crystallized	as	
well	 as	 many	 PI3K	 proteins,	 including	 PI3Kγ	 [50].	 The	 mTOR	 structure	 (3.2	 Å	
resolution)	is	an	N‐terminal	truncation	of	mTOR	such	that	some	of	the	HEAT	repeats	
are	removed	but	the	other	domains	remain	(PDB	code:	4JSV).	In	addition	to	mTOR,	
this	 structure	 contains	 the	 mLST8	 protein	 from	 mTOR	 complex	 1	 and	 2.	 In	 this	
structure,	 the	kinase	domain	rests	on	 the	FAT	domain	and	 interacts	with	both	 the	
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FATC	 domain	 and	 the	 PRD.	 The	 active	 site	 is	 recessed	 and	 most	 mutations	
associated	with	mTOR	hyperactivity	appear	to	increase	access	to	the	active	site	[48].	
The	FATC	domain	is	a	kinked	α‐helix	with	a	loop	at	the	C‐terminus	which	is	similar	
to	the	FATC	domain	of	Saccharomyces	cerevisiae	mTOR	(ScmTOR).	However,	in	the	
ScmTOR	analyzed	by	NMR	the	loop	at	the	end	of	FATC	was	shown	to	be	stabilized	by	
a	 disulfide	 bond	 linking	 cysteines	 2460	 and	 2467	 [51].	 	 Although	 these	 two	
cysteines	 are	 conserved	 in	 humans,	 the	 disulfide	 is	 not	 evident	 in	 the	 crystal	
structure.	This	 could	 be	 due	 to	 the	presence	of	mLST8	 in	 the	human	 structure	or	
differences	 in	 the	 preparation	 of	 the	 samples.	 Aligning	 the	 FAT,	 kinase,	 and	FATC	
domain	of	 this	mTOR	structure	with	porcine	PI3Kγ	(PDB	code:	1E8X)	[50]	reveals	
the	high	degree	of	similarity	between	the	kinase	domains	(Figure	1.2)		.	In	addition,	
some	of	 the	α‐helices	 from	 the	FAT	domain	as	well	 as	 the	highly	 conserved	FATC	
domain	 overlap	 with	 α‐helices	 from	 PI3Kγ	 suggesting	 similar	 mechanisms	 of	
regulation.	
The	DNA‐PKcs	structure	is	relatively	low	resolution	but,	after	refinement,	the	
structure	 agrees	 with	 previous	 EM	 results	 [49,	 52‐54].	 The	 DNA‐PKcs	 structure	
includes	a	ring	with	an	opening	at	the	bottom	and	a	crown	that	may	correspond	to	
the	arm	and	head	visible	in	the	ATM	structure.	The	HEAT	repeats	of	DNA‐PKcs	form	
the	ring	and	opposite	the	opening	the	other	domains	rest	on	the	HEAT	repeats.	The	
structure	 shows	 the	 FAT,	 PR,	 and	 FATC	 domains	 coming	 together	 and	 forming	 a	
base	 upon	 which	 the	 kinase	 domain	 sits	 suggesting	 these	 domains	 could	 control	
kinase	activity	through	direct	interactions	and	structural	rearrangements.	
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Figure	1.2	Alignment	of	mTOR	and	PI3Kγ	structures	reveal	similarities	between	
various	domains.		
Rotations	of	an	alignment	of	human	mTOR	residues	1385‐2549	and	Sus	scrofa	PI3Kγ	
residues	142‐1092.	The	colors	represent	 the	 following:	green,	mTOR	FAT	domain;	
red,	mTOR	kinase	domain;	purple,	mTOR	FATC	domain;	 and	yellow,	PI3Kγ	kinase	
domain;	black,	mTOR	ADP	and	PI3Kγ	ATP.	Alignments	and	figures	were	generated	
using	Pymol	version	1.3	and	the	PDB	files	mTOR	(4JSV)	and	PI3Kγ	(1E8X).	
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ATM	ACTIVATION	BY	DNA	DOUBLE‐STRAND	BREAKS	
ATM	functions	as	a	key	signaling	protein	in	the	cellular	response	to	DSBs.	Following	
a	DSB,	many	proteins	accumulate	at	the	site	and	form	foci.	Among	the	first	of	these	
proteins	is	Mre11/Rad50/Nbs1	(MRN),	a	complex	consisting	of	dimers	of	the	three	
individual	proteins.	After	a	DSB,	MRN	recruits	ATM	through	an	interaction	with	the	
C‐terminus	of	Nbs1	[32‐34,	55].	ATM	is	recruited	in	an	inactive	dimer	form	and	then	
undergoes	autophosphorylation	and	monomerization	 [8].	This	active	 form	of	ATM	
then	 phosphorylates	 hundreds	 of	 substrates	 to	 activate	 and	 recruit	 DNA	 repair	
proteins,	trigger	cell	cycle	checkpoints,	and	regulate	gene	expression	(Figure	1.3)	[1,	
11,	 12].	 As	 part	 of	 this	 process,	 ATM	 reinforces	 the	 formation	 of	 DNA	 damaged‐
induced	 foci	 through	 the	 phosphorylation	 of	 H2AX,	MDC1,	 and	 BRCA1	 [1,	 56].	 In	
addition	to	its	activity	at	the	site	of	the	DSB,	ATM	also	phosphorylates	substrates	in	
the	nucleoplasm	and	cytoplasm	after	DNA	damage	[57‐61].	
MRN	CONFORMATIONAL	STATES	
The	Mre11/Rad50/Nbs1(Xrs2)	 complex	 in	 eukaryotes	binds	 to	DSBs	and	 initiates	
DNA	repair	and	signaling.	Mre11	is	an	endonuclease	important	for	the	initiation	of	
resection	at	 the	DSB	 [62,	63].	Rad50	binds	DNA	and	also	has	ATPase	activity	 that	
affects	 the	 structural	 conformation	 of	 the	 entire	 complex	 [64‐67].	 The	 nuclear	
localization	of	MRN	is	controlled	by	Nbs1,	which	also	acts	as	a	scaffold	for	protein	
interactions	[55,	68,	69].		
	 ATM	 activation	 in	 response	 to	 DSBs	 requires	 the	 MRN	 complex	 [70].	
Immunodepletion	 experiments	 in	 Xenopus	 laevis	 extracts	 showed	 ATM	
monomerization	is	increased	in	an	MRN‐dependent	manner	[71]	in	agreement	with	
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Figure 1.3 Model of downstream effectors after ATM activation. 
Representative downstream effectors of ATM. After activation by DNA double-strand 
breaks or oxidative stress, ATM phosphorylates proteins involved in many different 
pathways. The underlined substrates are not phosphorylated by ATM after oxidative 
stress activation. Adapted from Kurz and Lees-Miller (2004) and Khalil, Tummala, 
Chakarov, Zhelev, and Lane (2012). 
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previous	results	using	purified	MRN	that	demonstrated	MRN	binding	directly	causes	
ATM	autophosphorylation	and	monomerization	[34].	Cells	deficient	in	Mre11,	Nbs1,	
or	 Rad50	 show	 defects	 in	 ATM	 activation	 after	 DSBs	 [72‐74].	 Hypomorphic	
mutations	 in	 the	 MRE11,	 NBS1,	 and	 RAD50	 genes	 are	 associated	 with	 diseases	
similar	to	A‐T	called	AT‐like	disorder	(ATLD),	Nijmegen	breakage	syndrome	(NBS),	
and	NBS‐like	disorder	 (NBSLD),	 respectively	 [73,	75,	76].	However,	 these	diseases	
have	some	unique	symptoms,	generally	show	a	slower	onset,	and	are	not	associated	
with	 all	 the	 symptoms	 of	 A‐T	 suggesting	MRN	 and	ATM	have	 related	 but	 distinct	
functions	[73,	75,	76].	
The	structures	and	domains	of	the	proteins	in	MRN	have	been	characterized	
and	 reveal	 which	 parts	 are	 important	 for	 its	 function.	 Rad50	 is	 a	member	 of	 the	
structural	 maintenance	 of	 chromosomes	 (SMC)	 family	 of	 proteins	 and	 has	 an	
extensive	antiparallel	coiled‐coil	domain	[64].	At	one	end	of	the	coiled‐coils,	the	N‐
termini	 and	 C‐termini	 of	 2	 different	 Rad50	molecules	 bind	 to	 form	 globular	 head	
domains	where	ATP	binds	and	is	hydrolyzed.	At	the	other	end	of	the	coiled‐coils,	a	
zinc	hook	tethers	two	Rad50	molecules	together	[70].	 	Crystal	structures	of	Mre11	
from	 Pyrococcus	 furiosus,	 Thermotoga	maritima,	 and	 Schizosaccharomyces	 pombe	
alone	or	in	complex	with	Rad50	or	Nbs1	have	helped	characterize	the	Mre11	dimer	
interface	and	Rad50	and	Nbs1	binding	domains	in	Mre11	[67,	77,	78].	Many	of	the	
mutations	associated	with	ATLD	are	 in	 the	Nbs1	binding	domain	of	human	Mre11	
[79].	 Analyses	 of	 Nbs1	 have	 shown	 it	 interacts	 with	 many	 DNA‐repair	 related	
proteins	 including	Mre11,	ATM,	MDC1,	CtIP,	ATR,	and	WRN	[80,	81].	Mutations	of	
Nbs1	 associated	 with	 NBS	 are	 mostly	 truncations,	 suggesting	 the	 C‐terminus	 is	
important	for	Nbs1	function	[76].	Notably,	the	C‐terminus	of	Nbs1	contains	the	ATM	
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and	 Mre11	 interaction	 domains	 as	 well	 as	 three	 potential	 nuclear	 localization	
signals	[55,	82,	83].	
Mre11	 and	 Rad50	 proteins	 are	 able	 to	 form	 a	 stable	 complex	 (MR)	 by	
themselves	 in	 a	 stoichiometry	 of	 Mre112:Rad502	 or	 Mre114:Rad504	 [84].	 The	
structures	 of	 the	 complex	 of	Mre11	 and	 the	 catalytic	 head	 domain	 of	 Rad50	with	
shortened	 coiled‐coils	 in	 the	 presence	 or	 absence	 of	 ADP	 and	 ATPγS	 have	 been	
described	and	suggest	a	mechanism	whereby	MRN	is	regulated	(Figure	1.4)	[65,	85].	
The	 structure	of	Methanococcus	 jannaschii	Mre11	and	Rad50	 (residues	1‐190	 and	
825‐1005;	designated	MjMRCC)	bound	to	ATPγS	showed	Mre11	affects	Rad50	dimer	
stabilization	 and	 key	 residue	 positioning	 for	 ATP	 hydrolysis	 [65].	 Comparison	
between	MjMRCC	bound	to	ATPγS	and	ADP	revealed	large	changes	in	the	structure	
upon	ATP	 hydrolysis	 including	 a	 rotation	 of	 the	 coiled‐coils	 that	 could	 unveil	 the	
active	 site	 of	 Mre11	 [65].	 Another	 recent	 study	 suggests	 the	 regulation	 of	 MRN	
occurs	 through	modulation	 of	 its	 various	 flexible	 subunits,	 including	 through	 the	
stabilization	of	Mre11	induced	by	Nbs1	binding	[81].		
The	 structure	 of	 Thermatoga	maritima	 MRNBD	 (TmMRNBD)	 (residues	 1‐190	
and	686‐852	of	Rad50)	in	the	absence	of	any	ATP	nucleotide	showed	an	extended,	
open	 conformation	 [85].	 Although	 TmMRNBD	 was	 unable	 to	 be	 crystallized	 in	 the	
presence	 of	 ATPγS,	 biochemical	 analyses	 showed	 a	 large	 conformational	 change	
upon	the	addition	of	ATP	and	DNA	[85].	A	later	structure	of	TmMRNBD	using	cysteine	
mutations	 to	 stabilize	 the	 ATP‐bound	 conformation	 showed	 the	 Rad50NBD	 flipped	
relative	to	Mre11	in	the	disulfide‐stabilized	form	versus	the	ADP‐bound	form	[66].	
These	 structures	 demonstrate	 that	 ATP	 binding	 and	 hydrolysis	 induce	 large	
conformational	shifts	that	affect	the	positioning	of	the	proteins.	However,	it	is	
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Figure	1.4	Schematic	model	of	MRN	in	the	absence	(open)	or	presence	of	ATP	(closed).		
Rad50	is	shown	as	light	gray	globular	domains	containing	Walker	A	(A)	and	Walker	
B	(B)	motifs	connected	by	intramolecular,	antiparallel	coiled‐coils	(CC),	that	attach	
to	 each	 other	 through	 the	 zinc	 hook	 motifs	 (Zn	 hook).	 Stars	 indicate	 the	
approximate	 positions	 of	 the	 ATP‐binding	 residues	 in	 Rad50.	 Mre11	 is	 shown	 as	
dark	gray	globular	domains	representing	the	nuclease/dimerization	domain	and	the	
capping	domain,	connected	to	the	linker	that	binds	to	the	coiled‐coils	of	Rad50.	The	
closed	 state	 is	 associated	 with	 a	 higher	 affinity	 for	 DNA	 ends	 and	 with	 DNA	
tethering,	 while	 the	 movement	 from	 the	 closed	 to	 the	 open	 state	 is	 required	 for	
Mre11	 nuclease	 activity	 and	 promotion	 of	 resection.	 The	 zinc	 hook	 is	 shown	
attached	here,	but	the	complex	has	also	been	observed	with	hooks	unattached,	both	
in	solution	and	bound	to	DNA.	This	research	was	originally	published	in	in	Journal	of	
Biological	 Chemistry.	 Lee	 JH,	 Mand	 MR,	 Deshpande	 RA,	 Kinoshita	 E,	 Yang	 SH,	
Wyman	 C,	 Paull	 TT.	 Ataxia	 Telangiectasia‐Mutated	 (ATM)	 Kinase	 Activity	 Is	
Regulated	 by	 ATP‐driven	 Conformational	 Changes	 in	 the	 Mre11/Rad50/Nbs1	
(MRN)	 Complex.	 Journal	 of	 Biological	 Chemistry.	 2013;	 288:12840‐12851.	 ©	 the	
American	Society	for	Biochemistry	and	Molecular	Biology.	
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unknown	which	nucleotide	binding	state	of	MRN	is	responsible	for	the	activation	of	
ATM.	
OXIDATIVE	STRESS	IN	A‐T	AND	ATM	ACTIVATION	
The	 loss	 of	 ATM	 kinase	 activity	 has	 been	 associated	with	 high	 levels	 of	 oxidative	
stress.	 A‐T	 patients	 have	 increased	 oxidative	 damage	 on	 lipids	 and	DNA	 [86]	 and	
lower	 levels	 of	 antioxidants	 in	 their	 blood	 plasma	 [87].	 Similarly,	 ATM	 knockout	
mice	 have	 changes	 in	 the	 activities	 of	 thioredoxin,	 catalase,	 and	 manganese	
superoxide	indicative	of	high	levels	of	reactive	oxygen	species	(ROS)	[88].	Oxidative	
stress	from	the	loss	of	ATM	may	be	involved	in	the	predisposition	for	cancer	as	ATM	
knockout	mice	have	higher	rates	of	 lymphoma	and	treatment	of	 the	mice	with	the	
antioxidant	 N‐acetylcysteine	 (NAC)	 reduces	 this	 incidence	 [89].	 In	 addition,	
oxidative	 stress	 may	 be	 partially	 responsible	 for	 immunodeficiency	 as	 NAC	
treatment	of	mice	rescues	the	inhibition	of	class‐switch	recombination	and	aberrant	
V(D)J	 recombination	 in	 ATM	 knockout	 mice	 [90].	 In	 A‐T	 fibroblasts,	 increased	
sensitivity	 to	 hydrogen	 peroxide	 [91]	 and	 nitric	 oxide	 donors	 also	 suggest	 a	 high	
basal	 level	of	 oxidative	 stress	 [92].	Notably,	 other	neurodegenerative	diseases	 are	
also	associated	with	oxidative	stress	suggesting	a	common	mechanism	of	neuronal	
loss	may	 be	 responsible	 [93].	 However,	while	 all	 of	 these	 observations	 suggested	
ATM	was	involved	in	ROS	regulation,	the	mechanism	was	unknown	for	some	time.	
Years	 after	 the	 first	 observation	 of	 increased	 oxidative	 stress	 in	 A‐T,	 ATM	
was	 shown	 to	 be	 activated	 specifically	 in	 the	 cytoplasm	 by	 ROS	 [14].	 In	 this	
pathway,	 mTORC1	 activity	 is	 inhibited	 through	 a	 signaling	 cascade	 initiated	 by	
ATM‐dependent	 phosphorylation	 of	 LKB1	 [14].	 However,	 the	 levels	 of	 hydrogen	
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peroxide	used	in	this	study	caused	γH2AX	foci	formation,	a	marker	of	DNA	damage.	
In	vitro	activation	of	ATM	by	ROS	showed	a	direct	method	for	ATM	activation	in	the	
absence	of	DNA	[5].	In	contrast	to	ATM	monomerization	during	DSB	activation,	ATM	
forms	an	active	disulfide	cross‐linked	dimer	after	hydrogen	peroxide	treatment	[5].	
This	active	dimer	requires	cysteine	2991	in	the	FATC	domain	as	replacement	with	
leucine	(C2991L‐ATM)	prevents	activation	by	ROS	[5].	In	addition	to	cysteine	2991,	
cysteines	540,	541,	819,	1045,	1177,	1396,	1494,	1495,	2021,	and	2801	were	also	
found	to	form	disulfide	bonds	after	treatment	with	hydrogen	peroxide	[5].	Although	
individual	mutations	of	these	cysteines	had	no	effect	on	kinase	activity,	these	bonds	
may	help	stabilize	the	critical	cysteine	2991	disulfide	bond.	
ATM	POST‐TRANSLATIONAL	MODIFICATIONS	
ATM	 undergoes	 multiple	 post‐translational	 modifications	 in	 different	 domains	
during	 its	 activation	 (Figure	1.5).	DNA‐damage	 induced	ATM	autophosphorylation	
has	been	identified	at	4	sites:	serines	367,	1893,	1981,	and	2996	[8,	11,	94,	95].	ATM	
autophosphorylated	at	any	of	these	four	serines	was	shown	to	localize	to	DSBs	but	
each	serine	 individually	was	not	required	for	the	recruitment	of	ATM	to	DSBs	[94,	
95].	However,	the	rescue	of	the	S‐phase	checkpoint	by	wild‐type	ATM	expression	in	
an	A‐T	 cell	 line	was	prevented	by	 individual	mutations	 of	 serines	367	or	 2996	 to	
non‐phosphorylatable	alanines	[95].	Furthermore,	mutation	of	either	serine	1981	or	
serine	 2996	 to	 alanine	 prevents	 the	 retention	 of	 ATM	 at	 DSBs	 suggesting	
phosphorylation	of	 these	 residues	 is	 important	 for	maintaining	ATM	at	 the	 repair	
foci	[11,	96].	
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Figure	1.5	ATM	domains	and	sites	with	known	post‐translational	modifications.		
Serines	367,	1893,	1981,	and	2996	are	autophosphorylation	sites.	Serines	794	and	
1403	 are	 phosphorylated	 by	 Cdk5	 and	 Aurora‐B,	 respectively.	 Tyrosine	 370	 is	
phosphorylated	by	EGFR.	Cysteine	2991	forms	a	disulfide	bridge	and	lysine	3016	is	
acetylated	 by	 Tip60.	 The	 colors	 represent	 domains	 present	 in	 ATM:	 blue,	 HEAT	
repeats	(residues	1‐1965);	green,	FAT	domain	(residues	1966‐2566);	red,	PI3K‐like	
kinase	 domain	 (residues	 2614‐2960);	 brown,	 PIKK	 regulatory	 domain	 (residues	
2961‐3024);	purple,	FATC	domain	(residues	3025‐3056).	
	 	
The	 requirement	 for	 these	 autophosphorylation	 events	 can	 vary.	 The	
phosphorylation	of	 serine	1981	was	not	 required	 for	 in	vitro	 activation	of	human	
ATM	[34].	In	mice,	autophosphorylation	at	the	serines	corresponding	to	367,	1893,	
and	1981	have	also	been	shown	to	be	dispensable	 for	ATM	activation	as	mutating	
serine	1981	or	all	 three	 to	alanine	had	no	phenotypic	effect	 [97,	98].	However,	all	
the	 DNA‐damage	 induced	 autophosphorylation	 sites	 of	 ATM	 so	 far	 identified	 are	
important	 in	 human	 cells	 as	 mutation	 of	 these	 residues	 to	 alanine	 inhibits	 ATM	
signaling	 after	DSBs	 and	prevents	 rescue	of	 ionizing	 radiation	 resistance	 [94,	 95].	
The	 discrepancies	 between	 the	 requirements	 for	 ATM	 autophosphorylation	 in	
humans	and	mice	are	still	unresolved.	
In	addition	to	autophosphorylation	at	multiple	sites,	ATM	is	phosphorylated	
by	other	kinases.	In	neuronal	cells,	ATM	is	stimulated	by	cyclin‐dependent	kinase	5	
phosphorylation	of	serine	794	in	a	DNA	damage‐dependent	manner	[99].	Recently,	
ATM	phosphorylation	by	 the	epidermal	growth	 factor	receptor	 (EGFR)	at	 tyrosine	
C2991
S2996
K3016
S1981S1893S367 S794
Y370
S1403
 
 
17
370	 was	 identified	 in	 response	 to	 irradiation	 [100].	 EGFR	 was	 shown	 to	 be	
important	for	ATM	activation	as	depletion	of	EGFR	or	addition	of	the	EGFR	inhibitor	
gefitinib	impaired	foci	formation,	DNA	repair,	and	Chk2	phosphorylation	[100].	ATM	
was	 also	 found	 to	 be	 activated	 during	mitosis	 in	 the	 absence	 of	DNA	damage	 [9].	
This	 activation	 required	 the	 activity	 of	Aurora‐B	kinase	 to	phosphorylate	ATM	on	
serine	 1403	 and	 was	 necessary	 for	 an	 efficient	 spindle	 assembly	 checkpoint	 in	
response	to	nocodazole	[9].	ATM	was	also	shown	to	constitutively	associate	with	the	
tyrosine	kinase	c‐Abl	and	phosphorylate	c‐Abl	after	DNA	damage	to	activate	it	[101,	
102],	in	addition	to	being	a	target	of	c‐Abl	phosphorylation	[103].	
Other	 post‐translational	 modifications	 also	 occur	 on	 ATM,	 most	 notably	
acetylation.		ATM	and	Tip60	form	a	stable	complex	and	Tip60	acetylates	lysine	3016	
of	 ATM	 after	 DNA	 damage	 [104].	 Knockdown	 of	 Tip60	 or	 the	mutation	 of	 lysine	
3016	 to	 arginine	 (K3016R)	 prevents	 DNA‐damage	 induced	 activation	 of	 ATM	 in	
human	cells	[104,	105].	However,	kinase	assays	with	K3016R‐ATM	have	shown	this	
modification	 is	 not	 essential	 in	 vitro	 (JH	 Lee,	 unpublished	 observations).	 Notably,	
Tip60	 phosphorylation	 by	 c‐Abl	 enhances	 the	 binding	 of	 Tip60	 to	 methylated	
histone	 H3	 (H3K9me3)	 suggesting	 a	 positive	 feedback	 loop	 between	 ATM,	 c‐Abl,	
and	Tip60	after	DNA	damage	[106].	
ATM‐DEPENDENT	PHOSPHORYLATION	EVENTS	
Upon	 activation	 by	DSBs	 or	 oxidative	 stress,	 ATM	phosphorylates	more	 than	 700	
substrates	 involved	 in	 multiple	 cellular	 processes	 including	 DNA	 repair,	
chromosomal	 organization,	 cell	 cycle	 regulation,	 gene	 regulation,	 apoptosis,	 stress	
responses,	 and	 RNA	 metabolism	 (Figure	 1.3)	 [4,	 10‐12,	 107].	 Additionally,	 ATM	
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phosphorylates	 and	 activates	 many	 kinases	 leading	 to	 signal	 amplification	 [108].	
These	downstream	effectors	include	the	checkpoint	kinases	Chk1	and	Chk2	as	well	
as	DNA‐PK	and	AKT	[109‐113].		
A	 phosphoproteomic	 study	 in	 an	 immortalized	 human	 B‐cell	 line	 treated	
with	 ionizing	 radiation	 found	 only	 around	 13%	 of	 phosphorylation	 events	 in	 the	
nuclei	 were	 in	 the	 canonical	 ATM	 recognition	 site	 pS/pTQ	 [10].	 Another	 study	
showed	 putative	 ATM	 sites	 were	 a	 similar	 percentage	 of	 all	 neocarzinostatin‐
dependent	 phosphorylation	 events	 in	 nuclei	 from	 human	 melanoma	 cells	 [11].	
However,	in	this	study	60%	of	all	the	phosphorylation	events	were	ATM‐dependent	
as	 addition	 of	 an	 ATM	 inhibitor	 prevented	 phosphorylation.	 Both	 of	 these	
phosphoproteomic	screens	found	relatively	few	phosphopeptides	with	the	pS/pTQ	
motif	(80	and	42	phosphorylation	events,	respectively).	Matsuoka	et	al.	enriched	for	
ATM	 substrates	 using	 antibodies	 to	 known	 ATM	 phosphorylation	 sites	 and	
identified	 over	 900	 phosphorylation	 events	 at	 pS/pTQ	 sites	 upon	 treatment	with	
ionizing	 radiation	 [12].	Thus	 there	may	be	hundreds	of	direct	 targets	of	ATM	and	
many	more	indirect	targets	through	the	activation	of	various	downstream	kinases.	
The	 substrates	 of	 ATM	 may	 change	 depending	 on	 the	 method	 of	 ATM	
activation.	 In	 the	 presence	 of	 oxidative	 stress	 ATM	does	 not	 phosphorylate	H2AX	
and	Kap1,	substrates	known	to	be	phosphorylated	after	DNA	damage	[5].	Similarly,	
ATM	activated	by	cell‐cycle	arrest	in	mitosis	does	not	phosphorylate	Smc1	or	p53	at	
sites	 phosphorylated	 after	 ionizing	 radiation	 [9].	 This	 suggests	 that	 ATM	 may	
activate	specific	downstream	effectors	in	addition	to	common	substrates	depending	
on	which	cellular	stress	is	present.		
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CASEIN	KINASE	2	
DNA	 double‐strand	 breaks	 induce	 large	 changes	 in	 the	 phosphoproteome	 beyond	
the	substrates	of	ATM.	Phosphoproteomic	investigations	have	shown	that	only	10%	
of	 DNA	 damage	 responsive	 sites	 conform	 to	 the	 ATM	 recognition	 sequence	 S/TQ	
[10,	11].	These	studies	showed	phosphopeptides	predicted	to	be	phosphorylated	by	
CK2	are	upregulated	after	DNA	damage	 [10,	11].	Notably,	CK2	 inhibition	has	been	
shown	to	suppress	DNA	repair,	suggesting	a	direct	role	 in	 the	cellular	response	to	
DSBs	[114,	115].	
The	 CK2	 holoenzyme	 is	 a	 heterotetramer	 consisting	 of	 two	 catalytic	 (α	
and/or	 α')	 subunits	with	 two	 regulatory	 β	 subunits	 (Figure	 1.6).	 Although	 the	N‐
terminal	catalytic	domains	of	CK2α	and	CK2α'	are	approximately	90%	identical,	the	
α	and	α'	subunits	show	some	differences	in	substrate	specificity,	probably	through	
their	 unrelated	 C‐termini	 [116].	 The	 holoenzyme	 (α2β2,	 αα’β2,	 or	 α’2β2)	 was	 first	
described	 as	 one	 of	 the	 kinases	 responsible	 for	 the	 phosphorylation	 of	 casein	 in	
vitro	[117,	118].	Subsequent	studies	have	shown	casein	is	a	physiological	substrate	
for	 a	 different	 kinase	designated	 the	Golgi	 apparatus	 of	 lactating	mammary	 gland	
casein	kinase	(GEF‐CK)	[119].	However,	CK2	has	since	been	shown	to	phosphorylate	
many	other	proteins	involved	in	diverse	pathways.	
CK2	functions	as	an	important	regulator	of	cell	survival.	In	yeast,	the	two	CK2	
catalytic	subunits,	CKα	and	CKα',	are	functionally	redundant	but	haploid	cells	with	
deletion	of	both	are	inviable	[120].	A	further	analysis	in	a	CKα	deletion	strain	with	
temperature‐sensitive	 CKα'	 showed	 cell	 cycle	 progression	 during	 G1	 and	 G2/M	
requires	CK2	activity	[121].	In	mice,	CK2α	and	CK2β	knockouts	are	embryonic	
 
 
20
 
Figure 1.6 Structure of the CK2 holoenzyme.  
The	regulatory	β	subunits	form	a	dimer	and	each	bind	an	α	or	α’	subunit	to	form	the	
holoenzyme.	 Sections	 are	 colored	 as	 follows:	 red	 ,	 CK2α/a’;	 orange,	 CK2α/a’	 β‐
interaction	 domain	 (residues	 36‐59,	 69‐73,	 103‐108);	 tan,	 CK2α/α’	 substrate	
binding	 domain/potential	 aggregation	 interface	 (residues	 74‐80,	 191,	 195,	 198);	
blue,	CK2β;	magenta,	CK2β	dimer	interface		(residues	109‐140);	yellow,	CK2β	α/a’‐
interaction	domain	(residues	186‐198);	green,	CK2β	potential	aggregation	interface	
(residues	 55‐64).	 Domain	 boundaries	 defined	 in	 [116]	 and	 [128].	 This	 figure	was	
generated	using	Pymol	version	1.3	from	the	PDB	file:	1JWH.	
	
lethal	[122,	123],	although	CK2α'	knockout	in	mice	only	causes	male	sterility	[124].	
There	are	no	known	human	null	mutations	of	CK2	but	increased	protein	levels	and	
kinase	activity	are	associated	with	various	cancers	[125,	126].	
CK2	SUBSTRATES	
CK2	is	a	prolific	kinase	and	the	number	of	discovered	substrates	has	risen	steadily	
over	 the	 years.	 There	 have	 been	 over	 300	 proteins	 previously	 reported	 to	 be	
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phosphorylated	by	CK2	[127]	and	a	recent	phosphoproteomic	approach	using	an	in	
vitro	CK2	kinase	reaction	with	previously	dephosphorylated	lysates	identified	605		
phosphosites	 on	 356	 proteins	 of	 which	 only	 36	 proteins	 had	 been	 previously	
characterized	 [129].	 The	 recognition	 site	 phosphorylated	 by	 CK2	 is	 a	 serine	 or	
threonine	 surrounded	 by	 a	 patch	 of	 acidic	 residues	where	 the	 amino	 acids	 at	 the	
n+1	 and	 n+3	 positions	 are	 particularly	 important	 [130].	 CK2β	 is	
autophosphorylated	at	serines	2	and	3	which	are	followed	by	glutamates	at	residues	
5	and	6	[131].	In	addition,	CK2	is	able	to	phosphorylate	tyrosine	residues,	including	
autophosphorylation	sites,	with	a	slightly	different	sequence	preference	[132‐134].	
The	 phosphorylation	 of	 CK2	 substrates	 is	 generally	 associated	 with	 enhanced	
proliferation	 and	 survival	 [135].	 These	 substrates	 are	 involved	 in	 many	 cellular	
functions,	 including	 transcription,	 translation,	 metabolism,	 signal	 transduction,	
apoptosis,	and	cytoskeletal	maintenance	(Figure	1.7)	[127,	136,	137].	Notably,	in	all	
the	cancers	that	have	been	examined,	CK2	protein	levels	and	kinase	activity	are	both	
elevated	[125,	126].	
CK2	AND	DNA	REPAIR	
CK2	localizes	to	DSBs	and	phosphorylates	many	proteins	involved	in	the	DSB	repair	
pathway	[138].	MRN	foci	at	DSBs	are	dependent	on	the	constitutive	phosphorylation	
of	MDC1	by	CK2	as	Nbs1	binds	phosphorylated	MDC1	 through	 its	 FHA	 and	BRCT	
domains	 [69,	 139,	 140].	 In	 addition,	 CK2	 was	 found	 to	 phosphorylate	 Mre11	
constitutively	 at	 serine	 649	 [141].	 Heterochromatin	 protein	 1	 beta	 is	
phosphorylated	 after	 IR	 and	 dissociates	 from	 DNA	 at	 DSBs	 in	 a	 CK2‐dependent	
manner	[142].	Finally,	phosphorylation	of	Rad51	by	Plk1	licenses	CK2	to		
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Figure	1.7	Schematic	showing	some	of	the	cellular	functions	affected	by	CK2.		
	
phosphorylate	 an	 adjacent	 residue	 to	 form	 a	 binding	 site	 for	 the	 FHA	 and	 BRCT	
domains	of	Nbs1	that	is	important	for	Rad51	recruitment	to	DSBs	[143].	Conversely,	
in	unstressed	 cells	CK2	phosphorylates	Murine	Double‐Minute	 clone	2	 (MDM2)	 to	
induce	the	degradation	of	p53	[144‐146].	Consistent	with	multiple	roles	in	the	DNA	
damage	response,	inhibition	of	CK2	suppresses	DSB	repair	[114,	115].	
ATM	and	CK2	interact	in	more	direct	ways	in	the	DSB	repair	pathway	also.	A	
recent	 study	 has	 shown	 5‐diphosphoinositol	 pentakisphosphate	 binds	 and	
stimulates	CK2	to	phosphorylate	the	Tti1/Tti2/Tel2	(TTT)	complex	[147].	The	TTT	
complex	is	a	cochaperone	that	binds	and	stabilizes	PIKKs	and	the	phosphorylation	
of	Tti1	and	Tel2	has	been	shown	to	be	 important	 for	 this	binding	[147‐150].	CK2‐
dependent	phosphorylation	of	TTT	stimulates	ATM	and	DNA‐PK	kinase	activity	as	
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measured	by	phosphorylation	of	p53	[147].	CK2	is	also	involved	in	the	inhibition	of	
Cylic	 AMP‐Response	 Element‐Binding	 protein	 (CREB)	 binding	 to	 CREB‐binding	
protein	(CBP)	after	DNA	damage	[151].	A	series	of	phosphorylation	events	with	CK1,	
CK2,	 and	ATM	 culminate	 in	 the	 crucial	ATM‐dependent	 phosphorylation	 of	 serine	
121	 on	 CREB	 that	 inhibits	 its	 interaction	 with	 CBP	 [151].	 Similarly,	 constitutive	
phosphorylation	of	a	residue	on	Structural	Maintenance	of	Chromosome	3	(SMC3)	
by	CK2	is	important	for	the	IR‐induced	activation	of	the	intra‐S	phase	checkpoint	by	
ATM	 phosphorylation	 of	 a	 nearby	 residue	 [152].	 ATM	 inhibition	 was	 shown	 to	
reduce	DSB‐induced	CK2	activity	suggesting	ATM	may	play	a	direct	role	upstream	of	
CK2	activity	during	DNA	repair	[11].	
CK2	REGULATION	
The	 CK2	 holoenzyme	 has	 historically	 been	 characterized	 as	 having	 constitutive	
kinase	activity	[153].	However,	in	recent	years	different	cellular	stresses	have	been	
shown	 to	 alter	 CK2	 activity	 and	 localization.	 CK2	 phosphorylates	 p53	 in	 vitro	 in	
response	 to	 UV	 irradiation	 [154].	 Hypoxic	 conditions	 affect	 the	 expression	 and	
localization	of	CK2	and	inhibitors	of	CK2	reduce	HIF‐1	transcriptional	activity	[155].	
Similarly,	 heat	 shock	 induces	 translocation	 of	 CK2	 subunits	 to	 the	 nucleus	 and	 a	
consequent	rise	in	kinase	activity	there	[156].	In	cardiomyocytes	treated	with	TNF‐
α,	CK2	 is	oxidatively	modified	and	has	reduced	kinase	activity	[157].	DNA	damage	
by	methyl	methanesulfonate	treatment	or	UV	irradiation	represses	RNA	polymerase	
III	activity	 in	Saccharomyces	cerevisiae	 through	the	dissociation	of	CK2	[158,	159].	
Although	 CK2	 is	 often	 considered	 to	 be	 constitutively	 active,	 cellular	 localization,	
and	protein‐protein	interactions	appear	to	be	important	for	modulating	the	effects	
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and	substrates	of	CK2.	Additionally,	CK2	is	known	to	aggregate	in	vivo	and	in	vitro	
and	this	property	has	been	shown	to	affect	its	kinase	activity.	
CK2	AGGREGATION	
In	 the	 initial	 biochemical	 characterizations	 of	 CK2,	 purifications	 from	 rabbit	
erythrocytes	 and	 rabbit	 reticulocytes	 revealed	multiple	 forms	of	 CK2	with	 unique	
sedimentation	rates	[160,	161].	Notably,	there	was	a	salt	dependent	decrease	in	the	
sedimentation	rate	of	purified	Drosophila	melanogaster	CK2	(DmCK2)	to	that	of	the	
tetrameric	holoenzyme	suggesting	the	forms	with	higher	sedimentation	rates	were	
aggregates	 [162].	 Furthermore,	 electron	 micrographs	 revealed	 multiple	 forms	 of	
DmCK2	in	physiologically	relevant	conditions,	including	small	units	and	two	types	of	
filaments	 (Figure	 1.8A)	 [163].	 A	 recent	 study	 using	 bioluminescent	 resonance	
energy	transfer	technology	(BRET2)	suggest	aggregation	occurs	in	vivo	[164].	CK2α‐
Rluc8	 and	 CK2α‐GFP	 expressed	 in	 cells	 showed	 a	 CK2β‐dependent	 increase	 in	
BRET2	signal	[164].	Overexpression	of	a	known	stable	CK2‐interacting	protein,	Gαs,	
decreased	 the	 BRET2	 signal	 while	 overexpression	 of	 a	 transiently‐interacting	
protein,	β‐	arrestin2,	did	not	[164].	Furthermore,	polylysine,	which	was	previously	
shown	 to	 induce	disaggregation,	decreased	 the	BRET2	signal	 [164].	The	models	of	
CK2	aggregation	include	a	thin	linear	filament	[165]	and	a	thick	filament	consisting	
of	stacked	rings	of	trimers	or	tetramers	of	the	holoenzyme	[166,	167]	(Figure	1.8B).	
Support	for	both	of	these	models	comes	from	their	presence	in	the	crystalline	state,	
relatively	 large	 interface	 sizes,	 and	 increased	kinase	activity	upon	mutation	of	 the	
putative	aggregation	interface	[167,	168].	
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Figure	1.8	Electron	microscopy	and	accompanying	models	of	CK2	aggregation.		
(A)	Purified	Drosophila	melanogaster	CK2	was	diluted	into	buffer	containing	10	mM	
Tris‐HCl,	pH	7.5,	1	mM	DTT,	50%	glycerol,	and	100	mM	NaCl	and	incubated	at	4	°C	
for	2	hours	before	visualization	by	electron	microscopy.	The	bar	represents	100	nm.	
This	research	was	originally	published	in	Journal	of	Biological	Chemistry.	Valero	E,	
De	 Bonis	 S,	 Filhol	 O,	 Wade	 RH,	 Langowski	 J,	 Chambaz	 EM,	 Cochet	 C.	 Quaternary	
structure	 of	 casein	 kinase	 2.	 Characterization	 of	 multiple	 oligomeric	 states	 and	
relation	 with	 its	 catalytic	 activity.		 Journal	 of	 Biological	 Chemistry.	 1995;	
270(14):8345‐52.	©	the	American	Society	for	Biochemistry	and	Molecular	Biology.	
(B)	Models	 of	 CK2	 holoenzyme	 (PDB	 code:	 1JWH)	 corresponding	 to	 structures	 in	
electron	micrographs	of	(A).	Brackets	represent	one	tetramer.	
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The	kinase	activity	of	CK2	is	increased	in	conditions	that	reduce	aggregation	
suggesting	aggregation	inhibits	CK2	kinase	activity	[162,	163,	169].	Several	groups	
have	proposed	models	of	CK2	regulation	by	aggregation	through	the	intermolecular	
binding	 of	 the	 basic	 substrate‐binding	 region	 of	 CK2α	and	 an	 acidic	 loop	 in	 CK2β	
(Figure	 1.6).	 Notably,	 mutations	 disrupting	 this	 putative	 aggregation	 interface	
generate	 a	 hyperactive	 holoenzyme	 suggesting	 a	 loss	 of	 regulation	 [170,	 171].	 A	
study	 using	 chemical	 crosslinking	 also	 showed	 in	 vivo	 interaction	 of	 these	 two	
regions	[172].	
HYPOTHESES	AND	GOALS	
The	activation	of	ATM	by	DSBs	is	an	important	step	in	the	initiation	of	DNA	repair.	
ATM	requires	the	multifunctional	protein	complex	MRN	for	several	roles	during	this	
activation.	 First,	 ATM	 is	 recruited	 to	 DSBs	 through	 an	 interaction	 with	 the	 C‐
terminus	of	Nbs1	[32,	74].	Once	at	the	DSB,	MRN	stimulates	the	transition	of	ATM	
from	an	inactive	dimer	to	an	active	monomer	and	increases	the	affinity	of	ATM	for	
its	substrates	[34].	The	Rad50	component	of	MRN	is	known	to	bind	and	hydrolyze	
ATP	and	this	 induces	 large	conformational	shifts	 in	the	MRN	complex	[65,	66,	85].	
However,	it	has	not	been	clear	whether	ATP	utilization	by	MRN	is	required	for	the	
activation	of	ATM.	Previously,	there	has	been	no	simple	method	to	separate	the	ATP	
binding	and	hydrolysis	of	Rad50	from	the	kinase	activity	of	ATM	as	both	can	utilize	
the	 same	 pool	 of	 ATP.	 In	 this	 study,	 I	 use	 an	 ATM	 variant	 that	 is	 able	 to	
phosphorylate	its	substrates	with	an	N6‐substituted	ATP	to	show	that	ATP	binding,	
but	 not	 hydrolysis,	 by	 Rad50	 is	 required	 for	 the	 activation	 of	 ATM.	 This	 suggests	
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ATP	binding	by	MRN	acts	as	a	 switch	 through	which	Rad50‐controlled	changes	 in	
the	conformation	of	MRN	regulate	the	activity	of	ATM.	
In	addition	to	DSBs,	ATM	is	also	activated	by	oxidative	stress	[5].	There	have	
been	 many	 studies	 characterizing	 the	 phosphoproteome	 of	 cells	 after	 treatment	
with	ionizing	radiation	or	radiomimetic	drugs	[10‐12,	107,	173].	These	studies	have	
identified	 numerous	 pathways	 affected	 by	 ATM	 both	 directly	 and	 indirectly,	
including	 the	 phosphorylation	 and	 activation	 of	 downstream	 kinases.	 However,	
these	 studies	 have	 not	 examined	 how	 the	 different	 activation	 pathways	 of	 ATM	
affect	 its	cellular	role	 in	 the	absence	of	exogenous	stress.	 It	was	previously	shown	
that	 ATM	 knockout	 mice	 recapitulate	 some	 of	 the	 symptoms	 of	 A‐T,	 but	 the	
expression	 of	 kinase‐dead	 ATM	 in	 mice	 is	 embryonic	 lethal	 demonstrating	 the	
presence	 of	 inactive	 ATM	 is	 more	 detrimental	 [21,	 22].	 Recently,	 separation‐of‐
function	mutations	of	ATM	have	been	characterized	 that	allow	selective	activation	
by	 either	 DSBs	 or	 oxidative	 stress	 [5].	 In	 the	 study	 described	 here,	 I	 use	 an	
established	A‐T	cell	line	to	examine	the	effects	of	these	separation‐of‐function	ATM	
mutants.	 I	 show	mutations	 that	prevent	either	pathway	of	ATM	activation	affect	a	
large	 group	 of	 proteins	 and	 also	 affect	mitochondrial	 homeostasis.	 Some	 of	 these	
proteins	appear	to	undergo	aggregation	in	the	absence	of	ATM	activity.	I	also	show	a	
reduction	 in	 the	 phosphorylation	 of	 CK2	 substrates	 in	 A‐T	 cells	 expressing	
oxidative‐stress‐insensitive	 ATM	 that	 is	 associated	 with	 a	 shift	 higher	 molecular	
weight	 complexes	 for	 CK2β.	 These	 studies	 provide	 novel	 insights	 into	 the	
mechanism	of	ATM	activation	and	the	DNA‐damage	independent	functions	of	ATM	
in	cells.	
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CHAPTER	2:	MATERIALS	AND	METHODS	
	
CHEMICALS	AND	ANTIBODIES	
The	 following	 antibodies	 were	 used	 for	 western	 blotting:	 rabbit	 anti‐ACLY	
(GeneTex,	GTX112387),	rabbit	anti‐ACSM1	(Abgent,	AP9284),	rabbit	anti‐ALDH4A1	
(Abgent,	AP7875c),	mouse	anti‐ATM	(GeneTex,	GTX70103),	mouse	anti‐ATM	(Santa	
Cruz,	 sc‐135663),	 rabbit	 anti‐β‐actin	 (CST,	 4970),	 rabbit	 anti‐CBS	 (Santa	 Cruz,	 sc‐
67154),	 rabbit	 anti‐CK2α	 (Pierce,	 PA1‐86381),	 rabbit	 anti‐CK2β	 (Millipore,	 04‐
1128),	 rabbit	 anti‐GPD1	 (Abgent,	 AP8507a),	mouse	 anti‐KAP1	 (Abcam,	 ab22553),	
mouse	 anti‐LHPP	 (Santa	 Cruz,	 sc‐376648),	 rabbit	 anti‐OTC	 (Abgent,	 AP6928c),	
rabbit	anti‐pS15‐p53	(EMD	Biosciences,	PC461),	mouse	anti‐TPM1	(Santa	Cruz,	sc‐
376541),	mouse	anti‐V5	(Invitrogen,	R960‐25),	rabbit	anti‐V5	(Novus,	NB600‐381),	
goat	 anti‐mouse	 IgG	 IRDye	 800	Conjugated	 (Rockland	 Immunochemicals,	 RL‐610‐
132‐121),	 and	 goat	 anti‐rabbit	 IgG	 IRDye	 700	 Conjugated	 (Rockland	
Immunochemicals,	 RL605‐430‐003).	 All	 chemicals	 were	 purchased	 from	 Sigma	
unless	otherwise	stated.	
LARGE‐SCALE	PLASMID	PURIFICATION	
Single	colonies	from	streaked	plates	were	inoculated	in	small	LB	cultures	(25	ml)	in	
the	 presence	 of	 the	 appropriate	 antibiotic	 and	 shaken	 overnight	 at	 30	 °C.	 The	
overnight	cultures	were	inoculated	into	large	cultures	(500	ml)	at	a	1:100	dilution	
and	shaken	at	30	°C.	At	an	OD600	of	0.8‐1,	1.5	ml	34	mg/ml	chloramphenicol	in	50%	
ethanol	was	added	and	the	cells	were	shaken	overnight	at	30	°C.	Pellets	were	made	
by	 spinning	 the	 overnight	 culture	 at	 5,000	 RPM	 for	 10	minutes.	 The	 supernatant	
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was	discarded	and	the	pellet	was	resuspended	 in	9	ml	Solution	I	 (25	mM	Tris,	pH	
8.0,	10	mM	EDTA).	The	cells	were	lysed	by	the	addition	of	20	ml	Solution	II	(200	mM	
NaOH,	 1%	 SDS),	mixed	 gently	 by	 inversion,	 and	 incubated	 for	 5	minutes	 at	 room	
temperature.	Plasmid	DNA	was	 renatured	with	15	ml	 Solution	 III	 (3	M	potassium	
acetate),	mixed	gently	by	inversion,	and	the	sample	was	centrifuged	for	30	minutes	
at	 4	 °C	 and	 18,000	 g.	 The	 supernatant	 was	 mixed	 with	 25	 ml	 isopropanol	 and	
centrifuged	at	12,000	g	for	10	minutes.	The	supernatant	was	then	discarded	and	the	
pellet	was	 resuspended	 in	 4.4	ml	TE	 (10	mM	Tris,	 pH	8.0,	 1	mM	EDTA).	 Proteins	
were	 precipitated	 with	 the	 addition	 of	 1.6	 ml	 7.5	 M	 ammonium	 acetate	 and	 the	
solution	was	placed	on	ice	 for	1	hour.	The	sample	was	then	centrifuged	at	4,000	g	
for	 10	minutes.	 The	 resulting	 supernatant	was	mixed	with	 6	ml	 isopropanol	 and	
centrifuged	at	4,000	g	for	10	minutes.	The	supernatant	was	discarded	and	the	pellet	
was	resuspended	in	3.4	ml	TE.	RNA	was	digested	with	5	µl	30	mg/ml	RNase	at	37	°C	
for	 30	minutes.	 The	 sample	 was	 prepared	 for	 centrifugation	 by	 addition	 of	 4.1	 g	
cesium	chloride	and	400	µl	10	mg/ml	ethidium	bromide	and	transferred	to	suitable	
tubes	 for	 centrifugation	 (Beckman‐Coulter,	 362185).	 The	 tubes	 were	 centrifuged	
overnight	 at	 300,000	 g	 in	 the	NVT	65.2	 rotor	 (Beckman‐Coulter).	 The	DNA	bands	
were	visualized	by	long‐wave	UV	light	and	the	lower	band	(plasmid)	was	extracted	
by	 hand‐drawn	 glass	 pipettes.	 The	 collected	 sample	 was	 placed	 in	 3	 inches	 of	
dialysis	 tubing	 (Pierce,	 68100),	 and	 the	 ethidium	 bromide	 was	 removed	 by	
sequential	2	hour	dialyses	at	4	°C	with	500	ml	TE	containing	100	mM	NaCl.	A	final	
dialysis	was	performed	overnight	at	4	°C	with	500	ml	TE.	
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RESTRICTION	DIGEST		
Purified	DNA	plasmids	were	checked	by	sequencing	for	the	first	purification	and	by	
restriction	digest	subsequently.	DNA	concentration	was	determined	on	a	NanoDrop	
2000	 (Thermo	 Scientific).	 Restriction	 digests	 were	 performed	 with	 New	 England	
Biolabs	 enzymes.	Briefly,	 300	ng	DNA,	1	μl	 of	 the	desired	 restriction	enzyme,	 and	
appropriate	 amounts	 of	 buffer	 and/or	 BSA	 were	 combined	 in	 10	 μl	 total	 and	
incubated	 according	 to	 the	 protocol.	 The	 resulting	 digests	 were	 loaded	 alongside	
250	 ng	 of	 the	 1	 Kb	 Plus	 DNA	 Ladder	 (Life	 Technologies,	 10787‐018)	 on	 suitable	
percentages	of	agarose	gels	according	to	the	size	of	the	predicted	fragments	and	run	
in	TAE	(40	mM	Tris‐HCl,	20	mM	acetic	acid,	1	mM	EDTA)	 for	1	hour	at	80	V.	Gels	
were	stained	for	10	minutes	with	5	μl	10	mg/ml	ethidium	bromide	in	water,	washed	
for	10	minutes	in	water,	and	visualized	on	a	Syngene	G‐Box.	
PROTEIN	EXPRESSION	
Wild‐type	MRN	complexes	were	expressed	in	Sf21	insect	cells	by	coexpression	with	
baculovirus	 prepared	 from	 the	 transfer	 vectors	 pTP11	 (Rad50),	 pTP813	 (Mre11),	
and	 pTP288	 (Nbs1)	 as	 described	 previously	 [174‐176].	 pTP11	 was	 directly	
transfected	 into	 Sf21	 cells	 with	 linearized	 baculovirus	 DNA	 (BD	 Pharmingen)	 to	
make	recombinant	baculovirus,	whereas	the	other	transfer	vectors	were	converted	
into	 bacmids	 pTP814	 (wild‐type	Mre11)	 and	 pTP291	 (wild‐type	 Nbs1)	 and	were	
used	 to	 make	 virus	 according	 to	 manufacturer	 instructions	 for	 the	 Bac‐to‐Bac	
system	(Invitrogen).	The	expression	construct	for	Flag‐tagged	wild‐type	ATM	was	a	
gift	from	M.	Kastan.	Y2755A‐ATM	was	generated	using	QuikChange	XL	site‐directed	
mutagenesis	(Stratagene,	200516)	from	wild‐type	ATM	pcDNA3	expression	plasmid	
(sequences	available	upon	request)	with	the	following	modifications	to	the	protocol.	
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The	amount	of	wild‐type	ATM	DNA	used	as	template	was	increased	to	300	ng,	DpnI	
was	incubated	for	4	hours,	and	the	resulting	digested	DNA	was	ethanol	precipitated,	
resuspended	 in	 5	 µl	 TE,	 and	 the	 entirety	 used	 to	 transform	 XL10‐Gold	
Ultracompetent	 cells	 (Stratagene,	 200315).	 The	 Escherichia	 coli	 expression	
constructs	for	GST‐p53	were	described	previously	[33].	
PROTEIN	PURIFICATION	 	
Wild	 type	 MRN	 was	 purified	 as	 described	 [174].	 Dimeric	 ATM	 was	 made	 by	
transient	 transfection	 of	 expression	 constructs	 into	 293T	 cells	 using	 calcium	
phosphate	 and	 purified	 as	 described	 previously	 [177].	 GST‐p53	 protein	 was	
expressed	 and	 purified	 in	 E.	 coli	 as	 described	 previously	 [33].	 Protein	
concentrations	 were	 determined	 by	 quantification	 of	 protein	 preparations	 with	
standards	on	colloidal	Coomassie‐stained	SDS‐PAGE	gels	using	the	Odyssey	system	
(LiCor).	
IN	VITRO	ATM	KINASE	ASSAYS		
ATM	kinase	assays	with	MRN	and	DNA	were	performed	with	1.4	nM	dimeric	ATM,	
150	nM	GST‐p53	substrate,	4.8	nM	MRN,	and	∼140	nM	1	Kb	Plus	DNA	Ladder	(Life	
Technologies,	 10787‐018)	 as	 indicated	 in	 the	 figure	 legends.	 Kinase	 assays	 were	
performed	in	kinase	buffer	(50	mM	HEPES,	pH	7.5,	50	mM	potassium	chloride,	5	mM	
magnesium	chloride,	10%	glycerol,	and	1	mM	ATP)	for	90	min	at	30	°C	in	a	volume	
of	40	µl	as	described	previously	[34].	Kinase	assays	with	oxidative	activation	were	
performed	 in	 the	 absence	 of	 MRN	 and	 DNA	 with	 varying	 amounts	 of	 H2O2	 as	
indicated.	The	ATP	analogs	N6‐(1‐methylbutyl)adenosine‐5′‐O‐	triphosphate	and	N6‐
furfuryladenosine‐5′‐O‐triphosphate	were	obtained	from	Biolog	(BLG‐M027‐05	and	
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BLG‐F007‐05,	 respectively)	 and	 used	 at	 final	 concentrations	 of	 1	 mM.	 ATM	 and	
phosphorylated	 S15‐p53	 were	 detected	 by	 western	 blot	 as	 described	 previously	
[34].	Each	experiment	was	performed	several	times,	and	a	representative	example	
is	shown	in	the	figure.	
MAMMALIAN	CELL	CULTURE	 	
293T	 cells	 (ATCC,	 CRL‐11268)	 were	 grown	 in	 DMEM	 (Invitrogen,	 11995073)	
supplemented	 with	 10%	 FBS	 (Gemini	 Bio	 Products,	 900‐208).	 AT1ABR	 cells	 and	
AT1ABR	 cells	 expressing	 the	 various	 pMAT1‐ATM	 constructs	were	 a	 gift	 from	M.	
Lavin.	 AT1ABR	 cells	 were	 grown	 in	 RPMI‐1640	 medium	 (Sigma,	 R8758)	
supplemented	 with	 15%	 FBS.	 The	 media	 for	 AT1ABR	 cells	 with	 pMAT1‐ATM	
constructs	 was	 supplemented	 with	 200	 μg/ml	 hygromycin	 B	 (EMD	 Millipore,	
400052)	to	select	for	pMAT1‐ATM	retention.	ATM	expression	was	induced	from	the	
metallothionein	II	promoter	for	16	hours	as	described	previously	using	2	μM	CdCl2	
[178].	
CELL	LYSIS	AND	PROTEIN	QUANTITATION	FOR	MASS	SPECTROMETRY	
AT1ABR	cell	pellets	were	 lysed	 in	4	volumes	of	cell	 lysis	buffer	(8	M	urea,	50	mM	
Tris,	pH	8,	5	mM	CaCl2,	30	mM	NaCl,	50	mM	NaF,	1	mM	sodium	orthovanadate,	10	
mM	 sodium	 pyrophosphate,	 1×	 mini	 EDTA‐free	 protease	 inhibitor	 (Roche	
Diagnostics)	 and	 1×	 phosSTOP	 phosphatase	 inhibitor	 (Roche	 Diagnostics).	 The	
lysate	 was	 sonciated	 until	 clear	 and	 centrifuged	 for	 10	minutes	 at	 20,000	 g.	 The	
supernatant	was	 collected	 and	 the	 protein	 concentration	was	 quantitated	 by	 BCA	
assay	(Pierce,	23227).	
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PROTEIN	DIGESTION	
Equal	 amounts	 of	 lysate	 from	 each	 cell	 line	 (1	 mg)	 were	 reduced	 with	 5	 mM	
dithiothreitol	 (DTT)	 for	 30	 minutes	 at	 37	 °C.	 Following	 reduction,	 the	 cysteine	
residues	were	alkylated	by	the	addition	of	15	mM	iodoacetic	acid	for	30	minutes	at	
room	temperature	protected	from	light.	The	lysates	were	then	reduced	again	with	5	
mM	DTT	for	15	minutes	at	room	temperature.	The	protein	sample	was	diluted	with	
50	mM	Tris,	pH	8	and	5	mM	CaCl2	to	a	final	concentration	of	1.5	M	urea.	To	digest	
the	 proteins,	 LysC	 (10	 μg)	 (Wako	 Chemicals,	 129‐02541)	 was	 added	 and	 the	
samples	were	digested	for	2	hours	at	37	°C.	Trypsin	(20	μg)	(Promega,	V5113)	was	
added	and	the	samples	were	digested	overnight	at	room	temperature.	
PEPTIDE	DESALTING	
Sep‐Pak	Accell	Plus	CM	Vac	cartridges	(Waters,	WAT023625)	were	prepared	under	
light	 vacuum	 using	 the	 following	 washes	 (all	 percentages	 represent	 V/V):	 3	 ml	
100%	acetonitrile	 (ACN);	 1	ml	70%	ACN,	0.25%	acetic	 acid	 (AA);	1	ml	40%	ACN,	
0.5%	AA;	1	ml	20%	ACN,	0.5%	AA;	 and	3	ml	0.1%	 trifluoroacetic	 acid	 (TFA).	The	
peptide	 samples	were	brought	 to	pH	2	with	TFA	and	 loaded	onto	 the	pre‐washed	
cartridge.	The	bound	peptides	were	washed	with	3	ml	0.1%	TFA	followed	by	300	μl	
0.5%	 AA.	 The	 peptides	 were	 eluted	 in	 sequential	 applications	 of	 1	ml	 40%	 ACN,	
0.25%	AA	and	by	750	μl	70%	ACN,	0.25%	AA	and	the	samples	were	dried	in	a	speed	
vacuum	concentrator.	
PEPTIDE	TMT	LABELING	
The	TMTsixplex	Isobaric	Label	Reagent	Set	(Pierce,	90061)	was	used	to	individually	
tag	 the	 samples	 with	 6	 unique	 mass	 tags.	 The	 dried	 peptide	 samples	 were	
resuspended	in	100	μl	200	mM	tetraethylammonium	bromide.	TMT	Label	Reagents	
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(0.8	mg/sample)	were	brought	to	room	temperature,	spun	down,	and	resuspended	
in	 50	 μl	 ACN.	 The	 peptide	 samples	 and	 TMT	 Label	 Reagents	were	 combined	 and	
incubated	at	room	temperature	for	2	hours.	The	labeling	reactions	were	quenched	
with	0.8	μl	50%	hydroxylamine	(V/V)	and	then	shaken	for	15	minutes.	Aliquots	(5	
μl)	 of	 the	 samples	 were	 combined	 with	 50	 μl	 water	 and	 dried	 down	 and	 the	
remaining	samples	were	immediately	frozen.	The	aliquots	of	labeled	peptides	were	
resuspended	in	0.2%	formic	acid	then	run	on	the	mass	spectrometer	to	determine	
the	ratios	of	the	samples	to	load	for	equal	spectral	counts.	The	frozen	samples	were	
thawed,	 mixed	 according	 to	 the	 determined	 ratios,	 dried	 down,	 and	 desalted	 as	
before.	
STRONG	CATION	EXCHANGE	FRACTIONATION	
Strong	 cation	exchange	 fractionation	was	performed	at	 a	 flow	 rate	of	3.0	mL/min	
using	 a	 polySULFOETHYL	 A	 column	 (9.4	 x	 200	 mM,	 PolyLC,	 209‐SE05)	 on	 a	
Surveyor	LC	quaternary	pump.	Tagged	samples	were	resuspended	in	buffer	A	(30%	
ACN,	5	mM	KH2PO4,	 pH	2.6)	 and	 separated	using	 the	 following	 gradient:	 0‐2	min,	
100%	buffer	A;	2‐5	min,	0‐15%	buffer	B	(30%	ACN,	350	mM	KCl,	5	mM	KH2PO4,	pH	
2.6);	5‐35	min,	15‐100%	buffer	B.	Buffer	B	was	then	held	at	100%	for	10	min.	The	
column	was	washed	with	buffer	C	(500	mM	KCl,	50	mM	KH2PO4,	pH	7.5)	and	water	
and	 re‐equilibrated	 with	 buffer	 A.	 All	 fractions	 were	 collected	 by	 hand,	 frozen,	
lyophilized	 and	 de‐salted	 over	 a	 Sep‐Pak	 Accell	 Plus	 CM	 Vac	 cartridges	 (Waters,	
WAT023625).		
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PHOSPHOPEPTIDE	ENRICHMENT	
Phosphopeptide	 enrichment	 was	 performed	 using	 immobilized	 metal	 affinity	
chromatography	with	metal	beads	(Qiagen).	Before	loading	the	peptides,	the	beads	
were	equilibrated	with	water	and	then	incubated	with	40	mM	EDTA,	pH	8.0	for	30	
minutes	with	 shaking.	EDTA	was	 removed	by	 three	 successive	water	washes,	 and	
then	the	beads	were	incubated	with	100	mM	FeCl3	for	30	minutes	while	shaking.	For	
a	 final	 wash,	 the	 beads	 were	 washed	 with	 four	 rounds	 of	 80%	 ACN,	 0.1%	 TFA.	
Peptides	were	 resuspended	 in	80%	ACN,	0.1%	TFA	and	 incubated	with	 the	beads	
for	one	hour	with	shaking.	Non‐phosphorylated	peptides	were	removed	by	washing	
the	beads	with	80%	ACN,	0.1%	TFA	and	these	were	used	for	the	proteomic	analysis.	
Phosphorylated	peptides	were	eluted	from	the	beads	with	50%	ACN,	0.7%	NH4OH	
and	immediately	acidified	with	4%	formic	acid.	
LC‐MS/MS	
Tandem	 mass	 spectrometry	 was	 performed	 using	 a	 NanoAcquity	 UPLC	 system	
(Waters)	coupled	to	an	OrbiTrap	Elite	(ThermoFisher).	Peptides	were	loaded	onto	a	
75	µm	inner	diameter	and	360	µm	outer	diameter	bare	fused	silica	capillary	packed	
with	10	cm	of	Magic	C18	particles	(Bruker‐Michrom)	 for	 twelve	minutes	at	a	 flow	
rate	of	1	µL/min.	Peptides	were	then	eluted	onto	a	50	µm	inner	diameter	and	360	
µm	 outer	 diameter	 analytical	 column	 packed	 with	 17	 cm	 of	 Magic	 C18	 particles.	
Peptides	 were	 separated	 over	 either	 a	 90‐minute	 or	 120‐minute	 gradient	 by	
ramping	 from	 2%	 to	 35%	 ACN,	 0.2%	 formic	 acid	 at	 a	 flow	 rate	 of	 0.3	 µL/min.	
Peptides	were	fragmented	by	HCD	and	analyzed	using	the	Coon	OMSSA	Proteomics	
Software	 Suite	 (COMPASS)	 [179].	 The	 mass	 tolerance	 was	 set	 to	 20	 ppm	 for	
precursors	and	0.01	Th	 for	 fragment	 ions.	The	 carbamidomethylation	of	 cysteines	
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and	 the	 6	 unique	 mass	 tags	 of	 TMTsixplex	 reagents	 were	 searched	 as	 fixed	
modification.	 Oxidation	 of	 methionine,	 TMTsixplex	 modification	 of	 tyrosine,	
phosphorylation	 of	 tyrosine,	 and	phosphorylation	with	neutral	 loss	 on	 serine	 and	
threonine	were	searched	as	variable	modifications.	COMPASS	software	was	used	to	
filter	peptides	to	a	1%	FDR	which	were	then	combined	and	used	to	filter	proteins	at	
a	1%	FDR.	
HIERARCHICAL	CLUSTERING	
Protein	and	phosphopeptides	levels	were	clustered	in	Cluster	3.0	using	Hierarchical	
Clustering	 with	 Centered	 Correlation	 and	 Average	 Linkage	 [180].	 Results	 were	
visualized	and	gene	lists	extracted	using	Java	TreeView	[181].	
PAIRWISE	COMPARISONS	
Pairwise	 comparison	 graphs	were	made	 in	Microsoft	 Excel	 2010.	 The	 proteins	 or	
phosphopeptides	were	ranked	from	lowest	intensity	to	highest	intensity	separately	
in	each	cell	line	and	the	Spearman's	coefficients	were	calculated	as	ߩ ൌ 1 െ ଺	Σ݀
2݅
௡ሺ௡మିଵሻ,	
where	di	=	xi	–	yi	 is	 the	difference	 in	ranks	 for	one	protein	between	two	cell	 lines.	
The	t	statistic	for	each	Spearman's	coefficient	was	calculated	as	ݐ ൌ ߩට ௡ିଶଵିఘమ	and	the	
significance	at	the	5	x	10‐16	level	was	calculated	using	the	qt()	function	in	R	version	
3.0.3.	
SEQUENCE	ANALYSIS	
Peptide	sequences	6	amino	acids	N‐terminal	and	C‐terminal	to	each	phosphorylated	
residue	were	extracted	and	formatted	for	submission	to	motif‐x	v1.2	10.05.06	[182,	
183].	 The	 following	 settings	 were	 used	 for	 analysis	 of	 the	 phosphoproteome:	
foreground	format	=	MS/MS;	extend	from	=	IPI	Human	Proteome;	central	character	
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=	 s,	 t,	 or	 y	 in	 three	 separate	 runs;	 width	 =	 13,	 occurrences	 =	 20,	 significance	 =	
0.000001;	background	=	IPI	human	proteome.	For	the	C2991	Dependent	Cluster,	the	
occurrences	were	reduced	to	10	to	reflect	the	smaller	number	of	phosphopeptides.	
KINASE	PREDICTION	
Peptide	sequences	6	amino	acids	N‐terminal	and	C‐terminal	to	each	phosphorylated	
residue	 were	 extracted	 and	 formatted	 for	 submission	 to	 Group‐based	 Prediction	
System	ver	3.0	(GPS)	[184].	The	program	was	run	with	the	threshold	set	to	high	and	
the	results	for	multiple	kinases	were	combined	in	one	table	for	further	analysis.	
KOLMOGOROV‐SMIRNOV	(K‐S)	TESTS	
The	 empirical	 distribution	 functions	 (EDFs)	 were	 generated	 and	 K‐S	 tests	 were	
performed	 in	 R	 version	 3.0.3.	 Briefly,	 the	 ratios	 of	 intensities	 from	 AT1BR	 cells	
expressing	 wild‐type‐ATM	 and	 C2991L‐ATM	 for	 the	 phosphopeptides	 from	 the	
entire	 phosphoproteome	 or	 those	 predicted	 to	 be	 phosphorylated	 by	 a	 specific	
kinase	using	GPS	were	calculated.	These	ratios	were	entered	 into	R	as	a	 table	and	
converted	 to	 numeric	 vectors.	 The	 empirical	 cumulative	 distribution	 function	 for	
the	 phosphoproteome	 and	 the	 phosphopeptides	 predicted	 to	 be	 substrates	 of	 a	
specific	kinase	were	plotted	with	the	plot()	and	ecdf()	functions	and	the	K‐S	test	was	
performed	using	the	ks.test()	function.	
AT1ABR	TISSUE	CULTURE	FOR	STAINING	AND	QPCR	 	
AT1ABR	 cells	 and	 AT1ABR	 cells	 expressing	wild‐type‐ATM	 or	 C2991L‐ATM	were	
counted	 using	 the	 Scepter	 2.0	 Handheld	 Automated	 Cell	 Counter	 (EMD	Millipore,	
PHCC20060)	with	Scepter	Cell	Sensors,	60	μm	(PHCC60250)	and	seeded	at	a	density	
of	500,000	cells/ml	in	15	ml.	The	following	day,	4	aliquots	of	1.5	ml	of	each	cell	line	
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were	harvested	for	the	uninduced	controls.	The	aliquots	were	pelleted	for	5	minutes	
at	100	g.	The	supernatant	was	removed	and	the	cell	pellets	were	washed	with	1	ml	
PBS	 and	 pelleted	 again.	 The	 pellets	 were	 immediately	 stained	 or	 frozen	 in	 liquid	
nitrogen	 for	 subsequent	 RNA	 or	 protein	 extraction.	 The	 remaining	 cells	 were	
induced	 for	16	hours	with	2	μM	CdCl2.	After	 induction,	 the	cells	were	gently	spun	
down	 for	 5	minutes	 at	 100	 g	 and	 resuspended	 in	 fresh	media	without	 CdCl2.	 The	
cells	were	allowed	to	recover	for	48	hours	and	4	aliquots	of	1.5	ml	of	each	cell	line	
were	harvested	and	 immediately	 stained	or	pelleted	and	 frozen	 in	 liquid	nitrogen	
for	subsequent	RNA	or	protein	extraction.	
H2DCFDA,	MITOTRACKER	GREEN,	AND	PROPIDIUM	IODIDE	STAINING	
For	 staining,	 all	 centrifugation	 occurred	 for	 5	minutes	 at	 100	 g	 unless	 otherwise	
stated.	 AT1ABR	 pellets	 were	 resuspended	 in	 PBS	 and	 stained	 with	 H2DCFDA	
(Invitrogen,	 D‐399),	 MitoTracker	 Green	 FM	 (Life	 Technologies,	 M7514),	 or	
propidium	iodide	as	follows.	For	analysis	of	ROS	levels,	washed	cells	were	incubated	
for	30	minutes	with	1	μM	H2DCFDA,	then	centrifuged,	and	the	supernatant	removed.	
The	pellets	were	washed	3	times	with	PBS	and	then	transferred	to	5	ml	polystyrene	
round	 bottom	 tubes	 (VWR,	 60818‐496)	 in	 0.3	 –	 1	 ml	 PBS	 for	 analysis	 by	 flow	
cytometry.	For	mitochondrial	mass	staining,	washed	cells	were	 incubated	with	0.2	
μM	MitoTracker	 Green	 FM	 for	 20	minutes,	 then	 centrifuged,	 and	 the	 supernatant	
removed.	The	pellets	were	washed	3	 times	with	PBS	and	then	transferred	to	5	ml	
polystyrene	round	bottom	tubes	 in	0.3	–	1	ml	PBS	 for	analysis	by	 flow	cytometry.	
For	propidium	iodide	staining,	washed	cells	were	resuspended	in	1	ml	PBS	in	a	15	
ml	polypropylene,	V‐bottom	tube	on	ice	and	allowed	to	cool.	Cold	ethanol	(3	ml)	was	
dripped	 onto	 the	 cells	 in	 PBS	 while	 vortexing	 the	 tube.	 The	 cells	 were	 fixed	
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overnight	at	4	°C,	pelleted	at	800	g	for	5	minutes,	and	washed	twice	with	PBS.	The	
fixed	 cells	were	 stained	with	 1	ml	 of	 propidium	 iodide	 staining	 solution	 (3.8	mM	
sodium	citrate	and	40	μg/ml	propidium	iodide	in	PBS)	and	50	μl	10	μg/ml	RNAse	A	
for	 3	 hours	 at	 4	 °C.	 Stained	 samples	 were	 stored	 in	 the	 5	 ml	 polystyrene	 round	
bottom	tubes	in	the	dark	at	4	°C	until	all	samples	were	prepared	and	then	analyzed	
together.	
FLOW	CYTOMETRY	
Stained	 samples	were	 analyzed	 on	 a	BD	 LSRFortessa	 cell	 analyzer	 using	 the	 FITC	
setting	 (excitation	 488	 nm/emission	 515‐545	 nm)	 for	 samples	 stained	 with	
H2DCFDA	or	MitoTracker	Green	FM,	and	 the	PE‐Texas	Red	setting	 (excitation	488	
nm/emission	 600‐620	 nm)	 for	 samples	 stained	with	 propidium	 iodide.	 Live	 cells	
were	 gated	 according	 to	 the	 forward	 scatter	 and	 side	 scatter	 before	 analysis	 of	
fluorescence.		For	each	sample,	10,000	cells	were	analyzed.	The	median	values	from	
4‐6	biological	replicates	were	used	to	calculate	the	means	and	standard	deviations.	
RNA	EXTRACTION,	RT‐PCR,	AND	QPCR	
RNA	was	purified	from	uninduced	and	induced	AT1ABR	cells	using	the	RNeasy	Mini	
Kit	(Qiagen,	74104)	and	quantitated	on	a	NanoDrop	2000	(Thermo	Scientific).		RNA	
(1	μg)	was	reverse	transcribed	using	the	High‐Capacity	cDNA	Reverse	Transcription	
Kit	 (Applied	 Biosystems,	 4386614).	 qPCR	was	 performed	 on	 the	 ViiA7	 Real‐Time	
PCR	 System	 (Applied	 Biosystems)	 using	 Sybr	 Green	 PCR	 Master	 Mix	 (Life	
Technologies,	 4368814)	 as	 described	 in	 the	 protocol.	 Primer	 sequences	 for	
SLC7A11,	 PGC1α,	 and	 ACTB	 available	 upon	 request.	 Fold	 inductions	 and	 error	
estimates	were	obtained	using	REST	2009	[185].	
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VIRUS	PRODUCTION		
293T	 cells	 were	 plated	 in	 10	 cm	 dishes	 and	 allowed	 to	 grow	 to	 confluency.	 A	
solution	of	OptiMEM	and	plasmids	was	made	using	20	μg	pLX304	vector	containing	
the	gene	of	interest,	12	μg	pCMV‐dR8.91	(Delta	8.9),	and	8	μg	VSV‐G	and	brought	to	
500	 µl	 with	 OptiMEM.	 In	 another	 tube,	 60	 µl	 Lipofectamine	 2000	 (Invitrogen,	
11668‐027)	 was	 mixed	 440	 µl	 OptiMEM.	 The	 plasmid	 and	 Lipofectamine	 2000	
solutions	were	combined,	 incubated	 for	5	minutes	at	 room	temperature,	and	 then	
added	to	the	293T	cells.	The	media	was	changed	the	next	day	and	left	for	48	hours.	
The	media	was	harvested	48	hours	and	replaced	and	then	harvested	again	24	hours	
later.	The	media	with	virus	were	combined,	filtered	with	0.45	µm	filters,	aliquoted	in	
500	µl	aliquots,	and	stored	at	 ‐20	°C	 for	 transduction.	K69M‐CK2α'	was	generated	
using	 QuikChange	 XL	 site‐directed	 mutagenesis	 on	 the	 wild‐type	 pLX304‐CK2α'	
with	the	primers	TP4209	and	TP4210	(sequences	available	upon	request)	using	the	
unmodified	protocol.	
VIRUS	TRANSDUCTION	
293T	or	U2OS	cells	were	plated	in	24‐well	plates	and	allowed	to	reach	confluency.	
The	media	was	 removed	and	replaced	with	500	µl	of	 the	viral	aliquots.	Polybrene	
(EMD	 Millipore,	 TR‐1003‐G)	 was	 added	 at	 a	 final	 concentration	 of	 10	 μg/ml	 to	
increase	 viral	 transduction.	 The	 cells	 were	 grown	 overnight	 and	 the	 media	 was	
replaced	 the	 next	 day.	 The	 following	 day	 selection	 agent	 was	 added,	 for	 pLX304	
plasmids	 cells	 were	 treated	 with	 10	 μg/ml	 blasticidin	 (InvivoGen,	 ant‐bl‐1),	 and	
cells	 were	 allowed	 to	 grow	 for	 approximately	 one	 week	 until	 the	 control	
untransduced	cells	had	died.	The	stable	cell	lines	were	checked	for	expression	of	V5‐
tagged	protein	and	used	in	subsequent	assays.	
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V5	IMMUNOPRECIPITATION	AND	WESTERN	BLOTTING	
293T	 cells	 stably	 expressing	 V5‐tagged	 CK2	were	 lysed	with	 1X	 Cell	 Lysis	 Buffer	
(Cell	 Signaling	 Technology,	 9803)	 according	 to	 the	 protocol.	 Protein	 quantitation	
was	 performed	 by	 Bradford	 assay	 with	 Coomassie	 Plus	 Protein	 Assay	 Reagent	
(Pierce,	23236).	For	each	immunoprecipitation,	2.5	μg	lysate	was	combined	with	4	
µl	mouse	anti‐V5	magnetic	beads	(Medical	and	Biological	Laboratories,	M167‐9)	and	
brought	to	a	final	volume	of	50	µl	with	1X	Cell	Lysis	Buffer.	Tubes	were	rotated	for	
30	minutes	at	4	 °C	and	 then	spun	briefly.	A	magnetic	 stand	was	used	 to	wash	 the	
beads	3	times	with	500	µl	1X	Cell	Lysis	Buffer.	Beads	were	immediately	used	for	the	
CK2	kinase	reaction.	
IN	VITRO	CK2	KINASE	REACTION	
CK2	kinase	assays	were	performed	with	either	1	μl	CK2	 (NEB,	P6010L)	or	on	 the	
beads	 of	 immunoprecipitated	 CK2.	 The	 reactions	 were	 performed	 with	 1X	 CK2	
Reaction	 Buffer	 (NEB)	 (20	 mM	 Tris‐HCl,	 pH	 7.5,	 50	 mM	 KCl,	 10	 mM	 MgCl2)	
supplemented	with	1	mM	ATP,	1	μl	ATP‐γ‐32P	(NEN	Radiochemicals,	BLU002H),	and	
75,	575,	or	1150	ng	GST‐CK2	substrate.	The	reaction	was	incubated	for	1	hour	at	30	
°C	 and	 then	 stopped	with	 6	 μl	 5X	 SDS	 loading	 buffer.	 Proteins	were	 run	 on	 SDS‐
PAGE	 gels	 and	 transferred	 to	 PVDF	membrane	 following	 standard	 protocols.	 V5‐
tagged	CK2	levels	were	probed	using	rabbit	anti‐V5	(Novus	Biologicals,	NB600‐381)	
and	 Alexa	 Fluor	 680	 goat	 anti‐rabbit	 (Invitrogen,	 A21076)	 and	 scanned	 and	
quantitated	 on	 the	 Li‐Cor	Odyssey	 system.	 Then	 the	membrane	was	 exposed	 to	 a	
PhosphorImager	 screen	 for	 at	 least	 16	 hours.	 The	 screen	 was	 scanned	 using	
Typhoon	 Imager	 to	 obtain	 32P	 incorporation.	 For	 the	 time	 course,	
immunoprecipitated	CK2β‐V5	was	split	into	5	tubes	and	the	reaction	was	stopped	at	
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the	 times	 shown.	 Quantitation	 was	 performed	 using	 GelQuant	 and	 normalized	 to	
protein	 levels	 quantified	 through	 western	 blots.	 Multiple	 experiments	 were	
performed	for	each	reaction	and	representative	results	are	shown.	
SUCROSE	GRADIENT	
Cell	lysates	were	made	in	the	presence	or	absence	of	detergent.	For	detergent	lysis,	
1X	 Cell	 Lysis	 Buffer	 (Cell	 Signaling	 Technology,	 9803)	was	 used	 according	 to	 the	
protocol.	 The	 lysis	without	detergent	was	performed	with	25	mM	Tris,	 pH	8,	 100	
mM	NaCl,	and	10%	glycerol	supplemented	immediately	before	use	with	1	mM	DTT,	
1	mM	PMSF,	1	mM	sodium	orthovanadate,	1	mM	β‐glycerophosphate,	and	2.5	mM	
sodium	pyrophosphate.	Lysis	was	performed	by	douncing	50	times	on	ice.	For	both	
methods,	 the	 protein	 concentration	 was	 quantitated	 by	 Bradford	 assay	 with	
Coomassie	Plus	Protein	Assay	Reagent	(Pierce,	23236).	The	different	concentrations	
of	 sucrose	 were	 made	 in	 20	 mM	 Tris,	 pH	 7.4	 and	 150	 mM	 NaCl	 and	 layered	 in	
ThinWall	Ultra‐Clear	 Tubes	 (Beckman‐Coulter,	 344059)	 using	 gravity	 flow	 from	 a	
pipet	bulb.	The	sucrose	percentages	 from	the	bottom	were	50%,	45%,	40%,	35%,	
30%,	25%,	20%,	15%,	10%,	and	5%	(W/V)	and	each	layer	was	1	ml.	Between	10	μg	
and	2	mg	of	lysate	in	500	µl	of	the	appropriate	cell	lysis	buffer	was	added	to	the	top	
of	 the	 sucrose	 gradient	 and	 then	 spun	 for	 16	 hours	 at	 4	 °C	 and	 180,000	 g	 in	 a	
swinging	 bucket	 SW	 41	 Ti	 rotor	 (Beckman‐Coulter,	 331362).	 Fractions	 of	 500	 µl	
were	 collected	 by	 pipet.	 Western	 blots	 were	 performed	 with	 16	 or	 120	 µl	 each	
fraction	 combined	with	 4	 or	 30	 µl	 5X	 SDS	 and	 loading	 controls	 of	 2.5	 or	 100	 μg	
lysates	were	run	on	each	blot.	The	blots	were	probed	as	before	and	the	percentage	
of	probed	protein	was	quantitated	using	the	Li‐Cor	Odyssey	system.		
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An	identical	sucrose	gradient	was	performed	with	molecular	weight	markers	
to	determine	the	fractions	corresponding	to	different	size	complexes.	The	fractions	
were	 run	 on	 a	 NuPage	 4‐12%	 Bis‐Tris	 Gel	 (Invitrogen,	 NP0336BOX)	 and	 the	
colloidal	 Coomassie‐stained	 gels.	 Aldolase	 (40	 kDa	monomer)	 appeared	mostly	 in	
fractions	6	and	7.	Catalase	(60	kDa	monomer,	240	kDa	tetramer)	ran	in	fractions	8‐
10.	 Ferritin	 (21	 kDa	 monomer,	 500	 kDa	 24‐mer)	 and	 thyroglobulin	 (330	 kDa	
monomer,	660	kDa	dimer)	showed	up	in	the	sucrose	gradient	starting	in	fraction	12.	
However,	 some	 amount	 of	 ferritin	 and	 thyroglobulin	 are	 present	 through	 the	 last	
fraction	suggesting	there	are	larger	complexes	or	aggregates	in	the	sucrose	gradient.	
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CHAPTER	3:	ATP‐DEPENDENT	CONFORMATIONAL	CHANGES	IN	
RAD50	CONTROL	ATM	ACTIVATION	
This	research	was	originally	published	 in	 Journal	of	Biological	Chemistry.	Lee	
JH,	 Mand	 MR,	 Deshpande	 RA,	 Kinoshita	 E,	 Yang	 SH,	 Wyman	 C,	 Paull	 TT.	 Ataxia	
Telangiectasia‐Mutated	 (ATM)	 Kinase	 Activity	 Is	 Regulated	 by	 ATP‐driven	
Conformational	 Changes	 in	 the	 Mre11/Rad50/Nbs1	 (MRN)	 Complex.	 Journal	 of	
Biological	 Chemistry.	 2013;	 288:12840‐12851.	 ©	 the	 American	 Society	 for	
Biochemistry	and	Molecular	Biology.	
ABSTRACT	
The	 Ataxia	 Telangiectasia‐Mutated	 (ATM)	 protein	 kinase	 is	 recruited	 to	 sites	 of	
double‐strand	DNA	breaks	by	the	Mre11/Rad50/Nbs1	(MRN)	complex,	which	also	
facilitates	ATM	monomerization	and	activation.	MRN	exists	 in	at	 least	 two	distinct	
conformational	 states,	 dependent	 on	 ATP	 binding	 and	 hydrolysis	 by	 the	 Rad50	
protein.	Here	we	use	an	ATP	analog‐sensitive	 form	of	ATM	to	determine	 that	ATP	
binding,	 but	 not	 hydrolysis,	 by	 Rad50	 is	 essential	 for	 MRN	 stimulation	 of	 ATM.	
These	results	show	that	the	ATP‐bound	form	of	MRN	is	the	critical	conformation	for	
ATM	activation.	
INTRODUCTION	
The	 ATM	 protein	 kinase	 plays	 a	 central	 role	 in	 signaling	 the	 presence	 of	 DNA	
double‐strand	 breaks	 (DSBs)	 in	 eukaryotic	 cells.	 Activation	 of	 ATM	 occurs	 very	
rapidly,	within	a	few	minutes	of	DNA	break	incidence	[8],	and	is	dependent	on	the	
Mre11/Rad50/Nbs1	 (MRN)	 complex	 for	 its	 recruitment	 to	 sites	 of	 DNA	 damage	
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[74].	 MRN	 also	 functions	 to	 promote	 a	 transition	 in	 ATM	 conformation	 from	 an	
inactive	 dimeric	 form	 to	 an	 active	monomeric	 form,	 and	 increases	 the	 affinity	 of	
ATM	for	its	substrates	[34].	
The	MRN	complex	is	a	large,	multifunctional	protein	assembly	that	possesses	
endo‐	and	exonucleolytic	activity	 through	the	Mre11	component	and	ATP	binding,	
hydrolysis,	 and	 adenylate	 kinase	 activity	 through	 the	 Rad50	 component.	
Mre11/Rad50	 (MR)	 complexes	 in	 prokaryotes	 and	MRN	 complexes	 in	 eukaryotes	
are	 important	 for	 DNA	 double‐strand	 break	 recognition	 and	 repair	 [83].	 The	
eukaryotic	 forms	 are	 also	 essential	 for	 meiotic	 DSB	 processing	 and	 telomere	
maintenance,	 as	well	 as	 for	 signaling	 through	 the	ATM	kinase	 [63].	 Rad50	has	 an	
overall	domain	organization	that	 is	similar	to	the	family	of	Structural	Maintenance	
of	 Chromosomes	 (SMC)	 proteins	 which	 regulate	 chromatid	 cohesion	 and	
chromosome	 condensation.	 The	Walker	 A	 and	Walker	 B	 ATP‐binding	 domains	 in	
each	 Rad50	 protein	 associate	 together	 through	 an	 antiparallel	 association	 of	 the	
coiled‐coil	domains	(Figure	3.1).	Each	Rad50	protein	binds	to	another	through	ATP‐
dependent	 association	 of	 the	 Walker	 A/B	 domains	 into	 a	 homodimer,	 and	 also	
through	another	association	at	the	apex	of	the	coiled‐coils	at	the	zinc	hook	domain.	
In	addition,	a	dimer	of	Mre11	also	links	the	ATP‐binding	domains	of	Rad50	through	
an	association	at	the	base	of	the	coiled‐coils.	
Recent	 structural	 analysis	 of	 Mre11/Rad50	 proteins	 from	 bacteria	 and	
archaea	showed	that	the	ATP‐binding	domains	of	Rad50	bound	to	Mre11	are	in	an	
open	configuration	in	the	absence	of	ATP	[85].	 In	contrast,	 the	ATP‐bound	form	of	
the	complex	is	a	closed	configuration	with	the	Mre11	nuclease	domains	in	a	dimer	
underneath	 the	 Rad50	 head	 domains	 [65,	 66].	 These	 results	 suggest	 that	
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Mre11/Rad50	complexes	are	in	a	dramatically	different	conformation	when	bound	
to	ATP	compared	with	the	nucleotide‐free	conformation	(Figure	3.1).	
	
	
	
Figure	3.1	Schematic	model	of	MRN	in	the	absence	(open)	or	presence	of	ATP	(closed).		
Rad50	is	shown	as	light	gray	globular	domains	containing	Walker	A	(A)	and	Walker	
B	(B)	motifs	connected	by	intramolecular,	antiparallel	coiled‐coils	(CC),	that	attach	
to	 each	 other	 through	 the	 zinc	 hook	 motifs	 (Zn	 hook).	 Stars	 indicate	 the	
approximate	 positions	 of	 the	 ATP‐binding	 residues	 in	 Rad50.	 Mre11	 is	 shown	 as	
dark	gray	globular	domains	representing	the	nuclease/dimerization	domain	and	the	
capping	domain,	connected	to	the	linker	that	binds	to	the	coiled‐coils	of	Rad50.	The	
closed	 state	 is	 associated	 with	 a	 higher	 affinity	 for	 DNA	 ends	 and	 with	 DNA	
tethering,	 while	 the	 movement	 from	 the	 closed	 to	 the	 open	 state	 is	 required	 for	
Mre11	 nuclease	 activity	 and	 promotion	 of	 resection.	 The	 zinc	 hook	 is	 shown	
attached	here,	but	the	complex	has	also	been	observed	with	hooks	unattached,	both	
in	solution	and	bound	to	DNA.	This	research	was	originally	published	in	in	Journal	of	
Biological	 Chemistry.	 Lee	 JH,	 Mand	 MR,	 Deshpande	 RA,	 Kinoshita	 E,	 Yang	 SH,	
Wyman	 C,	 Paull	 TT.	 Ataxia	 Telangiectasia‐Mutated	 (ATM)	 Kinase	 Activity	 Is	
Regulated	 by	 ATP‐driven	 Conformational	 Changes	 in	 the	 Mre11/Rad50/Nbs1	
(MRN)	 Complex.	 Journal	 of	 Biological	 Chemistry.	 2013;	 288:12840‐12851.	 ©	 the	
American	Society	for	Biochemistry	and	Molecular	Biology.	
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To	better	 understand	how	 these	 dynamic,	 ATP‐driven	 changes	 in	 the	MRN	
complex	 affect	 the	 regulation	 of	 ATM	 kinase	 activity,	 I	 employ	 here	 an	 analog‐
sensitive	version	of	ATM	to	separate	the	nucleotide	pools	used	by	the	kinase	and	by	
MRN.	These	experiments	show	that	the	“closed,”	ATP‐bound	state	of	MRN,	but	not	
ATP	hydrolysis,	is	essential	for	ATM	stimulation,	thus	explaining	why	it	is	important	
that	MRN	complexes	have	a	slow	rate	of	hydrolysis	for	signaling.	
RESULTS	
Both	the	MRN	and	ATM	complexes	utilize	ATP,	which	cannot	be	removed	from	an	in	
vitro	kinase	assay	since	the	activity	of	ATM	can	only	be	assessed	by	monitoring	ATP‐
dependent	phosphorylation.	To	specifically	manipulate	the	nucleotide	pool	used	by	
ATM,	 I	 generated	 a	mutant	 form	 of	 the	 kinase	which	 allows	 the	 utilization	 of	N6‐
substituted‐ATP	 analogs	 by	 generating	 a	 cavity	 within	 the	 ATP‐binding	 pocket	
(Figure	3.2)	[186].	Mutation	of	tyrosine	2755	in	the	ATP‐binding	pocket	of	ATM	was	
previously	shown	to	allow	the	kinase	to	accept	N6‐modified	ATP	analogs	[187].	
The	Y2755A	mutant	form	of	ATM	was	expressed	and	purified	as	previously	
described	[177]	(Figure	3.3),	and	tested	in	vitro	in	a	kinase	assay	(Figure	3.4A).	In	
this	 experiment,	 hydrogen	 peroxide	 was	 used	 to	 activate	 ATM	 [5],	 to	 assess	 the	
ability	of	ATM	to	utilize	ATP	analogs	in	the	absence	of	the	MRN	complex.	As	shown	
previously,	N6‐(1‐methylbutyl)‐ATP	was	utilized	by	the	Y2755A‐ATM,	and	was	not	
utilized	by	the	wild‐type	enzyme	(Figure	3.4A),	as	measured	by	phosphorylation	of	
a	GST‐p53	 substrate	 and	phospho‐specific	p53	antibody	 in	 a	quantitative	western	
blot	as	described	previously	[34].	However,	further	experiments	showed	that	N6‐(1‐	
methylbutyl)‐ATP	inhibited	the	activation	of	wild‐type	ATM	by	MRN/DNA,	even	in	
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Figure	3.2	Structure	of	PI3Kγ	and	mutations	in	the	ATP	binding	pocket.	
(A)	 Structure	 of	 the	 Phosphatidylinositol	 3‐Kinase	 gamma	 subunit	 (PI3Kγ):	 ATP	
binding	pocket,	 green;	 Y867	 (ATM	Y2755),	 red;	ATP,	 yellow;	 remaining	 structure,	
blue.	(B)	The	surfaces	view	of	the	ATP	binding	pocket	of	Y867A‐PI3Kγ.	(C)	Structure	
of	N6‐1‐methylbutyl‐ATP	(1)	and	N6‐furfuryl‐ATP	(2).	
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Figure	3.3	Recombinant	ATM	and	MRN	protein	complexes.	
(A)	 SDS‐PAGE	 of	 purified	 recombinant	 wild‐type‐	 and	 Y2755A‐ATM.	 *	 indicates	
position	 of	 Hsp70	 protein	 that	 copurifies	 with	 ATM	 (B)	 SDS‐PAGE	 of	 purified	
recombinant	MRN	complex	with	 individual	components	 labeled.	Gels	were	stained	
by	coomassie	blue	and	the	size	(kDa)	of	the	protein	standards	are	shown	to	the	left.	
	
	
the	presence	of	ATP	 (Figure	3.4B).	This	effect	was	specific	 to	 reactions	containing	
MRN,	so	we	conclude	that	N6‐(1‐methylbutyl)‐ATP	is	toxic	to	MRN	function.	We	also	
found	 that	 several	 other	 N6‐modified	 ATP	 analogs	 were	 similarly	 toxic,	 with	 the	
exception	of	N6‐(furfuryl)‐ATP.	This	nucleotide	was	utilized	by	Y2755A‐ATM	but	not	
by	wild‐type	ATM	when	activated	by	oxidation	(Figure	3.4A)	and	also	does	not	
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Figure	3.4	Usage	of	N6‐substituted	ATP	analogs	in	ATM	kinase	assays.		
(A)	Kinase	assays	were	performed	with	wild‐type	or	Y2755A‐ATM	and	either	ATP	
or	the	ATP	analogs	N6(1‐methylbutyl)‐ATP	or	N6(1‐furfuryl)‐ATP	as	indicated,	using	
2.7	mM	H2O2	to	activate	ATM	in	the	absence	of	MRN.	Recombinant	GST‐p53(1–100)	
was	 used	 as	 the	 substrate,	 and	 phosphorylation	 of	 p53	 Ser‐15	 was	 assessed	 by	
Western	blotting	and	a	phospho‐specific	antibody	directed	against	Ser‐15.	(B)	MRN	
and	DNA	were	 used	 to	 activate	wild‐type	 ATM	 in	 the	 presence	 of	 ATP	 and	N6(1‐
methylbutyl)‐ATP	 as	 indicated.	 Kinase	 activity	 was	 assessed	 as	 in	 A.	 (C)	 Kinase	
assays	were	performed	as	in	B	except	with	N6(1‐furfuryl)‐ATP	as	indicated.		
	
prevent	 MRN/DNA	 activation	 of	 wild‐type	 ATM	 in	 the	 presence	 of	 ATP	 (Figure	
3.4C).	
The	 Y2755A	 mutant	 ATM	 protein	 was	 tested	 in	 an	 MRN/DNA‐dependent	
assay,	 and	 was	 found	 to	 be	 unable	 to	 phosphorylate	 p53	 in	 the	 presence	 of	 N6‐
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(furfuryl)‐ATP	alone,	demonstrating	that	MRN	requires	ATP	to	activate	ATM	(Figure	
3.5A).	 The	 Y2755A	 mutant	 also	 shows	 some	 DNA‐independent	 activation	 that	 is	
only	observed	with	ATP,	not	with	the	N6‐(furfuryl)‐ATP	analog.	To	determine	if	ATP	
hydrolysis	is	required	by	MRN,	the	same	reaction	was	performed	in	the	presence	of	
the	 nonhydrolyzable	 ATP	 analog	 AMP‐PNP	 (Figure	 3.5B).	 Notably,	 Y2755A	 ATM	
phosphorylated	p53	in	the	presence	of	MRN/DNA,	N6‐(furfuryl)‐ATP,	and	AMP‐PNP	
while	 wild‐type	 ATM	 was	 inactive	 under	 these	 conditions.	 Taken	 together,	 these	
results	show	that	MRN	requires	ATP	 for	ATM	activation	but	 that	hydrolysis	 is	not	
essential.	
DISCUSSION	
Here	we	have	 investigated	 the	 enzymatic	 functions	 of	 the	MRN	 complex	 and	how	
these	affect	ATM	kinase	activity.	Clearly	 the	MRN	complex	plays	a	very	 important	
role	in	ATM	function,	particularly	considering	the	similarity	in	clinical	phenotypes	of	
patients	lacking	ATM	(A‐T)	compared	with	patients	expressing	hypomorphic	alleles	
of	MRE11	 or	 RAD50	 (A‐T‐like	 Disorder)	 or	Nbs1	 (Nijmegen	 Breakage	 Syndrome)	
[63].	 In	 addition,	 numerous	 studies	 using	 cell	 lines,	 extracts,	 and	 also	 purified	
systems	have	shown	the	importance	of	MRN	for	the	activation	of	ATM	by	DNA	DSBs	
[34,	74,	75,	188,	189].	MRN	has	several	distinct	activities,	however,	not	all	of	which	
are	essential	for	the	activation	of	ATM.	
Using	 separate	pools	of	ATP	 for	ATM	and	MRN	we	show	 that	ATP	binding,	
but	not	hydrolysis,	is	essential	for	ATM	activation	via	MRN.	This	suggests	that	MRN	
is	in	the	“closed”	configuration	when	bound	to	ATM	on	DNA	(Figure	3.1).	This	form	
of	MRN	is	long‐lived	since	the	rate	of	ATP	hydrolysis	by	Rad50	is	slow,	and	is	also	
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Figure	3.5.	MRN	stimulation	of	ATM	activity	requires	ATP	binding	but	not	hydrolysis.		
(A)	Wild‐type	or	Y2755A‐ATM	was	activated	by	DNA	and	MRN	 in	 the	presence	of	
either	 ATP	 or	 N6(1‐furfuryl)‐ATP	 as	 indicated.	 (B)	 Wild‐type	 or	 Y2755A‐ATM	
activated	by	DNA	and	MRN	with	either	ATP	or	N6(1‐furfuryl)‐ATP	in	the	presence	or	
absence	of	the	non‐hydrolyzable	ATP	analog	AMP‐PNP.	
	
the	 form	 of	 MRN	 that	 functions	 in	 DNA	 end	 tethering	 [63]	 Thus	 many	 of	 the	
important	 functions	 of	 the	 MRN	 complex	 take	 place	 with	 ATP	 bound	 but	 not	
hydrolyzed,	 consistent	 with	 the	 idea	 of	 ATP	 as	 a	 switch	 for	 Mre11/Rad50	
conformation	rather	than	an	energy	source	for	mechanical	work.	
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During	 the	 course	 of	 these	 experiments	 we	 found	 that	 MRN	 function	 is	
strongly	inhibited	by	ATP	analogs	containing	modifications	at	the	N6	position	of	the	
adenine	 base.	 This	 could	 be	 because	 the	 nitrogen	 at	 the	 N6	 position	 is	 the	 only	
solvent‐exposed	 part	 of	 the	 adenine	 base	 in	 the	 Rad50	 ATP‐bound	 conformation	
[190],	so	most	of	these	analogs	would	have	room	to	bind	in	the	ATP‐binding	pocket.	
The	N6‐(furfuryl)‐ATP	compound	was	the	only	available	N6‐modified	analog	that	did	
not	show	this	toxicity.	
Recent	 studies	 with	 the	 P.	 furiosus	 MR	 enzyme	 suggest	 that	 the	 nuclease	
activity	of	Mre11	 is	 triggered	by	the	change	 in	conformation	that	occurs	 following	
ATP	 hydrolysis,	 from	 the	 “closed”	 back	 to	 the	 “open”	 state	 (Figure	 3.1)	 [62].	 The	
enzyme	 in	 the	 closed	 state	 does	 not	 exhibit	 nuclease	 activity,	 consistent	with	 our	
observation	in	this	study	that	Mre11	nuclease	activity	is	also	not	required	for	ATM	
activation.	 Analysis	 of	 a	 knock‐in	 allele	 of	 the	 Mre11(H129N)	 nuclease‐deficient	
mutant	in	the	mouse	also	indicated	that	nuclease	activity	of	Mre11	was	not	required	
for	 ATM	 signaling,	 although	 there	 are	 clearly	 essential	 functions	 of	 the	 nuclease	
during	development	since	the	mouse	showed	early	embryonic	lethality	[191].	
The	rate	of	ATP	hydrolysis	by	Rad50	is	very	slow	relative	to	other	enzymes	
(∼0.1	 molecules	 of	 ATP/minute)	 [174,	 192].	 Functionally,	 the	 reason	 for	 this	
appears	to	be	that	many	of	the	activities	of	MRN	(DNA	end	binding,	DNA	tethering,	
and	ATM	activation)	occur	when	MRN	is	in	the	closed	state	in	which	ATP	is	bound	
but	not	hydrolyzed.	
Schematic	models	of	MRN	function	often	portray	Rad50	linking	two	broken	
DNA	molecules,	with	 the	 catalytic	 heads	 domains	 from	 one	monomer	 bound	 to	 a	
distal	 site	 rather	 than	 associating	 with	 catalytic	 heads	 that	 are	 connected	 to	 it	
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through	the	zinc	hook.	While	it	is	difficult	to	discern	the	conformation	of	structures	
within	the	tethered	complexes	we	have	observed	by	SFM,	our	data	suggest	that	MRN	
would	 be	much	more	 likely	 to	 form	 catalytic	 domain	 interactions	within	 a	 single	
dimeric	 unit	 (as	 depicted	 in	 Figure	 3.1),	 particularly	 in	 the	 presence	 of	 ATP	 as	
illustrated	previously	[63,	197,	198].	Association	between	head	domains	of	a	Rad50	
dimer	 is	 also	 driven	 by	 Mre11	 dimerization	 [85,	 199].	 While	 it	 remains	 to	 be	
determined	 how	 ATP	 hydrolysis	 by	 Rad50	 is	 regulated	 within	 cells,	 the	 physical	
characteristics	of	the	protein	support	a	model	in	which	multimeric	interactions	are	
built	upon	the	unit	of	a	Rad50	dimer	with	the	monomers	associating	within	this	unit	
at	both	the	catalytic	domains	as	well	as	the	zinc	hook	and	Mre11‐binding	interfaces.	
In	 summary,	 our	 results	 show	 that	 the	 closed	 conformation	 of	 the	 human	
MRN	complex	is	critical	for	the	activation	of	the	ATM	kinase	and	that	the	structural	
components	of	the	Rad50	protein	that	are	important	for	this	conformation	are	also	
important	 for	 the	 activation	 process.	 Other	 functions	 of	 MRN,	 including	 the	
stimulation	of	DNA	end	resection,	are	promoted	by	the	conformational	change	from	
the	closed	to	the	open	state	that	occurs	during	ATP	hydrolysis	but	are	not	required	
for	ATM	activation.	Thus	 there	 is	a	 temporal	sequence	of	DNA	end	tethering/ATM	
activation	followed	by	DNA	end	resection	that	is	orchestrated	by	MRN	binding	and	
hydrolysis	of	ATP.	
	 	
 
 
55
CHAPTER	4:	PROTEOMIC	AND	PHOSPHOPROTEOMIC	ANALYSIS	OF	
ATM	SEPARATION‐OF‐FUNCTION	MUTATIONS	
ATM	 is	 activated	 by	 both	 DNA	 double‐strand	 breaks	 (DSBs)	 and	 oxidative	
stress	 to	 initiate	 a	 robust	 signaling	 cascade	 [26].	 Previous	 studies	 have	 looked	 at	
changes	in	the	phosphoproteome	after	DNA	damage	using	ionizing	radiation	(IR)	or	
radiomimetic	drugs	[10‐12,	107,	173].	As	these	treatments	may	generate	both	DSBs	
and	oxidative	 stress,	 it	 is	 not	 possible	 to	 examine	 the	 effects	 of	ATM	activated	by	
only	 one	 of	 these	 cellular	 stressors.	 Notably,	 separation‐of‐function	 mutations	 in	
ATM	have	been	identified	that	allow	the	activation	of	ATM	by	only	one	mechanism	
[5]	 (JH	Lee,	unpublished	observations).	Expression	of	 these	constructs	 in	A‐T	cells	
lacking	functional	ATM	will	show	which	cellular	processes	ATM	is	important	for	in	
the	absence	of	exogenous	stress.	
The	 separation‐of‐function	 mutations	 in	 ATM	 prevent	 activation	 by	 either	
oxidative	stress	or	DSBs	in	vitro.	Guo	et	al.	identified	a	cysteine	(C2991)	in	the	PIKK	
regulatory	domain	that	was	required	for	activation	by	oxidative	stress	[5].	Mutation	
of	 this	 cysteine	 to	 leucine	 (C2991L‐ATM)	 abolished	 in	 vitro	 activation	 of	 ATM	 by	
oxidative	 stress	 but	 not	 DSBs	 	 (Figure	 4.1A)	 [5].	 The	 separation‐of‐function	
mutation	 that	 prevents	ATM	activation	 by	DSBs	was	 found	 by	 comparison	with	 a	
method	of	mTOR	activation.	Fang	et	al.	identified	in	mTOR	a	key	arginine	residue	N‐
terminal	 of	 the	 kinase	 domain	 that	 was	 important	 for	 mTOR	 activation	 by	
phosphatidic	acid	[200].	This	arginine	was	in	a	double	arginine	motif	that	was	also	
present	 in	ATM	a	 similar	 distance	 from	 conserved	 residues	 in	 the	kinase	domain.	
Mutation	 of	 both	 of	 these	 arginines	 to	 alanine	 in	 ATM	 (R2579A/R2580A‐ATM)	
prevents	activation	by	MRN	and	DNA	in	vitro	(Figure	4.1B)		
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Figure	 4.1	 Mutations	 in	 ATM	 cause	 differential	 activation	 by	 DNA	 double	 strand	
breaks	and	reactive	oxygen	species	in	vitro.		
(A)	In	vitro	kinase	ATM	kinase	activity	performed	with	0.2	nM	recombinant	purified	
wild‐type‐ATM	or	C2991L‐ATM	proteins	in	the	presence	of	3.6	nM	MRN	and	10	ng	
DNA	or	a	titration	of	H2O2	(0.27	and	0.81	mM	for	wild‐type‐ATM	and	0.27,	0.81,	and	
2.7	mM	H2O2	 for	C2991L‐ATM).	Kinase	activity	was	measured	by	western	blot	 for	
phospho‐p53.	 From	 “ATM	 Activation	 by	 Oxidative	 Stress”	 (Guo,	 Kozlov,	 Lavin,	
Person,	&	Paull,	 2010).	Reprinted	with	permission	 from	AAAS.	 (B)	 In	 vitro	 kinase	
assay	 performed	 as	 in	 (A)	 with	 wild‐type‐ATM	 or	 R2579A/R2580A‐ATM.	 (C)	 In	
vitro	 kinase	 assay	 performed	 as	 in	 (A)	 with	 wild‐type‐ATM	 or	 R2579A/R2580A‐
ATM	and	a	titration	of	H2O2	(0.27,	0.81,	and	2.7	mM	H2O2).	(D)	In	vitro	kinase	assay	
performed	as	 in	(A)	with	wild‐type‐ATM	or	R2579A/R2580A/C2991L‐ATM.	(E)	 In	
vitro	 kinase	 assay	 performed	 as	 in	 (A)	 with	 wild‐type‐ATM	 or	
R2579A/R2580A/C2991L‐ATM	and	2.7	mM	H2O2.	Figures	(B)	–	(E)	were	provided	
by	JH	Lee.	
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but	allows	normal	activation	by	oxidative	stress	(Figures	4.1C)	(JH	Lee,	unpublished	
observations).	 Purified	 ATM	 combining	 all	 three	 separation‐of‐function	mutations	
(R2579A/R2580A/C2991L‐ATM)	 lacked	 in	 vitro	 activity	 in	 the	 presence	 of	
oxidative	stress	or	DSBs	(Figures	4.1D	and	E).	The	various	ATM	constructs	and	their	
effects	on	ATM	activation	are	shown	in	Figure	4.2.	
	
	
		
Figure	 4.2	 Diagrams	 of	 the	 ATM	 separation‐of‐function	 mutations	 that	 prevent	
activation	by	DSBs	or	ROS.		
The	colors	represent	domains	in	ATM:	blue,	HEAT	repeats	(residues	1‐1965);	green,	
FAT	 domain	 (residues	 1966‐2566);	 red,	 PI3K‐like	 kinase	 domain	 (residues	 2614‐
2960);	orange,	PIKK	regulatory	domain	(residues	2961‐3024);	purple,	FATC	domain	
(residues	3025‐3056).	
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To	 analyze	 the	 effects	 of	 re‐expressing	 these	 different	 ATM	 constructs,	 I	
compared	 the	 proteomes	 and	 phosphoproteomes	 of	 six	 cell	 lines.	 Two	 main	 cell	
lines	 were	 used,	 GM07544	 and	 AT1ABR.	 Both	 cell	 lines	 are	 derived	 from	
lymphoblasts	 that	 have	 been	 transformed	 with	 Epstein	 Barr	 virus.	 However,	
GM07544	cells	are	from	a	healthy	individual	while	AT1ABR	cells	are	from	a	patient	
with	ataxia	telangiectasia.	The	AT1ABR	cells	have	a	9	base	pair	deletion	in	the	ATM	
gene	 corresponding	 to	 amino	 acids	 2546‐2548	 that	 abrogates	 kinase	 activity	 and	
destabilizes	 the	protein.	The	AT1ABR	cells	were	also	used	as	 the	parental	cell	 line	
for	 generating	 stable	 cells	 containing	 the	 four	 ATM	 constructs	 [17,	 178].	 ATM	
expression	in	these	cells	is	under	the	control	of	the	pMATII	promoter	and	inducibly	
expressed	with	the	addition	of	low	amounts	of	CdCl2.	
All	 the	 cell	 lines	 were	 exposed	 to	 2	 μM	 CdCl2	 for	 16	 hours	 for	 protein	
induction	 and	 harvested.	 The	 cell	 pellets	 were	 lysed	 and	 total	 protein	 was	
quantitated.	 The	 lysates	 were	 digested	 with	 trypsin	 and	 Lys‐C	 and	 the	 peptides	
were	labeled	with	Tandem	Mass	Tags	(TMT).	After	combining	the	tagged	peptides,	
the	 samples	 were	 fractionated	 by	 strong	 cation	 exchange	 with	 or	 without	
phosphopeptide	 enrichment	 by	 immobilized	 metal	 affinity	 chromatography.	 The	
resulting	samples	were	analyzed	by	quantitative	LC‐MS/MS	(Figure	4.3).	
THE	PROTEOME	IS	ALTERED	IN	THE	PRESENCE	OF	MUTANT	ATM	
The	 levels	of	ATM	protein	were	compared	by	western	blot	 in	cells	 treated	with	or	
without	2	μM	CdCl2	(Figure	4.4A).	Uninduced	AT1ABR	cells	all	showed	low	levels	of	
ATM.	There	was	a	visible	induction	of	ATM	in	the	AT1ABR	cell	 lines	with	the	ATM	
constructs	while	the	parental	cell	line	showed	no	change	in	the	presence	of	CdCl2.	
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Figure	4.3	Flowchart	of	sample	preparation	and	mass	spectrometry.	
The	ATM	constructs	are	abbreviated	as	follows:	wt:	wild‐type;	CL:	C2991L;	RA/RA:	
R2579A/R2580A,	RA/RA/CL:	R2579A/R2580A/C2991L.	
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AT1ABR	 cells	 expressing	wild‐type	 ATM	 had	 the	 highest	 amount	 of	 ATM	 and	 the	
three	 cell	 lines	 expressing	 ATM	with	 the	 various	mutations	 had	 lower	 levels	 but	
were	similar	when	compared	between	the	mutant	cell	 lines.	As	expected,	 the	ATM	
protein	level	in	the	normal	lymphoblast	cell	line	GM07544	was	unaffected	by	CdCl2	
treatment.	The	amount	of	ATM	protein	in	each	cell	line	was	also	calculated	using	the	
TMT	 tags	 in	 the	 quantitative	 LC/MS‐MS	 (Figure	 4.4B).	 In	 contrast	 to	 the	western	
blot	results,	GM07544	had	ATM	levels	similar	to	the	AT1ABR	cell	line.	However,	the	
AT1ABR	 cells	 that	 inducibly	 express	 ATM	 all	 had	 higher	 levels	 of	 ATM.	 The	
differences	between	 the	western	blot	 and	LC/MS‐MS	quantitation	could	be	due	 to	
ATM	fragments	that	do	not	appear	on	the	western	blot	but	would	be	digested	and	
quantitated	during	LC‐MS/MS.	
There	were	4,368	proteins	identified	in	the	different	cell	lines	although	52	of	
these	were	not	seen	in	the	AT1ABR	cells	expressing	C2991L‐ATM.	The	raw	intensity	
of	 each	protein	was	normalized	 to	 the	 raw	 intensity	 in	AT1ABR.	To	 get	 a	 general	
look	at	what	was	happening	in	the	proteome,	hierarchical	clustering	was	performed	
on	 the	relative	abundances	of	all	 the	proteins	 in	 the	remaining	 five	cell	 lines.	This	
clustering	revealed	a	group	of	362	proteins	with	much	lower	relative	abundance	in	
the	AT1ABR	cell	lines	expressing	any	of	the	three	mutant	ATM	proteins	that	will	be	
referred	to	as	Down	In	Mutants	(DIM)	proteins	(Figure	4.5).		
A	histogram	of	the	relative	intensity	of	each	protein	normalized	to	the	levels	
in	 the	AT1ABR	parental	 cell	 line	 shows	 a	 shift	 in	 the	 peaks	 in	 the	 three	 cell	 lines	
expressing	mutant	ATM	(Figure	4.6A).	The	loss	of	the	DIM	proteins	in	the	cell	lines	
expressing	mutant	ATM	skew	the	rest	of	the	proteome	to	the	right	such	that	there	
appears	to	be	higher	levels	of	the	remaining	proteins	in	comparison	to	the	AT1ABR		
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Figure	4.4	CdCl2	addition	causes	induction	of	ATM	in	AT1ABR	cells	with	pMATII.	
(A)	AT1ABR	 and	GM07544	 cells	were	 treated	with	 or	without	 2	 µM	CdCl2	 for	 16	
hours	and	harvested.	Western	blots	were	performed	on	20	μg	lysate	and	probed	for	
ATM	and	KAP1	levels.	(B)	Normalized	values	of	the	raw	intensities	of	ATM	from	the	
LC‐MS/MS	 quantitation	 of	 the	 cell	 lines	 after	 CdCl2	 addition.	 wt:	 wild‐type;	 CL:	
C2991L;	RA/RA:	R2579A/R2580A,	RA/RA/CL:	R2579A/R2580A/C2991L.	
	
	
	
	
Figure	 4.5	 Hierarchical	 clustering	 of	 normalized	 protein	 levels	 reveals	 a	 group	 of	
proteins	reduced	in	AT1ABR	cells	expressing	mutant	ATM.		
Raw	values	from	quantitative	LC‐MS/MS	were	normalized	to	the	AT1ABR	parental	
cell	 line	 and	 clustered	 using	 Cluster	 3.0.	 Results	 were	 visualized	 using	 Java	
Treeview.	 Each	 horizontal	 group	 represents	 all	 the	 proteins	 from	 that	 cell	 line.	
Vertical	 lines	 represent	 the	 same	 protein	 in	 each	 cell	 line.	 All	 protein	 levels	 have	
been	normalized	to	the	AT1ABR	parental	cell	line.	Green	represents	reduced	levels	
in	the	cell	line	listed,	red	represent	higher	levels,	and	proteins	represented	by	gray	
were	not	found.	CL:C2991L,	RA/RA:	R2579A/R2580A.	
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parental	 line.	 The	 same	 amount	 of	 total	 protein	was	 used	 from	 each	 cell	 line	 but	
approximately	8%	of	 the	proteome	(the	DIM	proteins)	 is	underrepresented	 in	 the	
mutant	 ATM	 cell	 lines,	 some	 vastly	 so.	 Thus,	 the	 relative	 abundances	 of	 the	
remaining	 proteins	 seem	 higher	 and	 shift	 the	 peak	 to	 the	 right.	 To	 compare	 the	
protein	 levels	 without	 the	 DIM	 proteins,	 the	 protein	 raw	 intensities	 were	
normalized	to	the	sum	of	the	raw	intensities	of	the	proteome.	Then,	all	the	cell	lines	
were	 normalized	 to	 the	AT1ABR	 cell	 line	 and	 compared.	 This	 histogram	with	 the	
DIM	proteins	removed	from	all	 the	cell	 lines	(the	4006	remaining	proteins)	shows	
similar	patterns	for	all	the	cell	lines	(Figure	4.6B).	
To	 investigate	 the	 differences	 in	 the	 levels	 of	 the	 DIM	 proteins,	 several	 of	
these	proteins	were	analyzed	using	 commercially‐available	antibodies.	 I	was	most	
interested	in	the	comparisons	between	the	AT1ABR	lines	expressing	wild‐type‐	and	
C2991L‐ATM	as	these	showed	the	largest	difference	in	protein	levels.	Western	blots	
of	5	proteins	from	the	DIM	group	showed	similar	levels	of	total	protein	in	the	lysate	
from	 the	 AT1ABR	 cell	 lines	 expressing	 wild‐type‐ATM	 and	 C2991L‐ATM	 (Figure	
4.7).	There	are	a	number	of	reasons	this	could	occur.	First,	these	proteins	could	have	
post‐translational	modifications	such	that	the	mass	spectrometry	software	is	unable	
to	identify	the	peptides	to	quantitate	the	protein.	However,	extensive	searches	of	the	
mass	 spectrometry	 data	 with	 many	 post‐translational	 modifications	 have	 not	
uncovered	any	that	match	the	differences	in	intensity	seen	here.	Another	possibility	
is	 that	 the	 proteins	 are	 lost	 during	 sample	 processing.	 	 This	 could	 occur	 if	 the	
proteins	were	 in	 an	 aggregated	 state	 and	were	 pelleted	 during	 the	 centrifugation	
step.	
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Figure	4.6	Overlapping	histograms	of	protein	 levels	 relative	 to	 the	parental	 cell	 line	
AT1ABR.		
Histograms	 were	 generated	 of	 the	 protein	 levels	 of	 the	 cell	 lines	 relative	 to	 the	
AT1ABR	cell	line	using	(A)	the	entire	proteome	and	(B)	with	DIM	proteins	removed.	
wt:	wild‐type;	CL:	C2991L;	RA/RA:	R2579A/R2580A.	
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Figure	4.7	AT1ABR	cells	expressing	wild‐type‐ATM	or	C2991L‐ATM	show	similar	total	
levels	of	a	sample	of	proteins	from	the	DIM	group.	
Cells	were	lysed	using	either	the	protocol	for	mass	spectrometry	or	in	the	absence	
of	 detergent.	 Western	 blots	 were	 performed	 on	 20	 μg	 lysate	 with	 the	 indicated	
antibodies.	ATM,	KAP1,	and	β‐actin	protein	levels	were	used	as	a	loading	control.		
	
To	examine	potential	aggregation,	 sucrose	gradients	were	used	 to	compare	
the	sedimentation	rates	of	a	subset	of	 the	DIM	proteins	 in	wild‐type‐	and	C2991L‐
ATM	 expressing	 AT1ABR	 cells.	 The	 DIM	 proteins	 with	 commercially	 available	
antibodies	that	showed	the	largest	differences	between	wild‐type‐	and	C2991L‐ATM	
expressing	cells	were	analyzed.	To	prevent	the	loss	of	aggregates,	cells	were	lysed	in	
the	 absence	 of	 detergent	 and	 the	 lysates	 were	 not	 pelleted.	 A	 representative	
western	of	 tropomyosin	1	 (TPM1)	showed	a	 large	shift	 to	 the	 last	 fraction	 in	cells	
expressing	 C2991L‐ATM	 (Figure	 4.8A).	 The	 western	 blots	 were	 quantitated	 and	
normalized	 to	 a	 sample	of	 the	 lysate	 (Figure	4.8B).	 TPM1	normally	 interacts	with	
the	actin	cytoskeleton,	which	was	enriched	in	the	DIM	list	(data	not	shown).		
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Figure	4.8	A	 sample	of	DIM	proteins	 show	a	 shift	 to	 the	denser	 fractions	of	 sucrose	
gradients	in	C2991L‐ATM	expressing	cells.	
(A)	 AT1ABR	 cells	 expressing	 wild‐type‐ATM	 (black)	 or	 C2991L‐ATM	 (gray)	 were	
induced	 with	 2	 µM	 CdCl2	 for	 16	 hours,	 pelleted,	 and	 lysed	 in	 the	 absence	 of	
detergent.	The	lysates	(2	mg)	were	added	to	the	top	of	sucrose	gradients	composed	
of	 1	ml	 layers	 of	 50%	 to	 5%	 sucrose	 in	 5%	 increments.	 After	 ultracentrifugation,	
500	 μl	 fractions	were	 collected	 and	 analyzed	 by	western	 blot.	 (A)	 Representative	
western	blot	for	tropomyosin	(TPM1,	35	kDa),	(B)‐(G)	Quantitation	of	western	blots	
for	(B)	TPM1;	(C)	DMGDH,	100	kDa;	(D)	CBS,	63	kDa;	(E)	LHPP,	29	kDa;	(F)	ACSM1,	
65	 kDa;	 and	 (G)	 KRT8,	 45	 kDa.	 Quantitation	was	 performed	 on	 the	 Licor	 system	
using	Image	Studio	Ver	4.0.	
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Previously,	changes	in	cellular	morphology	of	A‐T	cells	due	to	alterations	in	the	actin	
network	have	been	reported	[201].		
In	addition	to	TPM1,	quantitation	of	other	proteins	revealed	shifts	to	denser	
fractions	 in	AT1ABR	cells	with	C2991L‐ATM	relative	 to	wild‐type‐ATM	containing	
cells	 (Figure	 4.8B‐G).	 These	 proteins	 are	 involved	 in	 diverse	 cellular	 processes.	
Dimethylglycine	 dehydrogenase	 (DMGDH)	 functions	 in	 the	metabolism	 of	 choline	
and	 is	 found	 in	 the	mitochondrial	matrix	 (Figure	 4.8C).	 Cystathionine	 β‐Synthase	
(CBS)	 catalyzes	 a	 crucial	 step	 in	 the	 biosynthesis	 of	 cysteine	 and	 is	 important	 for	
mitochondrial	function	as	depletion	causes	a	reduction	in	mitochondrial	respiration	
and	ATP	 synthesis	 (Figure	4.8D)	 [202].	 Phospholysine	phosphohistidine	 inorganic	
pyrophosphate	 phosphatase	 (LHPP)	 removes	 phosphates	 from	 imidodiphosphate,	
3‐phosphohistidine	 and	 6‐phospholysine	 (Figure	 4.8E).	 Acyl‐CoA	 Synthetase	
Medium‐Chain	 Family	 Member	 1	 (ACSM1)	 is	 localized	 to	 the	 mitochondria	 and	
forms	acyl‐CoA	 from	 free	 fatty	 acids	 (Figure	4.8F).	Keratin	8,	 another	 cytoskeletal	
protein,	 also	 showed	 increased	 levels	 in	 the	 denser	 fractions	 in	 C2991L‐ATM	
expressing	 cells.	 However,	 at	 least	 one	 DIM	 protein,	 ATP	 citrate	 lyase	 (ACLY),	
showed	more	similar	patterns	of	distribution	in	AT1ABR	cells	expressing	wild‐type‐
ATM	and	C2991L‐ATM	(Figure	4.9A).	ATM,	KAP1,	and	β‐actin	were	used	as	controls	
in	 the	 sucrose	 gradient	 and	 showed	 no	 differences	 either	 (Figure	 4.9B‐D).	
Altogether,	 these	 results	 suggest	 the	 DIM	 proteins	 undergo	 changes	 in	
sedimentation	rate	in	AT1ABR	cells	expressing	C2991L‐ATM.	
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Figure	 4.9	 Control	 proteins	 and	 a	 DIM	 protein	 show	 similar	 patterns	 in	 sucrose	
gradients	in	both	wild‐type‐ATM	and	C2991L‐ATM	expressing	cells.	
(A)	Cell	treatment,	lysis,	sucrose	gradients,	and	western	blots	were	performed	as	in	
Figure	 4.8	 for	 wild‐type‐ATM	 (black)	 and	 C2991L‐ATM	 expressing	 cells.	
Quantitation	of	western	blots	for	(A)	ACLY,	120	kDa;	(B)	ATM,	350	kDa;	(C)	KAP1,	
100	kDa;	and	(D)	β‐actin,	450	kDa	are	shown.	Quantitation	was	performed	on	 the	
Licor	system	using	Image	Studio	Ver	4.0.		
	
EXPRESSION	OF	C2991L‐ATM	AFFECTS	THE	MITOCHONDRIA	
Although	not	 all	 the	 causes	of	 the	under‐representation	 in	 the	mass	 spectrometry	
screen	 are	 known,	 analysis	 of	 the	 DIM	 proteins	 has	 uncovered	 some	 interesting	
features.	The	proteins	in	the	DIM	group	were	characterized	using	the	Database	for	
Annotation,	Visualization	and	Integrated	Discovery	(DAVID)	v6.7	for	gene	ontology	
analysis	[203,	204].	All	three	domains	of	gene	ontology	–	Biological	Process,	Cellular	
Component,	and	Molecular	Function	–	showed	significantly	enriched	terms	 for	 the	
DIM	proteins	(Figure	4.10).	The	proteins	are	enriched	for	oxidation‐reduction	and		
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Figure	4.10	Gene	ontology	analysis	of	DIM	proteins.	
The	list	of	DIM	proteins	was	submitted	to	DAVID	version	6.7	and	the	top	results	are	
shown	 with	 the	 ‐log(p	 value).	 The	 red	 line	 shows	 p	 value	 =	 0.05.	 (A)	 Biological	
Process	(B)	Cellular	Component	and	(C)	Molecular	Function.	
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various	 metabolic	 processes	 in	 the	 Biological	 Process	 group.	 In	 the	 Cellular	
Component	group,	seven	of	the	top	ten	most	significantly	enriched	terms	are	parts	
of	 the	mitochondria.	The	Molecular	Function	group	shows	enrichment	for	cofactor	
binding	 and	 various	 specific	 cofactors	 as	 well	 as	 "Structural	 component	 of	
ribosome,"	 Hydrolase	 activity,"	 and	 "Oxidoreductase	 activity."	 The	 Cellular	
Component	 group	 showed	 DIM	 proteins	 were	 highly	 enriched	 for	 mitochondrial	
localization.	Interestingly,	the	mitochondria	from	patients	with	ataxia	telangiectasia	
have	 been	 shown	 to	 be	 defective	 [205].	 Lymphoblastoid	 cells	 from	 patients	 with	
ataxia‐telangiectasia	 have	 reduced	 mitochondrial	 membrane	 potentials	 and	
mitochondrial	respiration	rates	[206].	In	addition,	cells	lacking	functional	ATM	are	
known	to	have	higher	ROS	 levels	and	 increased	sensitivity	 to	ROS‐inducing	agents	
perhaps	due	to	abnormal	mitochondria	[91,	207,	208].		
To	 examine	 the	 requirements	 of	 ATM,	 and	 specifically	 C2991,	 in	 ROS	
regulation	 and	 mitochondrial	 homeostasis,	 I	 compared	 the	 AT1ABR	 parental	 cell	
line	and	AT1ABR	cells	inducibly	expressing	wild‐type‐ATM	or	C2991L‐ATM	with	or	
without	the	addition	of	CdCl2.	In	this	experiment,	the	cells	were	allowed	to	recover	
for	2	days	as	there	was	too	much	variation	at	earlier	time	points.	Propidium	iodide	
staining	showed	all	cells	were	in	similar	cell	cycle	phases	(data	not	shown).	The	ROS	
levels	and	mitochondrial	masses	of	the	cell	 lines	were	analyzed	by	flow	cytometry	
using	 H2DCFDA	 and	 MitoTracker	 Green	 staining,	 respectively.	 Cells	 expressing	
C2991L‐ATM	 showed	 higher	 levels	 of	 ROS	 than	 cells	 expressing	 wild‐type	 ATM	
although	 both	 were	 higher	 than	 the	 parental	 AT1ABR	 cell	 line	 (Figure	 4.11A‐B).	
Notably,	A‐T	cells	and	ATM‐/‐	mouse	tissues	have	been	shown	to	have	higher	basal	
levels	of	proteins	involved	in	oxidative‐damage	responsive	pathways	including	p53,		
 
 
70
	
	
Figure	4.11	The	levels	of	oxidative	stress	and	mitochondrial	mass	in	AT1ABR	cells	are	
affected	by	ATM	expression	and	depend	on	the	presence	of	C2991.		
(A)	 The	 mitochondrial	 masses	 of	 uninduced	 AT1ABR	 cells	 were	 measured	 by	
MitoTracker	 Green	 staining	 followed	 by	 analysis	 using	 flow	 cytometry.	 (B)	 Cells	
were	 induced	with	2	μM	CdCl2	then	recovered	for	48	hours	and	then	treated	as	 in	
(A).	 (C)	 The	 ROS	 levels	 of	 uninduced	 AT1ABR	 cells	 cells	 were	 measured	 by	
H2DCFDA	 staining	 followed	 by	 analysis	 using	 flow	 cytometry.	 (D)	 Cells	 were	
induced	with	 2	 μM	CdCl2	 then	 recovered	 for	 48	 hours	 and	 then	 treated	 as	 in	 (C).	
Median	values	 from	 independent	replicates	 (n	=4)	were	compared	and	used	 for	 t‐
tests.	Error	bars	represent	standard	deviation.	P‐values:	*	<	0.05;	**	<	0.005;	***	<	
0.0005	
	
A B
C D
0
500
1000
1500
2000
2500
3000
3500
4000
4500
AT1ABR AT1ABR wild‐
type‐ATM
AT1ABR
C2991L‐ATM
Fl
uo
re
sc
en
ce
 In
te
ns
ity
0
5000
10000
15000
20000
25000
AT1ABR AT1ABR wild‐
type‐ATM
AT1ABR
C2991L‐ATM
Fl
uo
re
sc
en
ce
 In
te
ns
ity
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
AT1ABR AT1ABR wild‐
type‐ATM
AT1ABR
C2991L‐ATM
Fl
uo
re
sc
en
ce
 In
te
ns
ity
0
2000
4000
6000
8000
10000
AT1ABR AT1ABR wild‐
type‐ATM
AT1ABR
C2991L‐ATM
Fl
uo
re
sc
en
ce
 In
te
ns
ity
ROS Levels in Uninduced Cells
Mitochondrial Mass in 
Uninduced Cells
ROS Levels in Induced Cells
Mitochondrial Mass in 
Induced Cells
***
** *
* ***
** *
 
 
71
p21,	 NFκB,	manganese	 superoxide	 dismutase,	 Gadd45,	 and	 hemeoxygenase	 [209‐
212].	 Re‐expression	 of	 ATM	 in	 this	 context	 could	 cause	 abnormal	 effects	 in	 these	
cells.	 Furthermore,	 other	 studies	 in	 our	 lab	 have	 shown	 after	 an	 inducible	 ATM	
knockout,	mouse	embryonic	 fibroblasts	undergo	an	adaptation	period	with	higher	
levels	of	ROS	and	then	adjust	and	reduce	oxidative	stress	to	below	the	levels	of	cell	
heterozygous	for	ATM	(S	Zhang	,	unpublished	observations).		
As	measured	by	MitoTracker	Green,	 the	induction	of	wild‐type	ATM	greatly	
increased	mitochondrial	mass	as	compared	to	AT1ABR	cells	while	the	AT1ABR	cells	
expressing	 C2991L‐ATM	 consistently	 showed	 a	 level	 of	 mitochondrial	 mass	
between	the	AT1ABR	cells	and	the	AT1ABR	cells	expressing	wild‐type‐ATM	(Figure	
4.11C‐D).	Previous	studies	have	shown	ATM	activated	by	DNA	damage	can	 induce	
mitochondrial	 biogenesis	 suggesting	 ATM	 activated	 by	 either	 pathway	may	 affect	
mitochondrial	growth	[213].		
To	 examine	 the	 transcriptional	 effects	 of	 expressing	 wild‐type‐ATM	 and	
C2991L‐ATM	 in	 AT1ABR	 cells,	 qPCR	 was	 performed	 with	 primers	 for	 SLC7A11,	
which	 encodes	 a	 cystine/glutamate	 transporter	 important	 for	 glutathione	
production	 and	 ROS	 reduction	 [214],	 and	 PPARGC1A,	 which	 encodes	 the	 protein	
PGC1α,	a	 transcriptional	coactivator	of	mitochondrial	biogenesis	 [215].	The	mRNA	
levels	of	SLC7A11	show	an	inverse	pattern	to	the	levels	of	ROS	after	the	addition	of	
CdCl2	(Figure	4.12A).	The	parental	cell	line	has	the	highest	levels	of	SLC7A11	mRNA,	
AT1ABR	 cells	 expressing	 wild‐type‐ATM	 are	 intermediate,	 and	 AT1ABR	 cells	
expressing	 C2991L‐ATM	 have	 the	 lowest	 amount	 of	 SLC7A11	 transcription.	 A	
western	blot	showed	a	similar	pattern	in	the	SLC7A11	protein	 levels	 in	these	cells	
(data	not	shown).	This	suggests	the	parental	AT1ABR	cell	line	is	able	to	upregulate	
 
 
72
an	antioxidant	pathway	more	 rapidly	 in	 this	 context.	A	previous	 study	has	 shown	
SLC7A11	 induction	 in	mouse	 cells	 upon	 treatment	with	 10	 µM	 cadmium	 chloride	
suggesting	 all	 the	 cells	 may	 be	 inducing	 SLC7A11	 expression	 in	 response	 to	 the	
inducing	 agent	 [216].	 A	 recent	 paper	 has	 uncovered	 p53‐mediated	 inhibition	 of	
SLC7A11	expression	that	may	explain	 the	differences	between	the	cell	 lines	 [217].	
Here,	 wild‐type‐ATM	 may	 be	 activated	 by	 ROS	 and	 affect	 p53	 activity	 directly.	
Conversely,	the	higher	levels	of	ROS	in	C2991L‐ATM	cells	may	induce	DNA	damage,	
ATM	activation,	and	then	p53	activity.	
The	mRNA	levels	of	PPARGC1A	in	uninduced	cells	were	not	correlated	with	
the	 levels	 of	 mitochondrial	 mass	 (Figure	 4.12B).	 Furthermore,	 upon	 addition	 of	
CdCl2,	 levels	 of	 PPARGC1A	 mRNA	 in	 AT1ABR	 cells	 and	 AT1ABR	 cells	 expressing	
wild‐type‐ATM	 are	 increased	 while	 the	 amount	 of	 PPARGC1A	 mRNA	 in	 AT1ABR	
cells	 expressing	 C2991L‐ATM	 is	 reduced.	 PPARGC1A	 has	 been	 shown	 to	 be	
regulated	 post‐transcriptionally	 in	 mice	 by	 miRNA	 [218]	 as	 well	 as	 post‐	
translationally	 by	 phosphorylation	 and	 acetylation	 [219].	 Such	mechanisms	 could	
modify	or	accentuate	the	transcriptional	effects	of	PPARGC1A	seen	here.	This	data	
suggests	 the	 low	 levels	 of	 wild‐type	 and	 C2991L‐ATM	 in	 uninduced	 cells	 primes	
them	for	mitochondrial	biogenesis.	However,	induction	of	more	C2991L‐ATM	has	a	
detrimental	effect	relative	to	the	parental	cell	line.	Notably,	the	levels	of	PGC1α,	the	
protein	 encoded	 by	 PPARGC1A,	 followed	 the	 pattern	 of	mitochondrial	mass	 (data	
not	shown).	
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Figure	4.12	qPCR	reveals	SLC7A11	and	PPARGC1A	mRNA	 levels	are	affected	by	ATM	
expression	and	depend	on	the	presence	of	C2991.	
(A)	RNA	from	cells	treated	with	2	μM	CdCl2	and	recovered	for	48	hours	was	reverse	
transcribed	and	the	cDNA	was	subjected	to	qPCR	with	SLC7A11	and	ACTB	primers.	
(B)	cDNA	from	(A)	was	subjected	 to	qPCR	with	PPARGC1A	and	ACTB	primers.	wt:	
wild‐type;	CL:	C2991L.	Ct	values	from	independent	replicates	(n	=4)	were	compared	
and	used	for	t‐tests.	Error	bars	represent	standard	deviation.	P‐values:	*	<	0.05;	**	<	
0.005;	***	<	0.0005	
PHOSPHOPROTEOME	
The	phosphoproteomic	 analysis	 of	 the	GM07544	 and	AT1ABR	 cell	 lines	 identified	
2,694	 phosphopeptides	with	 a	 false	 discovery	 rate	 of	 1%.	 The	 phosphoproteome	
showed	 similar	 characteristics	 to	 previous	 studies,	 with	 phosphorylated	 serine	
accounting	 for	 most	 of	 the	 phosphorylation	 events	 followed	 by	 phosphorylated	
threonine	 and	 a	 small	 percentage	 of	 phosphorylated	 tyrosine	 (Figure	 4.13).	 A	
histogram	of	 the	 raw	 intensities	 from	each	 cell	 line	 shows	 the	phosphoproteomes	
are	 grossly	 similar,	 as	 expected	 (Figure	 4.14).	 Further	 analysis	 of	 the	 AT1ABR	
phosphoproteomes	was	performed	using	pairwise	comparisons	of	the	log	of	the	raw	
intensities	of	the	phosphopeptides.	The	pairwise	comparisons	show	with	most	of		
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Figure	4.13	General	properties	of	the	identified	phosphoproteome.	
(A)	Distribution	of	serine,	 threonine,	and	tyrosine	residues.	 (B)	Distribution	of	 the	
number	of	phosphorylated	residues	on	each	peptide.	
	
the	phosphopeptides	lie	along	the	y	=	x	line	where	the	levels	are	similar	in	both	cell	
lines	 (Figure	 4.15).	 The	 nonparametric	 Spearman’s	 rank	 correlation	 coefficient,	 ρ,	
was	calculated	for	all	the	pairwise	comparisons.	Values	of	ρ	closer	to	1	suggest	the	
pairwise	comparisons	are	more	similar.	The	ρ	values	were	all	very	significant	(p	<	
10‐16)	 and	 examination	 of	 the	 ρ	 values	 reveals	 the	 AT1ABR	 cells	 expressing	
R2579A/R2580A‐ATM	and	C2991L‐ATM	were	the	most	different	while	the	two	cell	
lines	 expressing	 the	 C2991L‐ATM	 and	 R2579A/R2580A/C2991L‐ATM	 were	 the	
most	similar	(Figure	4.15).	C2991L‐ATM	cells	were	more	similar	to	the	parental	cell	
line	 than	 they	were	 to	 either	AT1ABR‐wt‐ATM	or	AT1ABR‐R2579A/R2580A‐ATM	
cells	 suggesting	 the	 C2991L	 mutation	 prevents	 some	 changes	 in	 the	
phosphoproteome.	 Notably,	 AT1ABR‐	 R2579A/R2580A/C2991L‐ATM	 cells,	 which	
should	 have	 the	 least	 active	 ATM,	were	 the	most	 similar	 to	 the	 parental	 cell	 line.	
These	 results	 support	 our	 understanding	 of	 these	mutations	 as	 affecting	 different	
pathways	of	ATM	activation.	Since	no	external	DNA	damaging	agents	were	added	in		
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Figure	4.14	A	histogram	of	phosphopeptide	normalized	values	reveals	overall	levels	of	
phosphorylation	are	similar	between	the	cell	lines.		
The	raw	values	for	each	cell	line	were	normalized	to	the	AT1ABR	parental	cell	line	
and	the	logarithm	base	2	was	taken.	The	ATM	constructs	are	abbreviated	as	follows:	
wt:	 wild‐type;	 CL:	 C2991L;	 RA/RA:	 R2579A/R2580A,	 and	 RA/RA/CL:	
R2579A/R2580A/C2991L.	
	
this	study,	the	R2579A/R2580A	mutations	should	have	little	effect	on	the	activity	of	
ATM	and	thus	these	cells	will	be	more	similar	to	wild‐type‐ATM	expressing	cells.	On	
the	 other	 hand,	 the	 expression	 of	 C2991L‐ATM	 has	 been	 shown	 to	 increase	
oxidative	stress	relative	to	the	expression	of	wild‐type‐ATM	even	under	conditions	
of	 normal	 growth	 [5]	 suggesting	 that	 ATM	 is	 activated	 in	 cells	 to	 counteract	
endogenous	oxidative	stress.	
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Figure	4.15	Pairwise	comparisons	of	the	phosphoproteomic	raw	data	from	AT1ABR	
cells	with	or	without	expression	of	ATM.	
The	raw	intensity	of	each	phosphopeptide	was	compared	between	two	cell	lines	at	a	
time.	The	cell	lines	and	raw	intensities	for	each	graph	are	shown	across	the	top	and	
right.	 The	 Spearman’s	 rank	 correlation	 coefficient,	 ρ,	 was	 calculated	 for	 each	
pairwise	 comparison	 and	 is	 shown.	 wt:	 wild‐type;	 CL:	 C2991L;	 RA/RA:	
R2579A/R2580A,	RA/RA/CL:	R2579A/R2580A/C2991L.	
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To	 estimate	 the	 activities	 of	 ATM	 in	 the	 different	 cell	 lines,	 putative	 ATM	
substrates	 were	 predicted	 by	 Group‐based	 Prediction	 Systems	 (GPS),	 a	 program	
which	compares	the	7	amino	acids	N‐terminal	and	C‐terminal	to	a	phosphorylated	
residue	 with	 all	 known	 sites	 phosphorylated	 by	 a	 specific	 kinase	 [220].	 The	
sequences	are	scored	using	the	amino	acid	substitution	matrix	BLOSUM62	and	the	
average	 value	 is	 used	 as	 the	 final	 score.	 The	 accuracy,	 sensitivity,	 and	 specificity	
vary	between	kinases	but	the	false	discovery	rate	was	set	at	2%.	However,	GPS	does	
not	 limit	 its	 predictions	 to	 any	 certain	 residue	 in	 the	 peptide	 submitted	 so	 the	
results	were	curated	to	ensure	the	only	predictions	included	were	on	the	identified	
residue	 phosphorylated	 in	 the	 phosphoproteomic	 screen.	 Similar	 to	 previous	
phosphoproteomic	experiments	with	enrichment	 for	ATM	substrates,	 I	 found	only	
53	phosphopeptides	predicted	to	be	phosphorylated	by	ATM	under	normal	growth	
conditions	[10,	11].	Of	these,	35	were	also	predicted	to	be	phosphorylated	by	one	of	
the	other	PIKKs:	ATR,	DNAPK,	or	FRAP.	In	the	remaining	18,	there	was	a	relatively	
stable	amount	of	phosphorylation	with	AT1ABR	cells	 expressing	wildtype‐ATM	or	
C2991L‐ATM	as	the	lowest	(Figure	4.16A).	
Of	 the	53	 identified	direct	ATM	candidate	proteins,	twenty	were	previously	
identified	 in	 a	 phosphoproteomic	 screen	 by	 the	 Elledge	 group	 in	 peptides	
immunoprecipitated	with	antibodies	to	known	ATM	phosphorylation	sites	[12].		The	
distributions	 of	 the	 intensities	 of	 the	 putative	 ATM	 substrates	 are	 similar,	
suggesting	there	was	no	major	effect	of	the	C2991L	or	R2579A/R2580A	mutations	
on	the	phosphorylation	of	these	ATM	substrates	in	untreated	cells	(Figure	4.16B).			
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Figure	4.16	The	phosphoproteome	of	the	putative	ATM	substrates	is	not	correlated	
with	ATM	protein	levels	and	is	similar	among	the	cell	lines.		
(A)	The	raw	intensities	of	the	18	phosphopeptides	predicted	to	be	phosphorylated	
by	 ATM	 and	 not	 the	 other	 PIKKs	 were	 summed	 and	 normalized	 to	 the	 levels	 in	
AT1ABR.	 (B)	 Grouped	 scatterplot	 of	 the	 raw	 intensities	 of	 all	 53	 putative	 ATM	
substrates	with	 the	 average	marked	 as	 a	 bar.	 wt:	 wild‐type;	 CL:	 C2991L;	 RA/RA:	
R2579A/R2580A,	RA/RA/CL:	R2579A/R2580A/C2991L.	
	
	
Analysis	 of	 the	 total	 phosphoproteome	 dataset	 by	 hierarchical	 clustering	
revealed	a	group	of	315	peptides	less	phosphorylated	in	the	parental	AT1ABR	cells	
and	AT1ABR	cells	expressing	ATM	with	the	C2991L	mutation,	hereafter	referred	to	
as	 the	 C2991	 Dependent	 Cluster	 (Figure	 4.17).	 Only	 6	 of	 the	 predicted	 ATM	
substrates	 appear	 within	 this	 group.	 Since	 ATM	was	 not	 the	 predominant	 kinase	
responsible	for	phosphorylating	the	proteins	in	this	group,	I	used	motif‐x	to	extract	
motifs	 from	the	phosphoproteome	and	the	C2991	Dependent	Cluster	to	determine	
which	 kinase(s)	 may	 be	 phosphorylating	 these	 proteins.	 	 Nine	 motifs	 were	
extractedfrom	 the	C2991	Dependent	 Cluster	 –	 tP,	 sPXK,	 sP,	 sDXE,	 sEXE,	RXXs,	 sD,	
and	 sE	 –	 and	 the	 results	 were	 compared	 to	 the	 motifs	 from	 the	 whole	
phosphoproteome.	The	motifs	with	phosphorylated	residues	followed	by	proline	or		
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Figure	 4.17	 Hierarchical	 clustering	 of	 all	 the	 phosphopeptides	 reveals	 a	 cluster	 of	
phosphopeptides	 less	phosphorylated	 in	AT1ABR	 cells	and	AT1ABR	 cells	
expressing	the	C2991L	mutation.		
Phosphopeptide	 levels	 were	 normalized	 to	 the	 parental	 AT1ABR	 cell	 line.	 Each	
vertical	 line	within	a	cell	 line	is	a	phosphopeptide	and	vary	from	green	to	black	to	
red	 to	 represent	 decreased,	 equal,	 and	 increased	 levels	 of	 the	 phosphopeptides	
compared	 to	 the	 parental	 AT1ABR	 cell	 line.	 The	 highlighted	 portion	 is	 the	 C2991	
Dependent	 Cluster.	 wt:	 wild‐type;	 CL:	 C2991L;	 RA/RA:	 R2579A/R2580A,	
RA/RA/CL:	R2579A/R2580A/C2991L.	
	
preceded	three	residues	by	an	arginine	showed	little	to	no	further	enrichment	in	the	
C2991	Dependent	Cluster	(Figure	4.18).	However,	there	was	a	striking	enrichment	
for	the	four	motifs	with	acidic	residues	following	the	phosphorylated	residue.	This	
motif	 is	 typical	 of	 substrates	 for	 the	 protein	 kinase	 CK2	 but	 further	 analysis	was	
necessary	 to	 confirm	 whether	 CK2	 was	 specifically	 less	 active	 in	 AT1ABR	 cells	
expressing	ATM	with	the	C2991L	mutation.	
The	 two‐sample	Kolmogorov‐Smirnov	 (K‐S)	 test	 is	 a	 nonparametric	 test	 to	
determine	whether	two	empirical	distribution	functions	(EDFs)	are	from	the	same	
or	separate	distributions.	The	EDFs	show	the	cumulative	probability	on	 the	y‐axis	
with	a	value	less	than	or	equal	to	the	value	on	the	X‐axis.	The	K‐	S	statistic	is	the		
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Figure	4.18	Analysis	by	motif‐x	shows	an	increase	in	enrichment	of	the	motifs	with	a	
phosphorylation	site	followed	by	acidic	residues	in	the	C2991	Dependent	
Cluster.		
Phosphopeptides	from	the	phosphoproteome	or	the	C2991	Dependent	Cluster	were	
submitted	 to	 motif‐x.	 The	 sequences	 contained	 6	 residues	 N‐terminal	 and	 C‐
terminal	of	each	phosphorylation	event.	
	
largest	difference	between	two	EDFs.	If	the	K‐S	statistic	is	above	a	critical	value,	the	
null	hypothesis	that	the	samples	are	drawn	from	the	same	distribution	is	rejected.	
Here,	 I	 used	 the	 K‐S	 test	 to	 compare	 the	 ratios	 of	 intensities	 of	 phosphopeptides	
from	 AT1ABR	 cells	 expressing	 wild‐type‐ATM	 or	 expressing	 C2991L‐ATM	 (wild‐
type/C2991L).	 If	CK2	substrates	are	phosphorylated	similarly	 in	 the	AT1ABR	cells	
expressing	 wild‐type‐ATM	 and	 C2991L‐ATM,	 then	 the	 EDFs	 of	 the	 ratios	 of	 the	
phosphopeptides	 should	 be	 similar.	 To	 predict	 the	 substrates	 for	 each	 kinase,	 I	
analyzed	 the	 phosphopeptides	 in	 GPS.	 For	 each	 phosphorylation	 site,	 multiple	
kinases	may	be	predicted	to	be	responsible.	These	putative	substrates	were	entered	
as	 the	 phosphoproteomes	 of	 the	 kinases	 and	 the	 ratios	 of	wild‐type	 and	C2991L‐
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ATM	expressing	 cells	were	 calculated.	 The	 EDFs	 of	 the	 kinase	 phosphoproteomes	
and	 the	 full	phosphoproteome	were	 compared	using	 the	K‐S	 test.	A	 sample	of	 the	
EDFs	and	the	results	from	all	the	K‐S	tests	are	shown	(Figure	4.19).	The	EDF	of	CK1	
tightly	overlaps	the	EDF	of	the	full	phosphoproteome	and	the	K‐S	test	has	a	p‐value	
of	 0.919	 suggesting	 there	 is	 no	 difference	 in	 the	 CK1	 phosphoproteome	 from	 the	
whole	phosphoproteome	(Figure	4.19A	and	D).	However,	ATM	and	CK2	both	show	a	
statistically	 significant	 shift	 to	 the	 right	 in	 their	 EDFs	 relative	 to	 the	 full	
phosphoproteome	 (Figures	 4.19	 B‐D).	 This	 shift	 reveals	 the	 presence	 of	 more	
phosphopeptides	 with	 a	 higher	 wild‐type/C2991L	 ratio	 demonstrating	 the	
phosphopeptides	 have	 lower	 intensities	 in	 the	 AT1ABR	 cells	 expressing	 C2991L‐
ATM.	Notably,	most	of	the	other	kinases	are	not	significantly	different	from	the	full	
phosphoproteome	(Figure	4.19D).		
CK2	ACTIVITY	IS	REDUCED	IN	THE	ABSENCE	OF	ACTIVE	ATM	
The	holoenzyme	of	CK2	is	a	tetramer	of	2	α	subunits,	the	catalytic	subunits,	and	2	β	
subunits,	 the	 regulatory	 subunits	 (Figure	 4.20A).	 There	 are	 two	α	 subunits,	 CK2α	
and	CK2α',	and	one	β	subunit,	CK2β.	The	holoenzyme	consists	of	2	CK2β	subunits	
bound	 to	 any	 combination	 of	 2	 CK2α	 and	 CK2α'	 subunits.	 To	 determine	 if	 the	
differences	in	the	CK2	phosphoproteome	were	due	to	a	change	in	the	protein	levels	
of	the	different	subunits,	I	compared	the	levels	of	the	CK2	subunits	between	the	cell	
lines	 without	 the	 DIM	 proteins(Figure	 4.20B).	 Contrary	 to	 the	 phosphoproteome	
data,	the	AT1ABR	cell	lines	expressing	C2991L‐ATM	and	R2579A/R2580A/C2991L‐
ATM	had	the	highest	levels	of	expression	of	all	three	subunits.	Thus	the	reduction	in	
CK2	activity	of	AT1ABR	cells	expressing	C2991L‐ATM	is	not	due	to	loss	of	protein.	
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Figure	 4.19	 AT1ABR	 cells	 expressing	 C2991L‐ATM	 have	 reduced	 intensities	 of	
phosphopeptides	predicted	to	be	phosphorylated	by	CK2	versus	cells	with	
wild‐type‐ATM.	
Empirical	 cumulative	 distribution	 functions	 of	 the	 ratio	 of	 phosphopeptide	
intensities	 of	 wild‐type‐ATM	 and	 C2991L‐ATM	 containing	 cells	 from	 (A)	 the	
phosphoproteome	 and	 the	 CK1	 phosphoproteome,	 (B)	 the	 phosphoproteome	 and	
the	 ATM	 phosphoproteome,	 and	 (C)	 the	 phosphoproteome	 and	 the	 CK2	
phosphoproteome.	(D)	Results	from	Kolmogorov‐Smirnov	tests.	The	red	dotted	line	
marks	p‐value	=	0.05.	
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To	 determine	whether	 there	 is	 a	 change	 in	 CK2	 activity	 in	 the	 absence	 of	
ATM	function,	I	attempted	to	immunoprecipitate	epitope‐tagged	CK2	from	AT1ABR	
cells	expressing	the	various	ATM	constructs	but	the	AT1ABR	lymphoblast	cells	are	
refractory	 to	 transfection	 and	 I	 could	 not	 get	 expression.	 Instead,	 to	 analyze	 the	
activity	of	CK2	in	the	presence	of	inactive	ATM,	I	expressed	V5‐tagged	CK2	proteins	
in	HEK‐293T	cells	and	left	 them	untreated	or	treated	them	with	an	ATM	inhibitor.	
The	V5‐tagged	CK2	subunits	were	immunoprecipitated	with	V5	magnetic	beads	and	
a	western	blot	was	performed	probing	for	V5,	CK2α,	and	CK2β	with	the	 input	and	
immunoprecipitated	 protein	 from	 each	 cell	 line	 (Figure	 4.20C).	 Western	 blots	 of	
CK2β‐V5	show	a	pair	of	bands	just	above	25	kDa.	These	separate	bands	could	be	due	
to	 post‐translational	modifications	 as	 CK2β	 is	 phosphorylated	 by	 the	 holoenzyme	
CK2	[131].	The	CK2	subunits	have	different	levels	of	expression	in	the	cell	 lines	as	
can	be	seen	in	the	input.	CK2α‐V5,	which	had	the	lowest	expression	level,	shows	no	
pull	down	of	endogenous	CK2α'	or	CK2β.	However,	CK2α'‐V5	immunoprecipitation	
pulls	 down	 CK2β	 and	 CK2β‐V5	 immunoprecipitation	 pulls	 down	 both	 CK2α	 and	
CK2α'.	
To	 assay	 the	 kinase	 activity	 of	 CK2,	 I	 generated	 a	 fusion	 of	GST	 and	 a	CK2	
substrate	 peptide,	 RRADDSDDDDDE.	 The	 kinase	 assay	 was	 first	 established	 with	
commercial	 CK2	 from	 NEB	 and	 the	 incorporation	 of	 32P	 from	 ATP‐γ‐32P	 was	
measured	 by	 PhosphorImager	 analysis.	 CK2	 phosphorylated	 GST‐CK2	 substrate	
peptide	 but	 not	 GST	 by	 itself	 and	 the	 phosphorylation	 was	 dependent	 on	 the	
addition	of	CK2	(Figure	4.21A).	 	The	kinase	assay	with	 immunoprecipitated	CK2α‐	
V5,	CK2α'‐V5,	and	CK2β‐V5	from	293T	cells	constitutively	expressing	these	proteins	
was	performed	with	the	proteins	bound	to	the	beads	(Figure	4.21B).	In	the	CK2β‐V5	
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Figure	 4.20	 CK2	 subunits	 are	 upregulated	 in	mutant	 ATM	 expressing	 cells	 and	 co‐
immunoprecipitate	other	proteins	from	the	holoenzyme.	
(A)	 Structure	 of	 the	 CK2	 holoenzyme	 (α2β2)	 (PDB	 code:	 1JWH).	 The	 regulatory	 β	
subunits	 form	a	 dimer	 and	 each	bind	 an	α	 or	 α'	 subunit	 to	 form	 the	 holoenzyme.	
Sections	 are	 colored	 as	 follows:	 red,	 CK2α/a’;	 yellow,	K68‐CK2α/K69‐CK2α’;	 blue,	
CK2β;	black,	AMPPNP.	 (B)	CK2	 levels	were	 recalculated	as	a	 fraction	of	 the	entire	
proteome	without	the	DIM	group	and	then	normalized	to	the	levels	in	the	parental	
AT1ABR	cell	 line.	wt:	wild‐type;	CL:	C2991L;	RA/RA:	R2579A/R2580A,	RA/RA/CL:	
R2579A/R2580A/C2991L.	 (C)	 Lysates	 (20	 μg)	 from	 293T	 cells	 stably	 expressing	
CK2α‐V5,	 CK2α'‐V5,	 or	 CK2β‐V5	were	 immunoprecipitated	with	magnetic	 anti‐V5	
beads	 and	 a	western	blot	was	 performed	with	 the	 input	 and	 immunoprecipitated	
protein	 and	 the	 indicated	 antibodies.	 *	 shows	 mouse	 antibody	 from	
immunoprecipitation.	
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immunoprecipitation,	 the	 endogenous	 CK2α	 and	 CK2α'	 subunits	 are	 pulled	 down	
and	phosphorylate	the	GST‐CK2	substrate	peptide.	Immunoprecipitations	using	any	
of	 the	 three	 subunits	 are	 able	 to	 phosphorylate	 GST‐CK2	 substrate	 peptide.	 The	
overall	activity	corresponded	to	the	levels	of	protein	expressed	in	the	cells	as	seen	
in	 Figure	 4.20B.	 Notably,	 immunoprecipitation	 of	 a	 previously	 identified	 kinase‐
dead	 mutant	 of	 CK2α'‐V5	 (K69M)	 showed	 little	 phosphorylation	 of	 GST‐CK2	
substrate	 peptide	 demonstrating	 the	 kinase	 activity	 is	 specifically	 from	
immunoprecipitated	CK2	(Figure	4.21C)	[221].	
The	established	in	vitro	kinase	assay	was	then	used	to	compare	the	activities	
of	CK2	in	the	presence	or	absence	of	ATM	kinase	activity.	For	this	assay,	293T	cells	
expressing	CK2β‐V5	were	used	so	that	both	endogenous	CK2α	and	CK2α'	would	be	
the	sources	of	any	kinase	activity.	293T	cells	expressing	CK2β‐V5	were	treated	with	
10	μM	Ku‐55933,	an	ATM	inhibitor,	or	an	equivalent	amount	of	DMSO	for	16	hours.	
The	 lysates	were	 immunoprecipitated	with	V5	beads	and	 the	 levels	of	CK2	kinase	
activity	 were	 assessed	 during	 an	 in	 vitro	 time	 course.	 The	 activity	 of	
immunoprecipitated	 CK2	 increased	 over	 time	 in	 the	 in	 vitro	 assay,	 for	 both	 the	
untreated	cells	and	cells	exposed	to	ATM	inhibitor	(Figure	4.22A).	The	CK2	isolated	
from	cells	treated	with	inhibitor	show	decreased	levels	of	phosphorylated	GST‐CK2	
substrate	peptide	relative	to	untreated	cells,	but	we	also	observed	decreased	levels	
of	 CK2	 recovered	 from	 inhibitor‐treated	 cells.	 When	 the	 kinase	 activity	 was	
normalized	to	the	level	of	CK2β‐V5	immunoprecipitated,	there	was	little	difference	
in	the	specific	activity	of	 the	kinase	with	or	without	ATM	inhibitor	(Figure	4.22B).	
The	 decrease	 in	 CK2β‐V5	 immunoprecipitated	 was	 similar	 between	 multiple	
experiments	(Figure	4.22C).	This	effect	was	reproducible	and	occurred	despite	a	
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Figure	4.21	Immunoprecipitated	CK2	subunits	phosphorylate	a	CK2	substrate	in	vitro	
and	activity	is	dependent	on	CK2	catalytic	activity.		
(A)	CK2	(1	μl)	was	incubated	in	1X	CK2	buffer	with	1.67	mM		ATP,	5	fCi	ATP‐γ‐32P	,		
and	the	amounts	of	each	substrate	shown	for	1	hour.	The	reactions	were	stopped	by	
addition	of	5X	SDS	loading	buffer	and	run	on	a	SDS‐PAGE	gel.	The	gel	was	dried	and	
a	 PhosphorImager	 Screen	was	 exposed	 overnight	 and	 visualized	 with	 a	 Typhoon	
Imager.	The	arrow	shows	the	position	of	the	GST‐CK2	substrate.	(B)	Lysate	(20	μg)	
from	 293T	 cells	 or	 293T	 cells	 stably	 expressing	 CK2α‐V5,	 CK2α'‐V5,	 or	 CK2β‐V5	
were	 immunoprecipitated	 with	 magnetic	 anti‐V5	 beads	 and	 a	 kinase	 assay	 was	
performed	as	 in	(A)	on	the	beads	with	1150	μg	GST‐CK2	substrate.	 (C)	Lysate	(40	
μg)	 from	 293T	 cells	 or	 293T	 cells	 stably	 expressing	 kinase	 dead	 CK2α'‐V5	
immunoprecipitated	with	magnetic	anti‐V5	beads	and	the	beads	were	split	 for	 the	
kinase	assay	as	performed	in	(B)and	western	blot	analysis.		
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Figure	4.22	ATM	 inhibition	affects	CK2β‐V5	 immunoprecipitation	but	not	the	activity	
of	CK2β‐V5.	
(A)	293T	cells	stably	expressing	CK2β‐V5	were	treated	with	10	µM	Ku‐55933	or	an	
equivalent	amount	of	DMSO	 for	16	hours	and	 then	 lysed	with	1X	Cell	Lysis	Buffer	
(Cell	 Signaling	 Technology).	 Lysate	 (12.5	 μg)	 from	 each	 sample	 was	
immunoprecipitated	 with	 magnetic	 anti‐V5	 beads	 and	 split	 into	 5	 tubes.	 Kinase	
reactions	were	performed	as	in	Figure	4.21	and	stopped	at	the	specified	time	points.	
The	 reactions	 were	 run	 on	 a	 gel,	 transferred	 to	 PVDF,	 probed	 for	 V5	 levels	 by	
western	 blot,	 and	 exposed	 to	 a	 PhosphorImager	 Screen.	 (B)	 Quantitation	 of	 the	
results	 from	 (A)	 with	 kinase	 activity	 normalized	 to	 protein	 level.	 (C)	 Normalized	
amount	 of	 immunoprecipitated	 CK2β‐V5	 from	 (A)	 with	 the	 levels	 of	 CK2β‐V5	 in	
untreated	cells	defined	as	1.	(D)	Quantitation	by	western	blot	of		CK2β‐V5	in	lysates	
from	 untreated	 and	 10	 µM	 Ku‐55933	 treated	 293T‐CK2β‐V5	 cells.	 Levels	 were	
normalized	to	KAP1	and	the	average	level	of	CK2β‐V5	in	untreated	cells	was	defined	
as	 1.	 Averages	 and	 standard	 deviations	 were	 calculated	 from	 two	 independent	
experiments	and	used	for	t‐tests.	P‐values:	*	<	0.05	
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similar	 amount	 of	 CK2β‐V5	 in	 the	 input	 lysates	 of	 the	 untreated	 and	 Ku‐55933	
treated	 cells	 (Figure	 4.22D).	 Thus	 ATM	 inhibition	 reduces	 the	 efficiency	 of	 CK2β	
immunoprecipitation	and	corresponding	levels	of	CK2	activity.	
CK2Α'	AND	CK2Β	AGGREGATE	IN	CELLS	WITH	INACTIVE	ATM		
CK2	has	 been	 shown	 to	 undergo	 aggregation	 in	 vitro	 and	 in	 cells	 [160‐164].	 This	
aggregation	may	prevent	CK2β‐V5	immunoprecipitation	and	explain	the	difference	
in	 the	 in	 vitro	 kinase	 assay	 in	 inhibitor‐treated	 cells.	 To	 test	 this	 hypothesis,	 I	
performed	a	sucrose	gradient	to	compare	the	migration	of	CK2β‐V5	from	293T	cells	
with	or	without	treatment	by	10	μM	Ku‐55933.	CK2β‐V5	from	untreated	cells	shows	
a	primary	peak	centered	around	fractions	6	and	7	which	is	similar	to	CK2β‐V5	from	
cells	treated	with	10	μM	Ku‐55933	(Figure	4.23A).	Fractions	6	and	7	correspond	to	
~40	kDa	while	8	and	9	correspond	to	~240	suggesting	fractions	6‐10	range	from	a	
dimer	 of	 CK2β‐V5	 to	 the	 holoenzyme	 consisting	 of	 two	 CK2A	 subunits	 and	 two	
CK2β‐V5	 subunits.	 Although	 the	peaks	 occur	 in	 fractions	 6	 and	7	with	 or	without	
Ku‐55933,	when	quantitated	and	normalized	across	all	 fractions	 there	 is	a	shift	 in	
the	 percentage	 of	 CK2β‐V5	 to	 later	 fractions	 in	 the	 presence	 of	 ATM	 inhibitor,	
suggesting	there	is	an	increased	amount	of	aggregation	occurring	in	the	absence	of	
ATM	activity	 (Figure	4.23B).	However,	 the	 lysis	was	performed	 in	 the	presence	of	
detergent	 (1%	Triton	X‐100)	and	pelleted	at	high	speeds	so	some	aggregates	may	
have	been	lost.		
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Figure	4.23	CK2β‐V5	shifts	to	later	fractions	after	cellular	treatment	with	ATM	
inhibitor.		
(A)	 Lysates	 from	293T	 cells	were	 treated	with	 10	 µM	Ku‐55933	 or	 an	 equivalent	
amount	of	DMSO	and	lysed.	Equal	amounts	of	the	lysates	(10	μg)	were	added	to	the	
top	of	 identical	 sucrose	gradients	 consisting	of	1	ml	 layers	of	5‐50%	sucrose,	150	
mM	NaCl,	and	20	mM	Tris,	pH	7.4		in	5%	increments.	A	western	blot	was	performed	
on	the	fractions	with	anti‐V5.	(B)	Quantitation	of	results	from	(A).	
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To	reduce	the	loss	of	any	aggregates	during	sample	processing,	a	gentle	lysis	
buffer	without	detergent	was	used	and	the	lysates	were	not	pelleted.	Lysates	from	
HEK‐293T	 cells	 expressing	 CK2α,	 CK2α',	 or	 CK2β	 treated	 with	 or	 without	 ATM	
inhibitor	were	 run	on	a	 sucrose	gradient	as	 in	Figure	4.23	and	 the	 fractions	were	
analyzed	by	western	blot	and	quantitated	(Figure	4.24).	CK2α‐V5	shows	very	little	
response	to	ATM	inhibition.	However,	both	CK2α'‐V5	and	CK2β‐V5	show	a	dramatic	
shift	to	the	denser	fractions,	including	a	doubling	of	the	amount	in	the	last	fraction	
(Figure	 4.24B‐C).	 The	 same	 lysis	 and	 sucrose	 gradient	 procedures	 were	 used	 on	
lysates	from	AT1ABR	cells	expressing	wild‐type‐ATM	or	C2991L‐ATM	(Figure	4.25).	
Although	CK2α	showed	similar	distributions	in	both	cell	lines,	CK2β	again	showed	a	
marked	 shift,	 most	 evident	 in	 the	 last	 fraction.	 CK2α'	 was	 not	 visible	 in	 these	
conditions.	 This	 is	 similar	 to	 previously	 seen	 aggregation	 and	 may	 provide	 an	
explanation	for	the	reduction	in	overall	CK2	activity	in	the	presence	of	ATM	with	the	
C2991L	mutation.	
SUMMARY	
ATM	is	activated	by	oxidative	stress	in	the	absence	of	DNA	damage	and	affects	many	
cellular	 processes	 beyond	 the	 DNA	 repair	 pathway	 [4].	 Here,	 I	 found	 8%	 of	 the	
proteome	was	 vastly	 reduced	 in	 cells	 expressing	ATM	with	 separation‐of‐function	
mutations.	Analysis	of	a	subset	of	these	proteins	revealed	that	some	exhibit	changes	
in	 their	 sedimentation	 rates	 in	 sucrose	 gradients	with	ATM	 inhibition,	 potentially	
from	aggregation.	ATM	has	been	shown	previously	to	phosphorylate	multiple	heat	
shock	 proteins	 [12].	 Phosphorylation	 of	 Hsp27	 promotes	 its	 interaction	 with	
glucose‐6‐phosphate	dehydrogenase	and	increases	the	metabolic	flow	through	the		
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Figure	4.24	Gentle	lysis	reveals	CK2α'	and	CK2β	aggregation	in	293T	cells	treated	with	
ATM	inhibitor.		
(A)	 293T	 cells	 expressing	 CK2α‐V5	 were	 treated	 with	 10	 μM	 Ku‐55933	 or	 an	
equivalent	 amount	 of	 DMSO	 for	 16	 hours,	 harvested,	 and	 lysed	 in	 the	 absence	 of	
detergent.	1	mg	of	lysate	in	500	μl	lysis	buffer	total	was	added	to	the	top	of	a	sucrose	
gradient	 made	 with	 1	 ml	 layers	 of	 50%	 to	 5%	 sucrose	 in	 5%	 increments.	 After	
ultracentrifugation,	 500	 μl	 fractions	were	 collected	 and	 analyzed	 by	western	blot.	
(B)	Cell	treatment	and	sucrose	gradient	as	in	(A)	with	293T	cells	expressing	CK2α'‐
V5.	 (C)	 Cell	 treatment	 and	 sucrose	 gradient	 as	 in	 (A)	 with	 293T	 cells	 expressing	
CK2β‐V5.	
0
5
10
15
20
25
30
35
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
Pe
rc
en
ta
ge
 of
 
CK
2α
’‐V
5 i
n f
ra
ct
io
n
Fraction
Untreated
10 μM Ku‐55933
0
5
10
15
20
25
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
Pe
rc
en
ta
ge
 of
 
CK
2β
‐V5
 in
 fra
ct
io
n
Fraction
Untreated
10 μM Ku‐55933
A
B
0
5
10
15
20
25
30
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
Pe
rc
en
ta
ge
 of
 
CK
2α
‐V5
 in
 fra
ct
io
n
Fraction
Untreated
10 μM Ku‐55933
C
 
 
92
	
	
		
Figure	4.25	Gentle	lysis	shows	CK2β	shifts	to	higher	molecular	weight	complexes	in	
AT1ABR	cells	expressing	C2991L‐ATM.		
	(A)	 Induced	AT1ABR	 cells	 expressing	wild‐type‐	 or	 C2991L‐ATM	were	 harvested	
and	lysed	in	the	absence	of	detergent.	Lysate	(1	mg)	in	500	μl	lysis	buffer	total	was	
added	to	the	top	of	a	sucrose	gradient	made	with	1	ml	layers	of	50%	to	5%	sucrose	
in	5%	increments.	After	ultracentrifugation,	500	μl	fractions	were	collected	and	16	
µl	 each	 fraction	 was	 analyzed	 by	 western	 blot	 for	 CK2a	 (45	 kDa),	 (B)	 Sucrose	
gradient	 and	western	 blot	 performed	 as	 in	 (A)	with	 2	mg	 lysate	 and	 120	 µl	 each	
fraction	probed	for	CK2β	(25	kDa).	Quantitation	was	performed	on	the	Licor	system	
using	Image	Studio	Ver	4.0.		
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pentose	phosphate	pathway	[222].	It	will	be	interesting	to	determine	how	this	and	
other	phosphorylation	events	affect	the	activity	or	substrates	of	these	chaperones.		
ATM	has	been	shown	to	be	activated	in	cells	over‐expressing	a	form	of	GFP	
that	 aggregates	 [223].	 Similarly,	 known	 ATM	 substrates	 were	 phosphorylated	 in	
fibroblasts	 from	 patients	 with	 Huntington's	 disease,	 a	 neurodegenerative	 disease	
associated	 with	 aggregation	 of	 the	 huntington	 protein.	 This	 evidence	 of	 ATM	
activation	during	aggregation	suggests	that	these	cellular	states	are	also	associated	
with	oxidative	stress	and	that	ATM	may	aid	in	the	clearance	of	aggregates.		
Although	 some	proteins	 appear	 to	 undergo	 aggregation,	 this	 does	 not	 fully	
explain	 the	 differences	 between	 the	 AT1ABR	 cells	 with	 wild‐type‐ATM	 versus	
C2991L‐ATM.	The	 increased	oxidative	stress	 in	C2991L‐ATM	cells	may	be	causing	
oxidative	 modifications	 on	 the	 proteins	 that	 prevent	 their	 identification	 by	 mass	
spectrometry.	Interestingly,	two	of	the	eight	known	proteins	involved	in	ferroptosis	
–	glutathione	peroxidase	4,	and	acyl‐CoA	synthetase	family	member	2	–	were	in	the	
DIM	 group.	 Ferroptosis	 is	 an	 iron‐dependent	 form	 of	 cell	 death	 that	 is	 associated	
with	large	amounts	of	oxidative	damage	in	the	cell	[224].	Here,	oxidative	damage	to	
proteins	may	be	modifying	them	beyond	recognition.	Notably,	some	of	the	proteins	
in	 the	 DIM	 group	 had	 some	 peptides	 that	 showed	 normal	 levels,	 but	 drastically	
reduced	levels	of	other	peptides,	suggesting	site‐specific	modifications.	
Proteins	in	the	DIM	group	were	enriched	for	localization	to	the	mitochondria.	
Previously,	cells	lacking	functional	ATM	were	shown	to	have	defective	mitochondria	
and	 increased	ROS	 levels	 [205].	My	results	show	separation‐of‐function	mutations	
in	 either	 pathway	 affect	 the	 levels	 of	 proteins	 involved	 in	 mitochondrial	
homeostasis.	Notably,	AT1ABR	cells	expressing	wild‐type‐ATM	had	large	 increases	
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in	 mitochondrial	 mass	 relative	 to	 the	 parental	 cell	 line.	 C2991L‐ATM	 expressing	
cells	 had	 an	 intermediate	 level	 of	 mitochondrial	 mass	 suggesting	 both	 activation	
pathways	 of	 ATM	 are	 important	 for	mitochondrial	 health.	 The	 ROS	 levels	 in	 both	
wild‐type‐	and	C2991L‐ATM	expressing	cells	were	increased	relative	to	the	parental	
AT1ABR	cell	 line.	Notably,	our	 lab	has	previously	characterized	the	 long‐term	ROS	
levels	of	 a	MEF	 cell	 line	with	 an	 inducible	ATM	knockout.	 Initially,	ATM	knockout	
causes	an	increase	in	ROS	but	over	time	the	cells	adapt	to	the	absence	of	ATM	and	
lower	their	ROS	levels	below	the	cells	heterozygous	for	ATM	(S	Zhang,	unpublished	
observations).	This	adaptation	could	include	an	increased	induction	of	SLC7A11	as	
was	seen	here.		
Examination	of	the	phosphoproteomes	from	all	six	cell	lines	revealed	a	group	
of	 315	 phosphopeptides	 that	 were	 lower	 in	 the	 cells	 expressing	 C2991L‐	 or	
R2579A/R2580A/C2991L‐ATM.	 This	 pattern	 suggests	 that	 a	 defect	 in	 ATM	
activation	 by	 oxidative	 stress	 is	 the	 cause.	Motif	 analysis	 of	 the	 phosphopeptides	
revealed	 an	 enrichment	 of	 sites	 predicted	 to	 be	 phosphorylated	 by	 CK2.	 A	
Kolmogorov‐Smirnov	analysis	of	 the	 levels	of	 these	phosphopeptides	 in	wild‐type‐
ATM	 and	 C2991L‐ATM	 containing	 AT1ABR	 cells	 relative	 to	 the	 entire	
phosphoproteome	 again	 showed	 a	 statistically	 significant	 lower	 amount	 of	
phosphorylation	in	C2991L‐ATM	AT1ABR	cells.	
Further	 analysis	 with	 293T	 cells	 expressing	 V5‐tagged	 CK2β	 showed	 an	
increased	portion	of	CK2	was	unable	to	be	immunoprecipitated	after	treatment	with	
an	 ATM	 inhibitor.	 Sucrose	 gradients	 of	 lysates	 from	 these	 cells	 revealed	 this	
coincided	 with	 a	 shift	 of	 CK2β‐V5	 to	 denser	 fractions.	 Similarly,	 AT1ABR	 cells	
expressing	 C2991L‐ATM	 showed	 a	 shift	 of	 CK2β	 corresponding	 to	 changes	 in	
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aggregation	state.	However,	CK2α	was	not	shown	to	undergo	this	change	suggesting	
the	components	of	the	CK2	holoenzyme	may	be	differentially	affected.		
Substrates	of	 the	calcium/calmodulin‐dependent	protein	kinase	 II	 (CaMKII)	
were	also	found	to	be	less	phosphorylated	in	AT1ABR	cells	expressing	C2991L‐ATM.	
Interestingly,	 experiments	 in	U2OS	 cells	with	V5‐CaMKIIδ	 showed	ATM	 inhibition	
affects	 immunoprecipitation	 and	 not	 kinase	 activity,	 similar	 to	 CK2	 (data	 not	
shown).	 Additionally,	 V5‐CaMKIIδ	 shifted	 to	 more	 dense	 fractions	 upon	 ATM	
inhibition	in	these	cells.	This	suggests	changes	in	aggregation	state	induced	by	ATM	
inhibition	 or	 C2991L‐ATM	 expression	 may	 affect	 the	 activity	 of	 multiple	 kinases	
through	a	type	of	auto‐sequestration.		
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CHAPTER	5:	DISCUSSION	
THE	CANONICAL	ROLE	OF	ATM	
The	role	of	ATM	in	the	cellular	response	to	DNA	double‐strand	breaks	has	been	well	
described	[4].	ATM	is	activated	minutes	after	a	DSB	and	phosphorylates	hundreds	of	
substrates	to	halt	the	cell	cycle,	initiate	DNA	repair,	and	regulate	gene	transcription	
[4].	 In	 vitro	 studies	 and	 cellular	 assays	 have	 demonstrated	 this	 pathway	 of	 ATM	
activation	requires	 the	protein	complex	Mre11/Rad50/Nbs1	(MRN)	 [8,	33,	34,	71,	
74].	 Patients	 with	 hypomorphic	 mutations	 in	 Mre11,	 Nbs1,	 and	 Rad50	 lead	 to	
Ataxia‐telangiectasia‐like	 disorder,	 Nijmegen	 breakage	 syndrome,	 and	 Nijmegen	
breakage	syndrome‐like	disorder	[73,	75,	76].	Patients	with	these	diseases	manifest	
some	 of	 the	 symptoms	 characteristic	 of	 A‐T	 such	 as	 chromosomal	 instability	 and	
sensitivity	 to	 ionizing	 radiation	 but	 have	 slower	 progressing	 or	 absent	 cerebellar	
ataxia	and	ocular	telangiectasia.	
MRN	REQUIREMENTS	FOR	DSB	ACTIVATION	OF	ATM	
Some	of	the	enzymatic	activities	and	domains	of	the	components	of	MRN	required	
for	 activation	 of	 ATM	 have	 been	 uncovered.	 Expression	 of	 a	 nuclease‐deficient	
Mre11	in	mouse	cells	demonstrated	the	Mre11	nuclease	activity	 is	dispensable	for	
ATM	 activation	 but	 necessary	 for	 DNA	 repair	 [191].	 In	 vitro	 kinase	 assays	 in	 the	
absence	 of	 Mre11	 nuclease	 activity	 also	 stimulated	 ATM	 activity	 [34].	 The	 C‐
terminus	 of	 Nbs1	 is	 necessary	 for	 the	 recruitment	 of	 ATM	 to	 DSBs	 [55],	 and	 the	
coiled‐coils	 of	 Rad50	 were	 also	 shown	 to	 be	 important	 as	 deletions	 within	 this	
domain	reduce	ATM	activation	[225].	Previously	it	was	shown	that	a	mutation	in	the	
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Walker	 A	 motif	 of	 Rad50	 that	 abrogates	 ATP‐dependent	 functions	 of	 Rad50	 was	
unable	to	activate	ATM	[34].	However,	it	was	unclear	from	this	mutant	whether	ATP	
binding	alone	or	binding	followed	by	hydrolysis	was	necessary	for	the	activation	of	
ATM.	
MRE11/RAD50	COMPLEXES	UNDERGO	ATP‐DEPENDENT	CONFORMATIONAL	CHANGES		
Recent	 structural	 analyses	 of	 the	 catalytic	 heads	 of	 archaeal	 and	 bacterial	 Mre11	
and	Rad50	in	the	presence	or	absence	of	various	nucleotides	have	demonstrated	a	
large	 conformational	 shift	 upon	 ATP	 binding	 [65,	 66,	 85].	 In	 the	 absence	 of	 ATP,	
Rad50	is	in	an	"open"	configuration	with	Mre11	bridging	the	catalytic	heads	(Figure	
5.1)	[85].	In	the	presence	of	ATP,	the	Rad50	head	domains	come	together	and	Mre11	
is	 flipped	 relative	 to	 the	 Rad50	 dimer	 to	 form	 the	 "closed"	 conformation	 [66].		
Several	 functions	 of	 MRN	 are	 dependent	 on	 ATP	 binding	 and/or	 hydrolysis	
including	DNA	end‐binding,	DNA	tethering,	and	resection	(Figure	5.1)	[70].	Recent	
studies	have	shown	the	nuclease	activity	in	the	MR	complex	of	Pyrococcus	 furiosus	
requires	 transitioning	 from	 the	 "closed"	 form	 back	 to	 the	 "open"	 form	 and	 the	
enzyme	in	the	closed	state	does	not	exhibit	nuclease	activity	[62].	
ATP‐DRIVEN	CONFORMATIONAL	CHANGES	OF	MRN	CONTROL	ATM	ACTIVATION	
Here,	 I	 showed	 that	 ATP	 binding,	 but	 not	 hydrolysis,	 by	 Rad50	was	 required	 for	
ATM	activation	by	the	MRN	complex.	This	agrees	with	previous	results	showing	the	
preference	 of	 DNA	 ends	 for	 the	 ATP‐bound	 form	 of	 MRN,	 the	 required	 DNA	
substrate	for	ATM	activation.	Notably,	the	ATP‐bound	form	of	Rad50	is	long‐lived	as	
it	 hydrolyzes	 0.1	 ATP	 molecules/minute	 [174,	 192].	 ATP	 binding	 and	 hydrolysis	
may	act	as	a	molecular	switch	to	trigger	new	activities	within	the	complex	instead	of		
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Figure 5.1 Schematic model of MRN in the absence (open) or presence of ATP (closed).  
Rad50 is shown as light gray globular domains containing Walker A (A) and Walker B 
(B) motifs connected by intramolecular, antiparallel coiled-coils (CC), that attach to each 
other through the zinc hook motifs (Zn hook). Stars indicate the approximate positions of 
the ATP-binding residues in Rad50. Mre11 is shown as dark gray globular domains 
representing the nuclease/dimerization domain and the capping domain, connected to the 
linker that binds to the coiled-coils of Rad50. The closed state is associated with a higher 
affinity for DNA ends and with DNA tethering, while the movement from the closed to 
the open state is required for Mre11 nuclease activity and promotion of resection. The 
zinc hook is shown attached here, but the complex has also been observed with hooks 
unattached, both in solution and bound to DNA. This research was originally published in 
in Journal of Biological Chemistry. Lee JH, Mand MR, Deshpande RA, Kinoshita E, 
Yang SH, Wyman C, Paull TT. Ataxia Telangiectasia-Mutated (ATM) Kinase Activity Is 
Regulated by ATP-driven Conformational Changes in the Mre11/Rad50/Nbs1 (MRN) 
Complex. Journal of Biological Chemistry. 2013; 288:12840-12851. © the American 
Society for Biochemistry and Molecular Biology. 
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the	normal	function	of	ATP	as	an	energy	source.	After	binding	ATP,	MRN	functions	
in	DNA	end‐binding,	DNA	tethering,	and	ATM	activation.	Upon	ATP	hydrolysis,	 the	
nuclease	 activity	 of	 MRN	 is	 initiated	 and	 it	 binds	 DNA	 non‐specifically	 [62].	 The	
conformational	and	 functional	 changes	 in	MRN	upon	ATP	binding	and	subsequent	
hydrolysis	allow	MRN	to	be	temporally	regulated	to	perform	distinct	functions.		
NON‐CANONICAL	ROLES	OF	ATM	IN	CELLULAR	HOMEOSTASIS	
ATM	has	many	roles	in	addition	to	its	canonical	role	in	the	cellular	response	to	DNA	
double‐strand	 breaks.	 A‐T	 patients	 show	 hypersensitivity	 to	 ionizing	 radiation	
consistent	with	the	deficiency	in	DSB	repair,	but	other	symptoms	such	as	cerebellar	
degeneration,	ocular	telangiectasia,	and	diabetes	seem	unrelated	to	this	dysfunction	
[205].	A‐T	cells	also	display	phenotypes	that	appear	unconnected	to	the	DNA	repair	
deficiency	 including	 defective	 mitochondria,	 changes	 in	 insulin	 signaling,	 and	
increased	oxidative	stress	[4].	ATM	has	been	shown	to	phosphorylate	substrates	in	
the	 absence	of	DNA	damage	 in	 response	 to	hypoxia	 [6],	 hyperthermia	 [7],	mitosis	
[9],	and	oxidative	stress	[5,	226,	227].	These	other	ATM‐activating	conditions	may	
explain	some	of	the	other	symptoms	of	A‐T.	
To	 more	 completely	 address	 the	 other	 pathways	 affected	 by	 ATM,	 I	
compared	 the	 proteomes	 and	 phosphoproteomes	 of	 lymphoblasts	 from	 a	 healthy	
person,	 A‐T	 lymphoblasts,	 and	 A‐T	 lymphoblasts	 re‐expressing	 various	 ATM	
constructs.	Separation‐of‐function	mutations	that	prevent	in	vitro	activation	of	ATM	
by	 DSBs	 (R2579A/R2580A‐ATM),	 oxidative	 stress	 (C2991L‐ATM),	 or	 both	
(R2579A/R2580A/C2991L‐ATM)	were	used	to	distinguish	the	effect	each	pathway	
has	on	ATM	downstream	effects	[5].	
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The	 proteomes	 in	 cells	 expressing	 any	 of	 the	 mutant	 ATM	 proteins	
underwent	an	apparent	loss	of	many	proteins.	This	Down	In	Mutants	(DIM)	group	of	
362	proteins	had	significantly	reduced	spectral	counts	in	the	LC‐MS/MS.	However,	
western	blotting	of	a	subset	of	this	group	revealed	similar	levels	of	protein	between	
wild‐type‐	 and	 C2991L‐ATM	 expressing	 cells,	 suggesting	 the	 total	 protein	 levels	
were	 the	 same	 but	 the	 proteins	 were	 not	 being	 identified	 during	 LC‐MS/MS.	
Analysis	at	the	peptide	level	showed	some	of	these	proteins	had	peptides	that	were	
systemically	 lower	 while	 other	 proteins	 had	 only	 a	 small	 subset	 of	 peptides	 that	
were	 lower.	 I	 investigated	 several	 of	 the	 proteins	 with	 systematic	 reductions	 in	
peptide	levels	and	found	these	exhibited	changes	in	their	sedimentation	coefficients	
in	 sucrose	 gradients	 corresponding	 to	 large	 increases	 in	 molecular	 weight	 or	
aggregation.	These	proteins	may	form	aggregates	after	expression	of	ATM	deficient	
in	one	or	both	of	the	activation	pathways.	ACLY,	a	protein	that	showed	lower	levels	
of	only	some	of	its	peptides,	did	not	have	a	shift	in	the	sucrose	gradient	in	AT1ABR	
cells	expressing	C2991L‐ATM.	It	is	also	possible	that	the	peptides	with	lower	levels	
from	 the	 other	 DIM	 proteins	may	 be	 due	 to	 oxidative	modifications	 that	 prevent	
identification	by	LC‐MS/MS.	We	are	continuing	to	characterize	the	modifications	of	
these	 proteins	 in	 lysates	 from	 the	 AT1ABR	 cells	 and	 particularly	 from	 the	 last	
fraction	of	the	sucrose	gradients.	
The	 cerebellar	 neurodegeneration	 in	 A‐T	 may	 be	 partially	 explained	 by	
protein	aggregation,	which	is	a	common	occurrence	in	neurodegenerative	diseases	
[228].	Notably,	a	combination	of	increased	oxidative	stress,	chaperone	dysfunction,	
and	 reduced	 ability	 to	 clear	 aggregates	 through	 autophagy	 are	 thought	 to	 be	
responsible	 for	 protein	 aggregation	 [228,	 229].	 ATM	may	 play	 in	 role	 in	 all	 three	
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mechanisms	 for	 managing	 protein	 aggregation	 (Figure	 5.2).	 Oxidative	 stress	
activates	ATM	and	prevention	of	this	activation	 leads	to	 increased	oxidative	stress	
[5].	 Active	 ATM	 increases	 the	 production	 of	 the	 antioxidant	 NADPH	 through	
activation	 of	 the	 pentose	 phosphate	 pathway	 [222].	 Promotion	 of	 the	 pentose	
phosphate	 pathway	 by	 ATM	 occurs	 through	 phosphorylation	 of	 the	 protein	
chaperone	 Hsp27,	 which	 then	 binds	 and	 stimulates	 G6PD	 [222].	 Additionally,	
multiple	heat	shock	proteins	important	for	protein	folding	and	chaperone‐mediated	
autophagy	 have	 been	 identified	 in	 screens	 for	 ATM	 substrates	 [11,	 12].	
Furthermore,	ATM	 itself	 co‐purifies	with	a	 chaperone	 (unpublished	observations).	
ATM	also	activates	autophagy	through	the	phosphorylation	of	LKB,	which	activates	
a	pathway	 leading	 to	stimulation	of	TSC2	 [14].	TSC2	 is	a	negative	regulator	of	 the	
autophagy‐suppressing	protein	mTORC1.	Notably,	inhibition	of	mTORC1	in	A‐T	cells	
with	rapamycin	reduced	the	 levels	of	oxidative	stress,	suggesting	that	unregulated	
mTORC1	is	at	least	partially	responsible	for	changes	in	ROS	[14].	In	the	absence	of	
ATM	kinase	activity,	 inhibition	of	 autophagy	by	mTORC1	may	prevent	 the	normal	
clearance	 of	 aggregates.	Notably,	 expression	 of	 a	 polyglutamine‐expanded	protein	
induced	activation	of	ATM	through	both	oxidative	stress	and	DNA	damage,	directly	
tying	both	activation	pathways	to	protein	aggregate	clearance	[223].	Thus	all	three	
methods	of	managing	protein	aggregation	may	be	compromised	in	cells	expressing	
mutant	ATM.	
The	proteins	in	the	DIM	group	were	enriched	for	mitochondrial	proteins	and	
further	 analysis	 demonstrated	 increased	 oxidative	 stress	 and	 reduced	
mitochondrial	 mass	 in	 cells	 expressing	 C2991L‐ATM	 relative	 to	 wild‐type‐ATM.	
Oxidative	modification	or	changes	in	the	aggregation	state	of	these	proteins	could		
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Figure 5.2 Model of ATM-mediated prevention of aggregation.  
Multiple pathways downstream of  ATM reduce oxidative stress and protein aggregation. 
	
potentially	 explain	 the	 defects	 seen	 in	mitochondria	 from	A‐T	 cells.	 Furthermore,	
the	 general	 chaperone	 defect	 will	 be	 interesting	 to	 pursue.	 Future	 experiments	
include	 the	 identification	 of	 the	 binding	 partners	 of	 the	 heat	 shock	 proteins	 in	
various	conditions	with	or	without	ATM	and	the	characterization	of	the	importance	
of	the	S/TQ	sites	in	chaperone	function.	
I	 also	 compared	 the	 phosphoproteomes	 of	 the	 normal	 lymphoblasts,	 A‐T	
cells,	 and	 A‐T	 cells	 expressing	 ATM.	 There	 were	 few	 putative	 ATM	 substrate	
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phosphopeptides	(pS/pTQ)	identified	 in	the	screen	and	these	had	little	differences	
in	their	levels.	 	However,	there	was	a	deficiency	in	the	phosphorylation	of	putative	
CK2	 substrates	 in	 cells	 expressing	ATM	with	 the	 C2991L	mutation.	 There	was	 no	
change	 in	 the	 levels	 of	 CK2α	 or	 CK2β	 by	 western	 blotting	 but	 under	 gentle	 lysis	
conditions	a	portion	of	CK2β	pelleted	in	a	sucrose	gradient	suggesting	formation	of	
aggregates.	Similarly,	CK2β‐V5	 from	cells	 treated	with	an	ATM	 inhibitor	showed	a	
shift	in	the	sucrose	gradient	similar	to	C2991L‐ATM	expressing	AT1ABR	cells.	These	
results	 suggest	 a	 similar	 mechanism	 of	 aggregation	 can	 cause	 changes	 in	 the	
phosphoproteome	of	A‐T	cells	unrelated	to	the	known	downstream	kinase	targets	of	
ATM.		
CK2	interacts	with	the	protein	chaperone	system	in	cells.	HSP90	binding	has	
been	 shown	 to	 prevent	 CK2	 aggregation	 and	 increase	 its	 kinase	 activity	 [230].	
Interestingly,	 CK2	 has	 been	 shown	 to	 phosphorylate	 HSP90	 and	 its	 co‐chaperone	
cdc37	[231].	While	CK2	phosphorylation	of	HSP90	appears	to	attenuate	its	activity,	
phosphorylation	of	cdc37	increases	its	binding	to	multiple	kinases	[231,	232].	CK2	
also	interacts	with	and	is	activated	by	HSPA1A	(HSP72)	[233].	In	addition,	CK2	can	
aid	 in	 the	 clearance	 of	 misfolded	 and	 ubiquitinated	 proteins	 through	
phosphorylation	 of	 HDAC6	 to	 activate	 its	 deacetylase	 activity	 [234].	 Thus,	 there	
could	 be	 a	 feedback	 loop	whereby	 aggregation	 of	 CK2	 reduces	 its	 kinase	 activity,	
HDAC6	 is	 less	 active,	 and	more	 aggregation	 occurs.	 Furthermore,	 CK2α	 has	 been	
shown	to	be	carbonylated	 in	 the	presence	of	oxidative	stress	 [157].	There	may	be	
more	modifications	of	CK2	in	A‐T	cells	that	affect	its	activity	and	these	are	currently	
being	explored.	
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DETRIMENTAL	EFFECTS	OF	THE	EXPRESSION	OF	INACTIVE	ATM		
The	 inhibition	 of	 ATM	 kinase	 activity	 has	 been	 shown	 to	 have	 effects	 that	 are	
distinct	from	the	absence	of	ATM	protein.	White	et	al.	demonstrated	a	loss	of	sister	
chromatid	 exchange	 in	 cells	 with	 wild‐type	 ATM	 after	 treatment	 with	 an	 ATM	
inhibitor	[235].	Notably,	A‐T	cells	had	levels	of	sister	chromatid	exchange	similar	to	
wild‐type	cells	and	the	addition	of	ATM	inhibitor	 to	A‐T	cells	had	no	effect,	 so	the	
presence	of	inactive	ATM	prevented	sister	chromatid	exchange.	Similarly,	Gamper	et	
al.	found	ATM	inhibition,	but	not	ATM	depletion,	decreases	DNA	synthesis	through	
an	interaction	with	PCNA	[236].	The	disparity	is	even	more	pronounced	in	mice	as	
ATM	knockout	mice	recapitulate	some	of	the	symptoms	of	A‐T	but	the	expression	of	
kinase‐dead	ATM	causes	embryonic	lethality	[22,	237].	In	my	studies,	in	the	absence	
of	exogenous	stress	stimuli,	inactivating	mutations	in	ATM	appear	to	have	dominant	
negative	 effects,	 including	 apparent	 changes	 in	 the	 aggregation	 state	 of	 some	
proteins.	
CONCLUDING	REMARKS	
The	 studies	 described	 here	 provide	 insights	 into	 the	 nature	 of	ATM	 activation	 by	
MRN	as	well	as	 the	cellular	effects	of	ATM	separation‐of‐function	mutations	 in	the	
normal	cellular	environment.	The	activation	of	ATM	by	MRN	in	the	presence	of	DSBs	
has	 been	 carefully	 analyzed	 in	 vitro	 to	 show	 the	 requirement	 of	 ATP	 binding	 by	
MRN	 for	 ATM	 activation.	 In	 the	 normal	 cellular	 environment,	 the	 separation‐of‐
function	 mutations	 in	 ATM	 prevented	 the	 identification	 of	 a	 large	 number	 of	
proteins	by	LC‐MS/MS.	Although	the	proteins	were	present	 in	similar	 levels	 in	the	
lysate,	 the	 loss	 of	 LC‐MS/MS	 identification	 was	 accompanied	 by	 a	 shift	 in	 the	
sedimentation	 rates	 of	 some	 of	 these	 proteins	 suggestive	 of	 aggregation.	 The	
 
 
105
proteins	 from	this	group	may	also	have	oxidative	modifications	 that	prevent	 their	
identification	by	LC‐MS/MS.	In	the	phosphoproteome,	phosphopeptides	predicted	to	
be	phosphorylated	by	CK2	were	shown	to	have	lower	levels	in	cells	expressing	ATM	
with	 the	 C2991L	 mutation.	 This	 was	 also	 accompanied	 by	 a	 shift	 in	 the	
sedimentation	 rates	 of	 the	 CK2α’	 and	 CK2β	 subunits	 similar	 to	 those	 seen	 in	 the	
proteome.	 Together	 these	 studies	 further	 characterize	 the	 mechanism	 of	 ATM	
activation	 by	DSBs	 and	 suggest	 ATM	helps	 prevent	 aggregation	 in	 the	 absence	 of	
exogenous	stress.	
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